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Abstract
Background and purpose: The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock
2016 (J-SSCG 2016), a Japanese-specific set of clinical practice guidelines for sepsis and septic shock created jointly
by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine, was first
released in February 2017 and published in the Journal of JSICM, [2017; Volume 24 (supplement 2)] https://doi.org/
10.3918/jsicm.24S0001 and Journal of Japanese Association for Acute Medicine [2017; Volume 28, (supplement 1)]
http://onlinelibrary.wiley.com/doi/10.1002/jja2.2017.28.issue-S1/issuetoc.
This abridged English edition of the J-SSCG 2016 was produced with permission from the Japanese Association of
Acute Medicine and the Japanese Society for Intensive Care Medicine.
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Methods: Members of the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute
Medicine were selected and organized into 19 committee members and 52 working group members. The
guidelines were prepared in accordance with the Medical Information Network Distribution Service (Minds) creation
procedures. The Academic Guidelines Promotion Team was organized to oversee and provide academic support to
the respective activities allocated to each Guideline Creation Team. To improve quality assurance and workflow
transparency, a mutual peer review system was established, and discussions within each team were open to the
public. Public comments were collected once after the initial formulation of a clinical question (CQ) and twice
during the review of the final draft. Recommendations were determined to have been adopted after obtaining
support from a two-thirds (> 66.6%) majority vote of each of the 19 committee members.
Results: A total of 87 CQs were selected among 19 clinical areas, including pediatric topics and several other
important areas not covered in the first edition of the Japanese guidelines (J-SSCG 2012). The approval rate
obtained through committee voting, in addition to ratings of the strengths of the recommendation, and its
supporting evidence were also added to each recommendation statement. We conducted meta-analyses for 29
CQs. Thirty-seven CQs contained recommendations in the form of an expert consensus due to insufficient evidence.
No recommendations were provided for five CQs.
Conclusions: Based on the evidence gathered, we were able to formulate Japanese-specific clinical practice
guidelines that are tailored to the Japanese context in a highly transparent manner. These guidelines can easily be
used not only by specialists, but also by non-specialists, general clinicians, nurses, pharmacists, clinical engineers,
and other healthcare professionals.
Keywords: Sepsis, Septic shock, Guidelines, Evidence-based medicine, Systematic review, Medical Information
Network Distribution Service (Minds),
Introduction
Sepsis is a serious disease affecting all age groups,
and the societal significance of developing high-
quality guidelines is very high. Japanese guidelines
formulated in consideration of the clinical environ-
ment in Japan were announced by the Japanese Soci-
ety of Intensive Care Medicine in 2012 [1, 2]. During
the 2016 revision, a joint committee was organized in
conjunction with the Japanese Association for Acute
Medicine. Rather than simply releasing another re-
vised edition, we strove to create high-quality guide-
lines that are still easy to understand for general
practitioners in order to encourage their spread
throughout the target medical community. These
guidelines are the English-language version prepared
in reference to The Japanese Clinical Practice Guide-
lines for Management of Sepsis and Septic Shock
2016 (J-SSCG 2016) [3, 4] originally published in
Japanese in February 2017. The Japanese version of
the J-SSCG 2016 [3, 4] is a large-scale guideline con-
taining 232 pages of main body content and 157
pages of appendix materials. While preparing the
English version, the content of the Japanese version
was digested and translated into English. It should
also be noted that these guidelines were originally
prepared while taking medical conditions in Japan
into consideration and are wholly independent of “Sur-
viving Sepsis Campaign: International Guidelines for
Management of Severe Sepsis and Septic Shock: 2016
(SSCG 2016)”. For this reason, these guidelines contain
some instances in which the recommendations offered dif-
fer from those offered for similar clinical questions (CQs)
in the SSCG 2016, or that address topics not covered in
the SSCG 2016. New topics not covered in the first edition
of the J-SSCG [1, 2] include controlling of the origin of in-
fection, blood transfusion preparations, management of
analgesia, sedation and delirium, acute kidney injury, body
temperature regulation, venous thromboembolism coun-
termeasures, intensive care unit (ICU)-acquired weakness,
and post-intensive care syndrome. Moreover, there are
few pediatric ICUs in Japan, and as healthcare profes-
sionals handling adult patients will inevitably need to treat
pediatric sepsis cases as well, new CQs related to pediatric
sepsis patients were also added to this edition. As a result,
these guidelines ultimately comprised a large-scale refer-
ence material covering a total of 19 clinical areas and 87
CQs. However, therapy administration to patients in the
prone position during respiratory management has been
recently addressed by the Japanese Acute Respiratory Dis-
tress Syndrome (ARDS) Clinical Practice Guidelines. As
such, some CQs in the J-SSCG 2016 avoid more special-
ized discussion of some topics related to this area and
some overlapping topics are not covered. To improve
quality assurance and workflow transparency, a mutual
peer review system was established, and discussions within
each team were open to the public. Public comments were
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collected once after the initial formulation of a CQ and
twice during the review of the final draft. These guidelines
were published simultaneously in both the Journal of In-
tensive Care, the English-language journal of the Japanese
Society of Intensive Care Medicine, and in Acute Medi-
cine & Surgery, the English-language journal of the Japa-
nese Association for Acute Medicine.
Overview and basic principles of these guidelines
Title
These guidelines were titled “The Japanese Clinical
Practice Guidelines for Management of Sepsis and
Septic Shock 2016”, which is abbreviated to “J-SSCG
2016”, in accordance with international versions
(SSCG2016).
Purpose
The purpose of these guidelines is to support the
capacity of healthcare professionals to appropriately
judge patient condition in the treatment of sepsis and
septic shock in order to improve prognosis.
Target patient population
These guidelines target pediatric to adult patients
presenting with confirmed or suspected sepsis or septic
shock. These patients may include not only those in
ICUs but also general wards or emergency outpatients.
However, although physicians may understand the
diagnosis and treatment of some cases, sepsis cases re-
quire advanced systemic management. As such, we
emphasize that prompt transfer of patients presenting
with confirmed or suspected sepsis to the ICU is desir-
able as circumstances permit.
Target audience (anticipated users of these guidelines)
These guidelines are meant for healthcare professionals
such as specialists, non-specialists, general practitioners,
nurses, pharmacists, and clinical engineering technicians
who perform or contribute to sepsis treatment.
Usage warnings
These guidelines were designed to improve overall
treatment outcomes. Although they are non-binding,
their societal impact is great. These guidelines are not
laws, and if other experts in this field achieve super-
ior treatment results through other methods, adhering
to these guidelines in their entirety is not necessary
in such instances. Accordingly, the contents of these
guidelines were designed to be easy for general practi-
tioners to understand, and highly specialized topics
were avoided. Clear recommendations could not be
offered for some CQs. Pathogens and infections cap-
able of causing sepsis are diverse, and the disease can
appear in varying degrees of severity. Sepsis cannot
be managed effectively by simply applying a standard-
ized algorithm or recommendation. Although it is im-
portant to abide by treatment guidelines, healthcare
professionals using these guidelines are encouraged to
do so as necessary based on the circumstances of
each case and to avoid becoming overly concerned
with adherence. The Guideline Creation Committee
does not allow these guidelines to be used or admit-
ted as evidence in court.
Organizational structure
Members of the Japanese Society of Intensive Care
Medicine and the Japanese Association for Acute
Medicine were selected and organized into 19 commit-
tee members and 52 working group members. The
Academic Guidelines Promotion Team was organized to
oversee guideline creation from a neutral position in
order to integrate each subject area into a single unified
guideline. The Academic Guidelines Promotion Team
audits the activities of each Guideline Creation Team to
ensure uniformity throughout the guidelines and also
creates academic materials and provides support to
improve systematic reviews.
In view of the broad range of advanced medical know-
ledge required to understand the complexity and patho-
physiology of sepsis, it was also decided that members of
patients’ families and patient advocates would be with-
held in a committee holding voting rights. Although a
separate organization, the Guideline Creation Commit-
tee occasionally acted based on the guidance and sup-
port of the Medical Information Network Distribution
Service (Minds).
Quality and transparency assurance
In addition to establishing the Academic Guidelines
Promotion Team, the following efforts were made to en-
sure quality and transparency.
Collaboration with the Minds and workshop activities
Occasional guidance was received from the Minds during
the process of formulating these guidelines. In addition,
external lecturers and librarians were invited to participate
in a seminar on “Literature Acquisition Techniques for
Systematic Reviews” we held independently.
Peer review
Activities were performed for various work processes
while mutual peer review was conducted by team mem-
bers across the region. Work products from each group
were repeatedly edited and revised, with each revised draft
being discussed by the Guideline Creation Committee.
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Multiple rounds of public comments
CQs underwent multiple rounds of public comments
generally from registered contributors: once after the ini-
tial formulation of a CQ and twice during the review of
the final draft. During finalization, public commenters
were requested to disclose any conflicts of interest.
Opinions regarding draft CQs were also solicited over
the internet.
Transparency
Although it is difficult to create guidelines that will
be accepted universally, improving visibility and trans-
parency in the development process is crucial. Mem-
bers of each team created an official mailing list (ML)
and discussions among team members were held
using these MLs as much as possible. Core members
and members of the Academic Guidelines Promotion
Team joined the MLs established by each team as
read-only members. Through these measures, we
aimed to increase the transparency of team discus-
sions, and by implementing the appropriate interven-
tions, we were able to coordinate the directions taken
by each team and achieve consistency throughout the
entirety of the guidelines.
Vote anonymization
Votes were tallied after all 19 committee members had
participated, and the rate of agreement achieved was
mentioned in each recommendation. To avoid con-
founding from academic conflicts of interest (COIs) of
committee members, committee votes concerning draft
recommendations were anonymized.
Disclosure of COIs and members’ roles
Financial and academic COIs as well as the role(s) of
each committee member are disclosed in the additional
file. Financial COIs were disclosed in accordance with
the standards used by the Japanese Association of
Medical Sciences since 2013 through 2016.
Funding
These guidelines were prepared with financial support
from the Japan Society of Intensive Care Medicine
and the Japanese Association for Acute Medicine. No
member of the Guideline Creation Committee
received any form of financial compensation during
the preparation of these guidelines. The views and in-
terests of these societies as well as Minds were not
reflected in the preparation of the guideline’s
recommendations.
Guideline dissemination strategy
The Japanese version of these guidelines is open ac-
cess. In addition, to promote ease of use, the digest
version of the guidelines booklet as well as apps view-
able on smartphones and tablet devices are available
for purchase at the affordable price of 2500 JPY. We
will strive to make these guidelines available at vari-
ous academic meetings and seminars and also moni-
tor activities related to sepsis practice as well as the
spread of these guidelines throughout the target med-
ical community.
Planned revisions
These guidelines are scheduled to undergo revision
every 4 years. The next revision will occur in 2020.
Should important new information warranting revision
be obtained beforehand, partial revision will be
considered.
The process of making recommendations in the
Japanese Clinical Practice Guidelines for
Management of Sepsis and Septic Shock 2016
Each recommendation in the Japanese Clinical
Practice Guidelines for Management of Sepsis and
Septic Shock 2016 went through four steps in its
formulation: (1) clinical question (CQ) development,
(2) systematic review, (3) evaluation of the quality of
evidence (QoE), and (4) determination of the recom-
mendation. In principle, this method proceeded in
accordance with the Minds 2014 system (http://mind-
s4.jcqhc.or.jp/minds/guideline/handbook2014.html).
When formulating the recommendations, teams
involved in the management of pediatric patients, in
addition to adult patients, were assembled, and each
team developed CQs, conducted systematic reviews,
evaluated the QoE, and drafted a recommendation in
one of the following areas: “Definition and diagnosis of
sepsis,” “Diagnosis of infection,” “Antimicrobial therapy,”
“Imaging diagnoses,” “Source control,” “Initial resuscitation
and vasoactive medications,” “Respiratory management”
“Nutrition,” “Corticosteroid therapy,” “Disseminated
Intravascular Coagulation (DIC) management,” “Acute
Kidney Injury (AKI)/Blood purification and renal re-
placement therapy,” “Immunoglobulins,” “Analgesia/
Sedation/Delirium,” “Post Intensive Care Syndrome
(PICS)/Intensive Care Unit-Acquired Weakness
(ICU-AW),” “Body temperature regulation,” “Glucose
control,” “Blood products,” and “Venous thrombo-
embolism prophylaxis.”
In three areas (Respiratory management, Nutrition,
and Analgesia/Sedation/Delirium), recommendations
were formulated based on the existing recently pub-
lished clinical guidelines in collaboration with members
of the clinical guideline committees of related local
academic societies.
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Strength of recommendations
The recommendations were made based on four factors:
QoE, the balance between benefit and harm, patients’
values and preferences, and the costs and resources in-
volved in carrying out the intervention. The strength of
the recommendations was defined based on the Minds
2014 system. The strength of the recommendations is
classified into one of four categories: recommend, sug-
gest, recommend against, or recommend against.
Following the formulation of statements through
discussion in each group and deliberation among all
committee members during face-to-face meetings at
which the groups presented their draft statements, all
committee members voted to indicate their agreement
or disagreement with the statement, or abstention. Ac-
ceptance of a statement required votes from 66.6% of
the 19 committee members. The accepted recommenda-
tions were edited and finalized by the committee. Voters
could provide feedback for consideration in revising
statements that did not receive consensus in up to two
rounds of voting.
As a result, the two CQs that were not accepted after
two rounds of voting are presented as expert consensuses.
Expert consensus presentation
An expert consensus is presented for CQs for which no
systematic review or randomized clinical trial could be
identified after a comprehensive literature search, or
when the recommendation statement was unable to be
accepted by the committee.
Recommendations are presented as an expert consensus
only when they are feasible clinical solutions (clinically im-
portant aspects that cannot be verified via intervention trials
as they are physiologically common phenomena) after con-
sideration of the appropriate physiological or pathophysio-
logical circumstances. When it was not possible to make
recommendations as an expert consensus, or if a consensus
could not be reached, it was stated that no recommendation
for that CQ could be offered with the related discussions.
CQ1: Sepsis: definition and diagnosis
Introduction
According to the Third International Consensus
Definitions for Sepsis and Septic Shock (Sepsis-3) [5–7],
sepsis is defined as a “life-threatening organ dysfunction
caused by a dysregulated host response to infection.”
The clinical criteria of sepsis are suspected or docu-
mented infection and an acute increase in the Sequential
Organ Failure Assessment (SOFA) score of 2 points or
more. Septic shock is defined as a subset of sepsis in
which the underlying circulatory and cellular/metabolic
abnormalities are profound enough to substantially
increase mortality. Septic shock can be clinically identi-
fied by a vasopressor requirement to maintain a mean
arterial pressure of 65 mmHg or higher and a serum
lactate level greater than 2 mmol/L (18 mg/dL) despite
the adequate volume resuscitation.
In out-of-hospital, emergency department, or general
hospital ward settings, adult patients with suspected
infection can be rapidly identified as being more likely
to have poor outcomes typical of sepsis if they have at
least 2 of the following clinical criteria that together con-
stitute the quick SOFA (qSOFA): a respiratory rate of 22
breaths/min or higher, altered consciousness, and a
systolic blood pressure of 100 mmHg or less [5–7]. The
qSOFA criteria can be used to prompt clinicians to fur-
ther investigate for organ dysfunction, to initiate or
escalate therapy as appropriate, and to consider referral
for critical care. Ultimately, an acute increase in the
SOFA score of 2 or more points constitutes a confirm-
ation of the diagnosis of sepsis. Daily routine sepsis
screening is recommended to support the early diagnosis
and treatment of sepsis.
Various biomarkers believed to be useful in diagnosing
sepsis have been reported; in the Sepsis-2 (2003) [8],
leukocyte count (> 12,000/μL or < 4000/μL or > 10% im-
mature forms), c-reactive protein level (CRP; > reference
value + 2 standard deviation (SD)), and procalcitonin
level (PCT; > reference value + 2 SD) were listed as
inflammatory biomarkers. CRP and PCT are also com-
monly used by physicians in Japan. In addition to this,
Japanese-developed presepsin (P-SEP; sCD14-ST) came
under the coverage of the National Health Insurance in
January 2014. Although the test for interleukin-6 (IL-6)
is not yet covered, a kit for clinical use has been devel-
oped and is currently in use by some medical facilities as
part of the management of sepsis. This guideline covers
Strength of Recommendation Recommend
(1)
Suggest
(2)
Suggest against (2) Recommend against (1)
Content of recommendation Strong recommendation
in support of an
intervention
(Weak) Suggestion in
support of an intervention
under certain conditions
(Weak) Suggestion against
an intervention under
certain conditions
Strong recommendation
against an intervention
Wording of recommendation We recommend—
[intervention].
We suggest—[intervention]. We suggest
against—[intervention].
—We recommend
against [intervention].
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CRP, PCT, PSEP, and IL-6 based on the background
described above.
CQ1-1: can we use procalcitonin (PCT), presepsin
(P-SEP,sCD14-ST), and interleukin-6 (IL-6) for the diagnosis
of sepsis?
Answer (recommendations)
1. (P-SEP: 2B, PCT: 2C) We suggest the measurement
of P-SEP or PCT levels as an adjunct to the diagnosis
of infection when sepsis is suspected in critically ill
patients such as those in intensive care units (rate of
agreement, 89.4%).We do not recommend the routine
measurement of IL-6 levels as an adjunct to the
diagnosis of infection in such patients (2C) (rate of
agreement, 89.4%).
2. We suggest against the routine measurement of
P-SEP, PCT, or IL-6 levels as an adjunct to the
diagnosis of infection when sepsis is suspected in
non-critically ill patients such as those in emergency
rooms or general wards (P-SEP: 2C, PCT: 2D, IL-6:
2D) (rate of agreement, 94.7%).
Rationale
This clinical question (CQ) offers recommendations re-
garding the validity of the three biomarkers, PCT, P-SEP,
and IL-6 to support the diagnosis of sepsis in two clin-
ical settings: (1) settings with critically ill patients, such
as in ICUs, where infection is suspected but difficult to
confirm and (2) settings in which infection is suspected
but patients are not critically ill such as the emergency
room or general ward. The clinical utility of each marker
was assessed individually in these two settings.
Hierarchical summary receiver operating characteristic
(ROC) analysis was used during meta-analysis (data inte-
gration) of the diagnostic test accuracy for each marker,
and the assessment of the quality of experience (QoE)
and the recommended settings were calculated based on
the estimated number of patients presenting as true
positives, false positives, or false negatives determined by
the “diagnostic Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) system,”
and the benefit-risk balance was assessed based on a
pre-examination probability of 40%. We adopted CRP, a
widely used biomarker in clinical practice, as a control.
Representative meta-analyses of PCT [9], P-SEP [10],
IL-6 [11], and CRP [12] were selected.
In the settings where most patients were critically ill,
the benefits were evaluated to outweigh risks regarding
the measurement of P-SEP or PCT, but not of IL-6
levels. As a result, we recommend the measurement of
P-SEP or PCT levels as supplementary tests in the diag-
nosis of infection in critically ill patients when sepsis is
suspected. In settings where most patients are not
critically ill, significant benefit has not been established
regarding the measurement of P-SEP, PCT, or IL-6
levels. Thus, we do not recommend the routine meas-
urement of any of these biomarkers as a supplementary
test in the diagnosis of infection in non-critically ill pa-
tients even when sepsis is suspected.
Access to tests for these biomarkers is variable among
hospitals or facilities. Currently, only a limited number
of hospitals or facilities in Japan are capable of measur-
ing P-SEP and IL-6 values as part of routine examina-
tions. Moreover, even in hospitals or facilities capable of
performing these measurements, these tests are per-
formed in central laboratories and may not be as useful
as point-of-care-testing (POCT).
CQ2: Diagnosis of infection
Introduction
Identifying the source of infection is important for the
diagnosis of sepsis or septic shock. It is necessary to nar-
row down the potential foci of infection as quickly as
possible based on the patient’s medical history, physical
examination, imaging examinations, and other records,
as well as to properly collect specimens from the sus-
pected foci and perform a blood culture examination.
The blood culture is the most important test in the
management of sepsis, and the clinical significance of
identifying the pathogenic microorganisms causing
bacteremia is substantial. Treatment optimization in-
cluding de-escalation can be achieved with the aid of the
results of culture and antimicrobial susceptibility tests of
blood samples or other specimens. On the other hand,
contamination is associated with unnecessary treatment
and increases in medical costs, which can be an impedi-
ment to treatment optimization. Therefore, it is critical
for all clinicians involved in the management of sepsis to
understand when and how to collect culture specimens.
In general, sepsis is to be suspected, and blood culture
examinations are to be performed proactively in patients
presenting with suspected symptoms of bacteremia
(fever, chills, hypotension, tachypnea, etc.), hypothermia
and hypotension of unknown cause, altered conscious-
ness (particularly in elderly patients), unexplained
increase or decrease in leukocyte count, unexplained
metabolic acidosis or respiratory failure, acute renal
damage, or acute liver damage of unknown origin in
immunocompromised patients [13].
Disinfectants used on the skin include chlorhexidine
gluconate, povidone iodine, and 70% alcohol, but their
effectiveness in suppressing potential contaminants has
not been established. According to a small-scale meta-
analysis [14] comparing alcohol-containing chlorhexi-
dine gluconate with povidone iodine, chlorhexidine
gluconate was shown to decrease contamination, but
some of these studies used 2% chlorhexidine gluconate,
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which is not used in Japan. Povidone iodine requires
approximately 2 min to take effect, and there is the con-
cern that medical staff tasked with collecting specimens
may not wait for a sufficient amount of time [15]. In
contrast, alcohol-containing chlorhexidine gluconate has
both immediate and sustained effects. Ensuring an asep-
tic procedure is crucial [16].
Because the quantity of bacteria in the blood during
sepsis is very small, the sensitivity of blood cultures de-
pends on the amount of blood collected [17]. It has been
reported that sensitivity increases by 10% if the quantity
of the blood sample increases from 40 to 60 mL [18],
but this increment in sensitivity gets smaller as more
blood is collected. In addition, as the volume of blood
collected increases, the risk of iatrogenic anemia
becomes a concern. In general, a blood sample volume
of 20 to 30 mL per set is recommended [15].
Cockerill et al. examined 163 patients presenting with
bloodstream infections (excluding infective endocarditis)
and collected more than two sets of blood cultures
within 24 h; the test sensitivity was 65.1% for the first
set, 80.4% for the first and second sets, and 95.7% for
three sets [17]. In addition, Lee et al. examined 629 pa-
tients whose blood culture tests yielded positive results
after three or more sets were collected within 24 h; the
sensitivity was 73.1% for the first set, 89.7% for the first
and second sets, and 98.2% for the three sets [19]. Based
on the above data, we conclude that a minimum of two
sets (three sets, if possible) should be collected within
24 h. A further increase in test sensitivity should not be
expected if the number of sets collected exceeds three. If
infective endocarditis is suspected, three sets must be
collected within 24 h [20].
In cases where catheter-related bloodstream infections
are suspected (signs of local infection, long-term
indwelling catheter, frequent use of stopcocks, catheter
occlusion, thrombus formation, etc.), one set of blood
culture should be aspirated from the catheter lumen. If
the test results from the catheter and peripheral vessels
are positive for the same pathogen, and the former
returns positive earlier by more than 2 h, the catheter is
considered to be the source of infection [21, 22]. Many
bacterial species from resident cutaneous flora can cause
contamination. Examples are coagulase-negative staphylo-
cocci, Bacillus, Corynebacterium, and Propionibacterium.
If test results are positive for these bacteria after 48–72 h
for only from one sample bottle or set, contamination
should be suspected [15].
Although there is no scientific basis for collecting
specimens from possible foci of infection prior to
administering antimicrobial agents, this practice is rec-
ommended in many guidelines [23–27]. De-escalation
based on the culture results is expected to reduce costs
and adverse events and prevent the emergence of
resistant bacteria without increasing the harm to pa-
tients. Therefore, it is reasonable to collect specimens
from suspected foci of infection prior to the administra-
tion of antimicrobial agents, so as not to decrease detec-
tion sensitivity.
Sputum can be contaminated together with the resi-
dent flora of the upper respiratory tract. In severe cases
of pneumonia, sputum cultures (specimens collected by
intratracheal aspiration if tracheal intubation is per-
formed), as well as urinary antigen testing for Legionella
pneumophila and Streptococcus pneumoniae, may be
performed in addition to blood culture [24]. When
switching to broad-spectrum antimicrobials in the man-
agement of hospital-acquired pneumonia or ventilator-
associated pneumonia, specimens should be taken from
the lower respiratory tract before switching to different
antimicrobials [25].
Urine specimens should also be taken before adminis-
tering antimicrobials. When interpreting test results, it is
necessary to differentiate urinary tract infection from
asymptomatic bacteriuria [26].
If a lumbar puncture is required, and can be per-
formed quickly, cerebrospinal fluid should be collected
prior to antimicrobial administration. However, bacterial
meningitis requires urgent treatment, and if lumbar
puncture cannot be performed for some reason, admin-
istration of antimicrobials should be given priority [27].
Even in such cases, blood cultures should be collected
prior to the administration of antimicrobial agents [28].
The practice of referring to Gram stain findings when
selecting empiric antimicrobial agents has been widely
adopted in Japan, and this practice is considered to have
some validity from the pathophysiological standpoint as
well. However, in general, the sensitivity and specificity
of Gram stain findings are greatly affected by the quality
of the specimen (i.e., presence or absence of contamin-
ation) as well as the level of experience of the assessor.
As such, when referring to Gram stain results in anti-
microbial agent selection, one should keep these factors
in mind.
CQ 2-1: When and how should a blood culture be taken?
Answer (opinion)
A blood culture should be taken prior to antimicrobial ad-
ministration in patients with sepsis or septic shock (expert
consensus/no evidence) (rate of agreement, 100%).
Rationale
No randomized controlled trial (RCT) was found to
conform to the Patient, Intervention, Comparison, Out-
come (PICO) process. The diagnosis of bacteremia forti-
fies the diagnostic accuracy of infection. Identifying the
causative microorganisms and subsequently performing
antimicrobial susceptibility tests lead to treatment
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optimization. However, as the volume of the blood
collected increases so does the risk of iatrogenic anemia,
but the benefits of taking a blood culture are considered
to outweigh the potential risks in all cases of sepsis.
Also, because the detection sensitivity is not expected to
increase beyond three culture sets, oversampling should
be avoided.
CQ 2-2: When and how should culture specimens other
than blood be collected?
Answer (opinion)
In patients presenting with sepsis or septic shock, various
culture specimens other than blood may be collected as
necessary prior to administering antimicrobials (expert
consensus/no evidence) (rate of agreement, 100%).
Rationale
No RCT conforming to the PICO process has been iden-
tified. Substantial benefits can be obtained from the cul-
ture results of suspected site of infection. Such benefits
are thought to outweigh the potential risks in any case
of sepsis. However, as there are risks associated with this
procedure, specimens should not be collected unless the
collection site is suspected to be a focus of infection.
CQ 2-3: Is Gram staining useful in the selection of anti-
microbial agents before obtaining culture results?
Answer (opinion)
When selecting antimicrobial agents for empiric treat-
ment, Gram staining may be considered (expert consen-
sus/no evidence) (rate of agreement, 100%).
Rationale
No RCT conforming to the PICO process has been identi-
fied; thus, the risk-benefit balance is unknown. However,
favorable specificity has been reported in community-
acquired pneumonia, urinary tract infections, and bacter-
ial meningitis. Considering the simplicity, rapidity, and
low costs associated with this technique, the benefits may
sufficiently outweigh any potential risks.
CQ3: Imaging diagnoses
Introduction
In sepsis, rapid therapeutic intervention to treat the
focus of infection is recommended [29, 30]. Therefore,
detecting the sites of infection is critical. Detection of
the sites of infection based on physiological findings and
culture tests from each suspected region is essential for
determining the intervention. Thus, the following
clinical question (CQ) concerning imaging diagnoses is
presented.
First, the question of whether imaging diagnoses
should be performed is addressed. There have been no
studies conducted to date that examine whether any
difference in prognosis can be obtained as a result of
performing diagnostic imaging, and such a study is not
expected to be conducted in the future. However, in the
clinical setting, some types of imaging examinations are
routinely performed depending on the disease and the
suspected sites of infection. The following paragraphs
offer an explanation for specific diagnostic imaging
techniques relevant to each organ and their associated
diseases.
In bacterial meningitis, it is generally accepted not to
perform a routine cranial computed tomography (CT)
scan prior to lumbar puncture. However, performing
brain CT examinations is recommended in patients
presenting with altered consciousness, neurological
symptoms, convulsions, and in patients over 60 years of
age [31]. In addition, magnetic resonance imaging (MRI)
yields more informative results than CT images and are
excellent for evaluating the spread of lesions. Fluid
attenuation inversion recovery (FLAIR) images are also
useful for identifying sites of inflammation [32].
Diagnoses based on transesophageal echocardiography
following transthoracic echocardiography is recom-
mended in cases where infective endocarditis is sus-
pected, particularly those involving prosthetic valve
replacement, when the clinical criteria indicate a strong
possibility of infective endocarditis, or in high-risk cases
accompanied by complications such as annular abscess
[33]. Performing a contrast-enhanced CT scan is neces-
sary to determine the drainage range for deep cervical
abscesses and descending mediastinitis. If symptoms do
not improve, a second contrast-enhanced CT scan
should be performed to identify the spread of the ab-
scess, after which prompt source control should be
taken [34]. Chest x-rays are important when diagnosing
respiratory infections. Pulmonary CT scans can also be
used to diagnose pleural effusion, atelectasis, and tumor-
ous lesions that are difficult to distinguish via chest
x-ray, and the use of this technique is recommended as
an auxiliary diagnostic method under the acute respira-
tory distress syndrome (ARDS) diagnostic criteria (Berlin
definition) [35].
For the diagnosis of intraperitoneal infections, abdom-
inal ultrasonography and abdominal CT examinations
are useful for identifying the origin of infection and are
recommended in line with relevant guidelines and treat-
ment policies [36]. Diagnostic imaging using ultrasound
is recommended in cases of acute suppurative cholan-
gitis, and reaching a definitive diagnosis via CT or mag-
netic resonance cholangiopancreatography (MRCP) is
important when local complications such as perforation
or abscess formation are suspected [37]. In cases of
sepsis caused by urinary tract infection (caused by a kid-
ney stone or indwelling catheter) or infection of the
male genitalia, the source of infection can be identified
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through abdominal ultrasonography or abdominal CT
examination [38]. Although kidney, ureter, and bladder
simple X-ray image (KUB) is useful in diagnosing condi-
tions such as kidney stones, performing a CT scan is
necessary for evaluation of perinephric inflammation. It
has also been reported that ultrasonography can be
utilized to assess the presence of hydronephrosis or
nephromegaly and may also be useful as a diagnostic
imaging method in cases of obstructive urinary tract
infections [39].
There are no randomized controlled trials (RCTs) evalu-
ating the validity of whole body contrast-enhanced CT
examination in patients without apparent infectious foci.
Yanagawa et al. have reported in a retrospective study that
the detection rate for infectious foci was 38.8% when esti-
mating by chief complaints and physical examination find-
ings, whereas it increased to 88.8% when using whole-
body contrast-enhanced CT examination in geriatric
patients with suspicion of infection [40].
In addition, in a retrospective study by Just et al.,
examining emergency room patients for whom the
origin of infection was unknown [41], out of 144 CT
photographs taken, infectious foci were identified in 76
(52.8%), of which 65 (85.5%) had undergone surgery in
connection with the change in treatment plan. Based on
the above, an expert consensus that performing whole-
body contrast CT examination is recommended when
the infectious focus is unknown was reached.
It is known that the availability of CT apparatus per
population is much higher in Japan in comparison
with Europe and the USA. Therefore, it can be pre-
sumed that imaging by whole body contrast-enhanced
CT when the foci of infection are unknown is easy to
perform. However, the risk of contrast-induced ne-
phropathy (CIN) may increase. No RCT has been
conducted to evaluate the relationship between the
administration of contrast media and CIN in patients
with sepsis or septic shock. Therefore, the existence
of a causal relationship is not clear. In a systematic
review/meta-analysis performed in 2013, McDonald
et al. [42] found that the relative risk (RR) of acute
kidney injury (AKI) development, requiring intermit-
tent hemodialysis, and mortality were 0.79, 0.88, and
0.95, respectively, and no significant differences were
observed (15,582 patients exposed to contrast agents,
10,368 patients not exposed.). Ng et al. [43] and
Polena et al. [44] have reported in retrospective
studies that the incidence of AKI development after
contrast media administration did not increase in
ICU patients. Therefore, it is unlikely that the fre-
quency of the onset of AKI increases after intraven-
ous administration of a contrast agent in comparison
to patients who were not injected with a contrast
agent.
However, the guideline for the use of iodine contrast
medium in patients with kidney injury [45] states that in
patients with impaired renal function, (1) reduction in
the amount of contrast agent used and (2) performing
fluid transfusion prior to conducting the contrast CT
may reduce the likelihood of CIN onset. Nevertheless,
because there is a large amount of information concern-
ing CT examination using a contrast agent and this
technique is an important method of diagnosing infec-
tions and determining a therapeutic approach, there is
no need to hesitate to perform contrast-enhanced CT
examinations due to concern over the onset of CIN.
CQ 3-1: Should imaging examinations be used to diagnose
the foci of infection?
Answer (opinion)
The use of imaging examinations is recommended in the
diagnosis of the foci of infection in sepsis/septic shock
patients (expert consensus/no evidence) (rate of agree-
ment, 100%).
Rationale
There is currently no supporting RCT that conforms to
the PICO process, and there is little evidence available
in support of performing diagnostic imaging. The detec-
tion of infectious foci is important in sepsis and septic
shock. If the diagnosis of an infectious focus can be
performed accurately through imaging, the optimal
treatment method can be selected, and unnecessary
treatments can be avoided. However, various complica-
tions may also occur, such as allergic reaction to the
iodine-based contrast agents, impaired renal function, or
gadolinium-based contrast-associated nephrogenic sys-
temic fibrosis, and caution is required when treating
patients who are at risk. In addition, there are some con-
cerns that the condition of patients with unstable
hemodynamics and respiration might worsen when they
are transported to the examination room. In consider-
ation of the above, in patients with sepsis and septic
shock, “performing imaging examinations for diagnosis
of infectious foci is recommended (expert consensus)”
while paying attention to the complications and dangers
associated with patient transportation.
CQ 3-2: Can early-stage (whole body contrast) CT
examination be useful when the foci of infection are
unknown?
Answer (opinion)
Performing early (whole-body contrast enhanced) CT
examination is recommended to aid in diagnosing the
foci of infection in patients with sepsis/septic shock (ex-
pert consensus/no evidence) (rate of agreement, 89.5%).
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Rationale
There is no RCT that conforms to the Patient, Interven-
tion, Comparison, Outcome (PICO) process, and the
evidence for performing whole-body contrast-enhanced
CT at an early stage is poor. The diagnosis of the foci of
infection is important for the diagnosis of sepsis/septic
shock, but sometimes, it is difficult to determine the
origin of infection based on simple CT examination
alone. Infectious foci become apparent on contrast-
enhanced CT images, which can lead to the selection of
a more effective treatment for the infection. However,
various complications may also occur, such as allergic
reaction to the iodine-based contrast agent, impaired
renal function, or gadolinium-based contrast-associated
nephrogenic systemic fibrosis, and caution is required
when treating at-risk patients. In sepsis and septic shock,
“performing CT scans (whole body contrast enhanced)
at an early stage is recommended (expert consensus).”
while paying ample attention to possible complications.
CQ4: Controlling the origin of infection
Introduction
The two basic principles guiding the approach to con-
trolling infectious foci are that measures should be taken
“early” and should be “effective while minimally inva-
sive.” This guideline offers a discussion about determin-
ing the source of infection, which is key to controlling it.
In addition, the following five examples of infection
sources are evaluated: (1) intra-abdominal infection, (2)
infectious pancreatic necrosis, (3) vascular catheter-
associated infection, (4) acute pyelonephritis resulting
from ureteral obstruction, and (5) necrotizing soft tissue
infection. The clinical questions (CQs) accompanying
this guideline were formulated based on these discussion
components. It was concluded that each infection source
exhibits clear and distinct characteristics after compiling
research findings regarding their respective methods of
control. As having a deep understanding of these charac-
teristics is believed to be helpful when attempting to
control infections, specific details of each example are
provided in their corresponding CQ.
No randomized controlled trial (RCT) has been con-
ducted to date to compare the prevalence of surgery to
address intra-abdominal sepsis between two groups.
However, prospective multicenter observational studies
examining factors related to outcomes of cases of gener-
alized peritonitis have reported that the success or fail-
ure in controlling the foci of infection has the highest
odds ratio pertaining to patient outcome [46]. The
Surviving Sepsis Campaign Guidelines (SSCG) 2012 [23]
as well as guidelines published by the Infectious Diseases
Society of America (IDSA) and the Surgical Infection
Society (SIS) regarding intra-abdominal infections [47]
each emphasize the importance of achieving adequate
control of intra-abdominal infections sources. As no
RCT demonstrating the efficacy of achieving early con-
trol of infected lesions has been conducted to date, this
guideline discusses the results of a systematic review and
one observational study. This study targeted cases in
which intra-abdominal infection persisted following sur-
gical intervention, and conducted a two-group compari-
son of the elapsed time until reoperation. The results
indicated that the mortality rate was lower in the group
that underwent reoperation sooner [48]. In addition, the
30-day mortality rate rises by 2.4% for each hour treat-
ment is delayed for an intra-abdominal infection arising
from peptic ulcer perforation [49], and extension of the
preoperative period has been linked to poor outcomes in
patients presenting with septic shock caused by gastro-
intestinal perforation [50]. Accordingly, achieving con-
trol of the focus of infection as soon as possible is
considered to be the favored approach when treating
cases of sepsis arising from intra-abdominal infection.
Regarding the classification of local pancreatic compli-
cations accompanying acute pancreatitis, in the 2012
revision of the Atlanta Classification [51], peripancreatic
fluid collections can be categorized into “fluid collec-
tions” pertaining to the liquid component only (which
causes interstitial edematous pancreatitis), or “necrotic
collections” (occurring after the onset of necrotizing
pancreatitis), referring to solid components mixed with
necrotic materials and liquids. “Fluid collections” may be
further categorized as acute peripancreatic fluid collec-
tions within the first 4 weeks after onset and pseudo-
cysts after the first 4 weeks, and “necrotic collections”
may be categorized as acute necrotic collections within
the 4 weeks after onset and walled-off (pancreatic)
necrosis after the first 4 weeks. In addition, infectious
pancreatic necrosis has been reported to be accompan-
ied by acute necrotic collections or bacterial/fungal
infections in conjunction with walled-off necrosis as
described previously [51]. Based on this classification,
any significance of performing early (within 72 h after
onset) surgery in necrotizing pancreatitis cases can be
ruled out with respect to achieving control of the source
of infection, and reports state that as a general rule, con-
servative treatment should be offered, and interventional
treatment is appropriate when necrotizing pancreatitis is
complicated by infection (infectious pancreatic necrosis).
Therefore, both the timing of treatment and method
were evaluated in the context of controlling the source
of infection in cases of infectious pancreatic necrosis.
An indwelling vascular catheter can be a source of
infection. Accordingly, a CQ was prepared to examine
the types of cases in which early removal of a vascular
catheter is recommended after it is determined to be a
source of infection. Early removal of a vascular catheter
is limited to cases where bloodstream infection has been
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confirmed or when a patient’s hemodynamics have
become unstable with the aim of reducing instances of
unnecessary removal of vascular catheters, which is
believed to reduce both medical costs and risks to pa-
tients associated with reinsertion. According to the 2009
IDSA guideline [52], routine catheter removal should
not be performed (B-II) in ICU patients based solely on
the observation of novel fever symptoms not accom-
panying severe sepsis or bloodstream infection findings.
However, in the event of other unexplained sign of sepsis
or redness/suppuration at the catheter insertion site, the
central venous catheter (and the arterial catheter if
placed) should be removed (B-II). Based on these recom-
mendations, early removal of vascular catheters is
believed to be beneficial only for patients in whom a
vascular catheter was placed as part of sepsis treatment
where bloodstream infection has been confirmed or
where hemodynamics have become unstable, and not
when a bloodstream infection is merely suspected.
Pyelonephritis caused by obstruction of the ureter is
one of the several conditions requiring control of the
source of infection. No RCTs were found to examine
whether infections in patients who developed sepsis due
to pyelonephritis caused by ureteral obstruction should
be controlled more quickly. However, removal of the
ureteral obstruction can be an effective means of con-
trolling the infection source, and therefore, reopening
the ureter as quickly as possible is believed to be benefi-
cial. Guidelines published by the American Urological
Association and the European Association of Urology
[53–55] both recommend swift cystectomy at grade A in
cases of sepsis caused by urinary tract obstruction due
to ureteral calculus, and although there is no RCT-based
evidence, the importance of taking action quickly is
widely accepted. Treatment methods for this condition
also include percutaneous nephrostomy and transureth-
ral ureteral stent placement. While target patients are
those who have contracted infection as a result of
ureteral calculus obstruction rather than sepsis patients,
both methods were shown to be equally effective in a
small-scale RCT conducted by Pearle et al. [56] (1998,
enrolling a total of 42 subjects). Both of the guidelines
mentioned previously [53–55] also support this result.
Based on these observations, it is believed that quickly
achieving control of the origin of infection through
approaches such as percutaneous nephrostomy or trans-
urethral ureteral stent placement is beneficial in cases of
sepsis caused by acute pyelonephritis arising from
ureteral obstruction.
No RCT could be found that compared the usefulness
of achieving early source control in sepsis caused by
necrotizing soft tissue infection, although there exist
guidelines [57, 58] and a review [59] on this subject.
Although early diagnosis and administration of broad-
spectrum antimicrobials can be effective in improving
the prognosis of patients with necrotizing soft tissue
infection, when treating patients with organ dysfunction
arising from necrotizing soft tissue infection, that is,
patients with sepsis, surgical intervention including swift
and aggressive drainage of infected lesions is recom-
mended by two different guidelines [57, 58]. A review
study examining the timing of surgical procedures also
suggests that initiating surgery within 24 h after diagno-
sis can improve the mortality rate by approximately 20%
more than surgeries performed after this period [59]. If
clinical symptoms persist after surgery, practical
guidelines [57] recommend performing reoperation
while continuing antimicrobial administration for an
additional 24–36 h. Based on the above, it is believed
that surgery should be initiated at the earliest opportun-
ity in cases of sepsis arising from necrotizing soft tissue
infection.
CQ4-1: What approach should be taken to control the
source of intra-abdominal infection?
Answer (opinion)
Controlling the source of infection as soon as possible is
recommended in cases of sepsis arising from intraperito-
neal infection (expert consensus/quality of evidence “D”)
(rate of agreement, 100%).
Rationale
No RCTs conforming to the Patient, Intervention, Com-
parison, Outcome (PICO) process could be found, and
so, a systematic review of observational studies was con-
ducted. As a result, one observational study was
extracted [48]. If sepsis arises from an intraperitoneal in-
fection, controlling the source of infection at an early
stage may improve patient outcome. Performing surgery
to control the infection is invasive to the patient, but it
is believed that no side effects will result if the surgery is
performed early. Based on this study, it was concluded
that performing an early surgery may improve patient
outcomes and that the benefits to patients outweigh the
potential harms.
CQ4-2: What approach should be taken to control the
source of infectious pancreatic necrosis?
Answer (recommendations and opinion)
We suggest the following:
1. Waiting to perform interventional treatment until
week 4 after onset that acute necrotic collections
become walled-off, in cases of sepsis arising from
infectious pancreatic necrosis with stable general
condition (2C) (rate of agreement, 100%)
2. Performing interventional treatment without waiting
until week 4 after onset, in cases of sepsis arising
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from infectious pancreatic necrosis with unstable
general condition (expert consensus/no evidence)
(rate of agreement, 100%)
3. Performing drainage first (percutaneously or
endoscopically) and then resection of necrotic tissue (via
retroperitoneal or endoscopic approaches) if
improvement is not seen (2C) (rate of agreement, 100%)
Rationale
Infectious pancreatic necrosis is a disease in which the
early initiation of intervention, the usual principle in
controlling the source of infection, does not apply. In an
RCT comparing mortality rates with regard to differ-
ences in the timing of treatment approaches to control
the source of infection [60], 36 patients presenting with
severe necrotizing pancreatitis were included in the early
intervention group and underwent necrotic tissue resec-
tion 48–72 h after onset, while the late intervention
group underwent surgery 12 days after onset. As a result
of the comparison, the mortality rate was lower in the
late intervention group compared to the early interven-
tion group [60]. Two RCTs have been reported on the
treatment of infected pancreatic necrosis [61, 62]. In the
first RCT, the minimally invasive step-up approach to
treating infectious pancreatic necrosis was compared
with open necrosectomy, and no significant difference in
mortality rates was observed (19 vs. 16%). However, the
ICU stay times and hospitalization times associated with
the minimally invasive step-up approach tended to be
shorter. Regarding the frequency of complications, few
incident cases of multiple organ failure or general com-
plications, intraperitoneal bleeding requiring treatment,
enterocutaneous fistula requiring treatment, or perfor-
ation into intraperitoneal organs were observed in the
minimally invasive step-up approach group (a significant
difference was observed with respect to the incidence of
multiple organ failure and systemic complications). The
second RCT was a comparison of endoscopic transgas-
tric necrosectomy and surgical necrosectomy. As a
result, it was found that the mortality rate was lower in
the endoscopic transgastric necrosectomy group, and
the incidence of complications such as multiple organ
failure, intraperitoneal bleeding requiring treatment,
enterocutaneous fistula requiring treatment, perforation
into intraperitoneal organs, and pancreatic fistula was
low in the endoscopic transgastric necrosectomy group.
A significant difference was observed with respect to the
incidence of multiple organ failure and pancreatic
fistulas. Although there was no difference in survival
outcomes between these two RCTs, the effectiveness of
a minimally invasive approach was demonstrated by the
reduction in the incidence of complications.
Based on the above observations, controlling infected
lesions in patients with sepsis due to infectious
pancreatic necrosis by first performing drainage (percu-
taneously or endoscopically) and then resecting necrotized
tissue (via retroperitoneal or endoscopic approaches) is
considered to be beneficial.
CQ4-3: What circumstances call for the early removal of
vascular catheters in patients with sepsis?
Answer (recommendation)
We suggest removing vascular catheters only when blood-
stream infection is suspected (2D) (rate of agreement,
94.7%).
Rationale
One RCT [63] was found as the result of a comprehen-
sive literature search. In this study of 144 patients in
whom vascular catheter-related bloodstream infection
was suspected, 64 patients (excluding 80 cases predicted
to have been caused by vascular catheter infection) were
divided into two groups (with 32 patients each). As a re-
sult, no significant difference in ICU mortality rate was
observed. Accordingly, unnecessary vascular catheter re-
movals can be reduced by restricting early withdrawals
to cases when bloodstream infection is confirmed or
when the patient becomes hemodynamically unstable.
Such measures can be expected to lead to reductions in
medical costs and risks arising from catheter reinsertion.
However, it has been reported that after a catheter-
related bloodstream infection is diagnosed, removal of
the catheter within 24 h is associated with improved
patient outcomes [64]. Based on these observations, the
early removal of a vascular catheter from a patient with
sepsis is considered to be beneficial only in cases where
a bloodstream infection has been confirmed, or the
patient has become hemodynamically unstable.
CQ4-4: What approach should be taken to control the
source of infection in cases of sepsis arising from acute
pyelonephritis resulting from ureteral obstruction?
Answer (opinion)
Controlling the source of infection as quickly as possible
via percutaneous nephrostomy or transurethral ureteral
stent placement is recommended in cases of sepsis arising
from acute pyelonephritis caused by ureteral obstruction
(expert consensus/no evidence) (rate of agreement, 94.7%).
Rationale
As no RCTs conforming to the PICO process could be
found, this CQ referred to the American Urological
Association (AUA) guidelines [53]. When considering
the treatment of acute pyelonephritis caused by ureteral
obstruction as well as the costs of transporting patients
to specialist facilities, it is believed that the potential
benefits obtained by performing a percutaneous
nephrostomy or transurethral ureteral stent placement
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likely outweigh potential complications such as bleeding
or the spreading of infection to the retroperitoneum.
CQ4-5: What approach should be taken to control the
source of necrotizing soft tissue infection?
Answer (opinion)
Proceeding with early surgical intervention is recom-
mended in cases of sepsis arising from necrotizing soft
tissue infection (expert consensus/no evidence) (rate of
agreement, 100%).
Rationale
No RCTs conforming to the PICO process could be
found. When complicated by organ failure due to necro-
tizing soft tissue infection (i.e., cases of sepsis) it is likely
that initiating surgical intervention including aggressive
and early drainage of the infected lesion will be more
beneficial to the patient. Although there is a risk of harm
caused by the surgery, the benefits outweigh the risk,
compared to when surgery is not performed despite the
development of sepsis. Therefore, although no RCT
conforming to the PICO process could be found, it was
concluded that there is a strong possibility that the
benefits outweigh the potential harms.
CQ5: Antimicrobial therapy
Introduction
Antimicrobial therapy is an essential fundamental com-
ponent in the management of sepsis. One concern re-
lated to antimicrobial use is the threat of drug-resistant
bacteria. The excessive use of antimicrobials is linked to
a greater risk of loss of effective drugs in the future due
to the emergence of drug-resistant bacteria. These
guidelines were formulated with specific regard to the
management of sepsis cases and do not offer guidance
related to antimicrobial drug selection. However, the
selection of antimicrobials in sepsis cases is similar in
principle to the treatment of general infections. Antimi-
crobials should be selected based on factors such as the
patient’s background, organs suspected to be affected,
epidemiological information pertaining to the region and
the medical facility, and recent history of antimicrobial
use, after anticipating to the extent possible the specific
microbial strain to be targeted, as well as any drug resis-
tances. However, prompt administration of an effective
antimicrobial targeting the causative microorganism is
more critical in comparison to non-severe cases. The
issue of microbial drug resistance also warrants consid-
eration, and consultation with an infectious disease
specialist is also important at facilities where such spe-
cialists are available.
The evidence currently available for the clinical ques-
tion (CQ) “Should antimicrobial therapy be initiated
within 1 hour?” was reexamined and a recommendation
offered by the Guideline Creation Committee. According
to the results of a retrospective cohort study, the mortal-
ity rate among septic shock patients increases by 7.6%
for each hour antimicrobial administration is delayed
[65]. In addition, in emergency outpatient sepsis cases,
time to initiation of antimicrobial therapy and patient
mortality were factors related to the severe patient group
[66]. Contrastively, in a meta-analysis of observational
studies, no benefit was found with respect to mortality
risk in patients who received antimicrobial drugs within
1 h of shock onset [67]. However, we believe that aban-
doning the widely accepted clinical target of initiating
antimicrobial therapy within 1 h based on the results of
a meta-analysis of observational studies is inappropriate.
Combination therapy in the context of antimicrobial
therapy refers to antibiotic combination therapy target-
ing Gram-negative bacilli. In addition to the therapeutic
effects of combination therapy, the recommendation was
evaluated with emphasis on the potential risks of treat-
ment, such as kidney injury. As a result, these guidelines
recommend against the routine use of combination ther-
apies. However, physicians should decide whether to use
such therapies on a case-by-case basis when handling re-
fractory infection cases involving multidrug-resistant
Gram-negative bacilli, origination from artificial mate-
rials, or immunocompromised patients.
Regarding the various types of antifungal therapy, a
CQ specifically addressing anticandidal therapy was
judged to be beyond the scope of these guidelines on the
reasoning that such infections and other fungal infection
cases requiring intensive care were infrequent and that
expert knowledge and experience may be required
depending on the decisions made regarding the
initiation of treatment. Known risk factors for deep
Candida infection include deposition of live Candida
into the body, artificial ventilation, high Acute Physi-
ology and Chronic Health Evaluation (APACHE) II
score, use of broad-spectrum antimicrobials, use of im-
munosuppressants, central venous catheter use, total
parenteral nutrition, neutropenia (< 500/mm3), recent
surgery (especially gastrointestinal surgery), renal failure,
hemodialysis, malnutrition, severe acute pancreatitis,
diabetes, recent organ transplantation, indwelling
urinary catheter use, advanced age, chemotherapy, ma-
lignant tumor presence, and the use of antacids [68–71].
The combined use of anticandidal drugs as well as con-
ventional antimicrobials should be considered when
handling sepsis cases involving patients exhibiting more
than one of these risk factors. Whether physicians
should consider serum (1-3)-β-D-glucan values when
determining whether to add anticandidal drugs when
treating sepsis patients exhibiting the aforementioned
risk factors remains unclear and is a question to be
addressed in the future.
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The bactericidal action and therapeutic effects of
β-lactam drugs correspond to periods when the drug
serum concentration exceeds the minimum inhibitory
concentration (MIC) of the target bacteria. In view of
this characteristic, extended infusion time or continuous
infusion lengthens the drug’s time above MIC (the
proportion of time within a 24-h period during which
drug serum concentration exceeds the applicable MIC),
and these techniques are expected to result in superior
clinical efficacy [72]. In environments such as the inten-
sive care unit (ICU) in particular, pathogenic bacteria
tend to exhibit a higher MIC, raising concern that inter-
mittent infusion, a standard practice in many care
settings, will be unable to achieve sufficient time above
MIC [73]. The respective efficacy profiles of the continu-
ous infusion, extended infusion, and intermittent infu-
sion methods of drug administration were evaluated
during meta-analysis, and as a result, no significant
differences were observed between ICU mortality rate,
in-hospital mortality rate, and rate of achievement of the
target drug serum concentration. Accordingly, we
believe that consideration of utilizing continuous infu-
sion of β-lactam antibiotics has low significance.
As there are some concerns regarding the safety of the
de-escalation approach in Japan, we decided to offer
recommendations after reorganizing our findings. De-
escalation is supported by the results of numerous ob-
servational studies. The first randomized controlled trial
(RCT) enrolling sepsis patients, albeit in a small number,
was completed only recently, and as a result, de-
escalation had no observable impact on either total ICU
stay time or 90-day mortality rate [74]. Based on the
above, de-escalation can be assumed to be safe, and
these guidelines suggest that physicians implement
de-escalation in the usual manner.
Decreased procalcitonin (PCT) levels have been re-
ported to be linked to a lower risk of mortality [75–77],
and active research efforts have focused on instances
where the decision to discontinue antimicrobial therapy
regimens is made based on a protocol using PCT values
to determine whether the period of antimicrobial drug
use can be shortened without negatively influencing
turning points in a patient’s course. We referred to nine
RCT reports during our meta-analysis on this topic
[78–86]. No significant differences were observed between
the intervention and control groups with respect to ICU
stay time, hospitalization period, 60-day mortality rate,
and 90-day mortality rate. However, a significant improve-
ment in the 28-day mortality rate was observed. The dur-
ation of antimicrobial use in days was also significantly
shortened. Based on the above, the use of PCT values in
determining whether to discontinue antimicrobial therapy
in sepsis cases is suggested, as the potential benefits out-
weigh the potential risks.
Typical antimicrobial treatment periods and the ratio-
nales for decisions to discontinue such treatment in sep-
sis cases may differ by country. Meanwhile, no Japanese
RCTs investigating the discontinuation of antimicrobial
therapy based on PCT values have been completed to
date. Whether basing discontinuation decisions on PCT
values can reduce the period of antimicrobial use or im-
prove survival prognosis also remains unclear in sepsis
treatment in Japan. We expect that research in these
areas will progress in the years to come.
Lastly, it is known that the pharmacokinetic properties
of antimicrobial drugs can change drastically in sepsis
patients as a result of vital reactions and therapeutic in-
terventions [87]. As such, it may become necessary to
reduce or increase dosage or to extend or shorten the
administration interval more than has conventionally
been believed when treating sepsis patients. Although
this is a critical area of concern, current research activity
is inadequate. Because of this, we determined that a rec-
ommendation and a CQ addressing this topic could not
be offered at this time.
CQ5-1: Should antimicrobial therapy be initiated within
1 h after recognition of sepsis?
Answer (opinion)
Sepsis and septic shock patients should begin receiving
an effective antimicrobial within 1 h (expert consensus/
no evidence) (rate of agreement, 100%).
Rationale
Initiating antimicrobial therapy within 1 h when hand-
ling sepsis cases is now recommended in the Surviving
Sepsis Campaign Guidelines based on the results of
observational studies and has gained global acceptance.
However, it is also true that there is no particularly
strong basis for this recommendation, as no relevant
RCTs have been completed to date. As such, although
we have strong reservations regarding the possibility of
negatively impacting patient prognosis by refraining
from promptly administering antimicrobials in sepsis
cases, we decided that it was necessary to offer our opin-
ion as a target although it comes in the form of an
expert consensus.
No RCTs investigating the impact of antimicrobial ad-
ministration within 1 h could be found, and only results
of observational studies were considered as evidence.
Although the results of multiple observational studies
indicate that initiation of antimicrobial therapy within
1 h or earlier reduces the risk of mortality, no significant
improvement in mortality risk was observed in a system-
atic review of such observational studies [67].
Initiating antimicrobial therapy within 1 h after diag-
nosis may contribute to a lower risk of mortality, and no
associated adverse effects have been reported. The
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increased burden placed on medical staff when anti-
microbial therapy is ordered to be initiated within 1 h
after diagnosis arising from the need to prioritize the
corresponding preparatory tasks over others (e.g., con-
firmation of drugs dispensed and transportation from
the hospital pharmacy) may be considered as an
assumed burden. Another obstacle is the issue of space
limitations for drug storage accompanying the need to
routinely prepare a variety of antimicrobials for emer-
gency outpatients. Even with the above considered, we
believe that the potential benefits of this practice likely
exceed any potential harms.
CQ5-2: Should combination therapy be used when
administering empirical antimicrobial therapy in sepsis
cases?
Answer (recommendation)
We recommend against routinely administering anti-
microbial combination therapy when treating infections
caused by Gram-negative bacilli (1B) (rate of agreement,
89.5%).
Rationale
In the past, there has been a view that combination ther-
apies using antimicrobial drugs for sepsis and septic
shock cases, especially in the treatment of Gram-
negative bacilli, will expand the antimicrobial spectrum
and that a synergistic effect should be expected. How-
ever, due to the considerable risks associated with anti-
microbial combination therapies, it was important to
present an opinion based on clear reasoning that was
also reflective of the realities of clinical practice.
We referred to a single meta-analysis that verified the
effects of using aminoglycosides in combination with
β-lactam drugs [88]. No difference in mortality rate was
observed for monotherapy in comparison to combin-
ation therapy, but a significant increase in the frequency
of kidney injury, believed to be a side effect of aminogly-
coside antimicrobials, was observed with respect to the
use of combination therapy. In addition to this meta-
analysis, another RCT verified the effect of using a quin-
olone antimicrobial (moxifloxacin) in combination with
a carbapenem (meropenem), a β-lactam antibiotic [89].
This study found that while mortality rate remained
unchanged as a result of using this combination therapy,
the frequency of side effects associated with these drugs
increased.
No significant difference in mortality rate was ob-
served between the intervention and control groups in
this study, and apart from there being no observable
benefit, the frequency of kidney injury was significantly
higher in patients receiving combination therapy com-
pared with those who received monotherapy only. The
development of new onset kidney injury may increase
patient burden as well as medical costs as a result of the
greater need for related treatment interventions. In
addition, in consideration of the time and cost of
prescribing, dispensing, and administering multiple anti-
microbials, the potential harms associated with this
practice clearly outweigh the benefits.
CQ5-3: In what situations should anticandidal drug
therapy be initiated?
Answer (opinion)
The administration of anticandidal drugs in addition to
general antimicrobials should be considered when treat-
ing sepsis and septic shock patients exhibiting multiple
risk factors for invasive candidiasis (expert consensus/no
evidence) (rate of agreement, 78.9%).
Rationale
It is known that the Candida genus of fungi is a primary
cause of fungal sepsis, and also that the mortality rate asso-
ciated with candidemia is higher than the rates attributed
to other forms of bacteremia. Despite this, candidiasis is
also frequently overlooked. As such, it is necessary to estab-
lish criteria for administering anticandidal drugs when
handling cases refractory to conventional antimicrobial
therapies.
No RCTs evaluating the use of anticandidal drugs in
sepsis cases could be found, and the evidence considered
for this CQ considered candidemia or invasive candidia-
sis. Multiple observational studies have been conducted
with respect to the known risk factors for these condi-
tions, and risk factors specific to ICU patients have also
been reported. In addition, the sensitivity and specificity
of (1-3)-β-D-glucan, a serum biomarker, have also been
evaluated in the context of invasive candidiasis.
The administration of antifungal drugs following risk
assessment may improve patient prognosis in invasive
candidiasis or candidemia cases, but at the same time,
poses a risk of adverse reactions. However, no assess-
ment of this risk as it pertains to sepsis patients has been
conducted to date. In consideration of the above, we be-
lieve that the potential benefits of anticandidal drug use
likely outweigh the potential risks.
CQ5-4: Should β-lactam drugs be continuously infused or
should their infusion period be extended when treating
sepsis or septic shock patients?
Answer (recommendation)
We suggest against administering β-lactam drugs using
continuous infusion or extended infusion periods when
treating sepsis and septic shock patients (2B) (rate of
agreement, 100%).
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Rationale
To date, intermittent administration of antimicrobial
drugs has been a common practice. However, it has been
found that time-dependent β-lactam drugs may be more
effective in terms of pharmacokinetic characteristics
when administered continuously or over an extended
period. Verification of the efficacy of continuous infusion
of β-lactam drugs may lead to improved patient out-
comes in sepsis cases and is considered to be an import-
ant clinical issue.
We referred to four RCT reports [72, 90–92]. Among
these studies, no significant differences were observed be-
tween the respective study groups with respect to 90-day
mortality rate (odds ratio, 0.94; 95% confidence interval
(CI) 0.69–1.28, p = 0.68), ICU mortality rate (odds ratio,
0.79; 95% CI 0.59–1.06, p = 0.11), in-hospital mortality
rate (odds ratio, 0.78; 95% CI 0.59–1.03, p = 0.08), or
target serum drug concentration achievement rate (odds
ratio, 1.88; 95% CI 0.89–3.98, p = 0.10).
Although decreased mortality frequency is an antici-
pated benefit of this intervention, no significant differ-
ences were observed between the intervention and
control groups in any study regarding 90-day mortality
rate, in-hospital mortality rate, and ICU mortality rate.
In addition, no significant differences were observed
with regard to target serum drug concentration achieve-
ment rate. However, although no evaluation of side
effects was conducted, because β-lactam drugs are nor-
mally administered to ICU patients via intravenous infu-
sion, we believe that few burdens that arise from this
intervention warrant consideration. We have determined
accordingly that the risks and benefits associated with
this intervention are comparable.
CQ5-5: Is de-escalation a recommended approach with
respect to antimicrobial therapy for sepsis and septic
shock patients?
Answer (recommendation)
We suggest the use of de-escalation in conjunction with
antimicrobial therapy administered to sepsis and septic
shock patients (2D) (rate of agreement, 84.2%).
Rationale
Although broad-spectrum antimicrobials are frequently
given at an early stage to address sepsis cases in the
ICU, this practice is linked to the appearance of drug-
resistant bacteria and accompanying increases in medical
costs. As such, the capacity to de-escalate, or switch
treatment regimens from broad-spectrum antimicrobials
to drugs with narrower therapeutic indices, without risk-
ing patient safety, can be regarded as a favorable practice
from the perspectives of both infection control and
medical economics.
We referred to one RCT report [74]. No significant
differences were observed with respect to 90-day mortal-
ity rate between the two groups, and a significant
increase in the frequency of coinfection was observed in
the de-escalation group.
The primary benefit expected as a result of de-
escalation is the prevention of the development of drug-
resistant bacteria, but this outcome could not be evalu-
ated based on this body of evidence. Meanwhile,
although de-escalation did not increase mortality rate,
the results suggested that it may increase patients’ risk
of contracting coinfections. However, all of the evidence
considered originated from a single RCT; thus, we
believe this body of evidence lacks the strength neces-
sary to constitute a basis for overriding the notion that
de-escalation can be implemented safely, which is based
on the results of observational studies conducted to
date. In consideration of the above, we have determined
that the potential benefits of de-escalation likely exceed
any potential harms.
CQ5-6: Should PCT values be used as an index to
determine whether to discontinue antimicrobial therapy?
Answer (recommendation)
We suggest using PCT values as an index when deter-
mining whether to discontinue antimicrobial therapy
administered to address sepsis or septic shock (2B) (rate
of agreement, 78.9%).
Rationale
The measurement of PCT levels has become feasible in
routine treatment, and studies investigating the use of
PCT values in cases of infection have also increased;
RCTs examining the discontinuation of antimicrobial
therapy in accordance with the PCT guide have been
conducted. However, there is still a paucity of high-
quality systematic reviews of the subgroup of these RCTs
that focused on sepsis cases. To establish criteria for
discontinuing antimicrobial therapy in sepsis cases, the
validity of interventions calling for antimicrobial therapy
discontinuation based on PCT values, particularly those
accumulated by RCTs, must be evaluated.
We referred to nine RCT reports [78–86]. No signifi-
cant differences were observed between the intervention
and control groups with respect to ICU stay time,
hospitalization period, 60-day mortality rate, and 90-day
mortality rate, but significant improvement in 28-day
mortality rate was observed. The number of days of
antimicrobial drug use also decreased significantly (a
meta-analysis was conducted only with respect to studies
that clearly described the mean administration period.
Significant reduction in the number of days of therapy
was also observed in the studies providing median value
data). In the intervention group, no significant increase
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in mortality rate or the period of antimicrobial drug use
was observed in comparison to the control group.
Potential harms could not be considered as no other side
effects were assessed. PCT is measured in conjunction
with other blood parameters and can be grouped among
routine blood tests. As such, we believe that this inter-
vention adds minimal additional burden, and its poten-
tial benefits likely exceed any potential harms.
CQ6: Intravenous immunoglobulin therapy
Introduction
Intravenous immunoglobulins (IVIGs) comprise anti-
bodies specific to various bacteria, toxins, and viruses. In
addition to exerting an opsonic effect and complementary
component activation when bound to antigen particles,
IVIGs also have a neutralizing effect on toxins and viruses
and inhibit inflammatory cytokines [93, 94]. In 60% of
septic shock patients, apparent hypogammaglobulinemia
(serum IgG level < 650 mg/dL) is present from the begin-
ning, due to suppressed immunoglobulin production,
protein leakage, and exhaustion [95]. Although serum IgG
level has been linked to the incidence of shock and mor-
tality rate of patients entering the intensive care unit
(ICU) [96], IVIG administration, when used in combin-
ation with adequate antibiotics and appropriate fluid
resuscitation, may improve the survival of patients with
sepsis [97].
According to the results of a study conducted by
Masaoka et al. [98] in Japan, IVIG is listed in the National
Health Insurance Registry as a supplementary treatment
for severe infections, and as such, IVIGs are often admin-
istered in patients with severe sepsis/septic shock. A logis-
tic regression analysis to investigate whether early IVIG
administration within 48 h of onset affects the 28-day sur-
vival rate of patients with septic shock was conducted by
the Special Sepsis Registry Committee of the Japanese
Association for Acute Medicine using the data of 624
patients with severe sepsis between May 2009 and May
2011. Early IVIG administration was found to be an
independent factor contributing to improved prognosis
(odds ratio, 1.904, 95% confidence interval (CI) 1.044–
3.471, p = 0.036) [99], supporting the assertion that IVIG
administration results in improved prognosis in cases of
severe sepsis. In contrast, Tagami et al. used Diagnosis
Procedure Combination (DPC)-based data of patients
with septic shock requiring mechanical ventilation to
extract 1081 cases involving emergency laparotomy to ad-
dress lower gastrointestinal perforation [100] and 1045
cases of severe pneumonia [101] and examined the 28-day
mortality rate through propensity analysis. As a result,
Tagami et al. reported no significant improvement in the
IVIG administration group (emergency laparotomy: IVIG
group 20.6% vs. control group 19.3%; 95% CI − 2.0–4.5;
severe pneumonia: IVIG group 36.7% vs. control group
36.0%; 95% CI − 3.5–4.8). However, DPC data alone does
not give detailed information such as the definition of sep-
sis, the severity (Acute Physiology and Chronic Health
Evaluation II score), and the time to administration of
IVIGs after the onset of sepsis. Although there are reports
suggestive of a prognostic improvement effect based on
large-scale retrospective studies, this effect has not yet
been established.
CQ6-1: Should IVIG be administered to adult patients
with sepsis?
Answer (opinion)
The prognostic improvement effect of IVIG administra-
tion in adult patients with sepsis is unknown based on the
current randomized controlled trial (RCT) results avail-
able, and accordingly, clear recommendations pertaining
to IVIG administration cannot be offered (expert consen-
sus/quality of evidence “C”) (a rate of agreement of 67%
or higher in support of its use could not be obtained).
Rationale
While formulating this clinical question, it was consid-
ered to be critical to examine the effectiveness of im-
munoglobulin administration to patients with sepsis
while considering benefits based on reductions in all-
cause mortality rate, ICU mortality rate, and ICU treat-
ment period, and side effects caused by IVIG administra-
tion as potential harms.
In the literature search, 978 references are screened
without limits on investigation period, the severity of
sepsis, or IVIG dosage. Six papers were secondarily ex-
tracted via peer review of abstracts [98, 102–106]. The
all-cause mortality rate in the IVIG group was signifi-
cantly lower than that of the control group (n = 6, risk
ratio, 0.7 [95% CI 0.56–0.95]) and the ICU mortality rate
was also significantly lower (n = 1, risk ratio 0.71 [95%
CI 0.60–0.84]). Reduced ICU stay time, which was the
second most important and significant benefit, was also
shortened significantly (n = 3, mean difference: − 3.71
[95% CI − 7.32 to − 0.09]). There was no significant
increase in the risk ratio for the onset of side effects due
to IVIG administration (1.63, 95% CI 0.65–4.11). The
side effects were minor symptoms such as skin rash, and
no serious cases or deaths were reported. IVIG adminis-
tration to adult patients with sepsis resulted in improved
all-cause mortality and ICU mortality rates and also sig-
nificantly shortened ICU stay time without increasing
the frequency of side effects in comparison to the con-
trol group.
When considering the benefit-risk balance in terms of
outcomes, although there was an increase in complica-
tions, emphasis was placed on reduction in the all-cause
mortality rate and ICU mortality rate, and it was deter-
mined that the potential benefits likely outweigh the
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potential harms. However, members of the guideline
committee expressed concerns about the quality of the
systematic review and the body of evidence. Another
body of evidence was proposed by the Academic Guide-
lines Promotion Team that narrowed the subjects to
cases of severe sepsis, and the internal peer review team
proposed the 2013 Cochran Review [107]. The team re-
sponsible for immunoglobulin treatments suggested that
“IVIGs may be administered to adult patients with sepsis
(2C (weak))”, but only a 63.2% agreement was obtained
in the initial vote of the committee. The reasons for this
were as follows: (1) we could not evaluate the effect as
there were no new studies with current sepsis definitions
and standard treatment and (2) although ICU mortality
rates were improved based on the three bodies of
evidence presented, there was no consistency with re-
gard to evidence for the benefit in the 28-day mortality
among the three bodies of evidence. The rate of agree-
ment was still 63.2% after the second committee vote,
and the required proportion for agreement of an over
two-thirds majority was not obtained. The guideline
committee reached an expert consensus that “the prog-
nostic improvement effect of IVIGs in adult patients
with sepsis is unknown based on the RCT results cur-
rently available, and a clear recommendation concerning
IVIG administration cannot be presented at this time.”
CQ7: Initial resuscitation/inotropes
Introduction
In response to infection, various self-defense mediators
are released. These mediators dilate peripheral vessels,
resulting in a relative decrease in intravascular volume. As
such, the treatment strategy for septic shock is focused on
early-stage control of infection (administering antimicro-
bials, gaining control of infected lesions) and appropriate
control of circulation (improving cardiac output and
oxygen supply, managing tissue hypoperfusion).
According to a meta-analysis assessing goal-directed
therapy (GDT) that set target values and circulatory
management for septic shock, the mortality rate was not
reduced by achieving the goals alone, but was reduced if
the goal was achieved within 6 hours [108]. Stated differ-
ently, time is a critical factor with respect to the effect-
iveness of initial resuscitation in septic shock. The early
goal-directed therapy (EGDT) capable of improving tis-
sue hypoperfusion within 6 h introduced by Rivers et al.
[109] was strongly recommended in both the Surviving
Sepsis Campaign Guidelines (SSCG) 2012 [29] and the
Japanese Clinical Practice Guidelines for the Manage-
ment of Sepsis and Septic Shock (1st edition) [2]. How-
ever, the three large-scale randomized controlled trials
(RCTs) (Protocolized Care for Early Septic Shock
(ProCESS) [110], Australasian Resuscitation in Sepsis
Evaluation (ARISE) [111], and Protocolised Management
in Sepsis (ProMISe) [112]) subsequently reported in
2014 and 2015 failed to demonstrate the usefulness of
EGDT. As such, the guideline committee for this clinical
question (CQ) conducted a systematic review based on
the question, “CQ7-1: Is EGDT recommended for initial
resuscitation in patients with sepsis or septic shock?”
The EGDT discussed herein refers to the resuscitation
method proposed by Rivers et al. [109] (calling for initial
fluid resuscitation and administration of vasoconstrictors
with the goal of achieving a central venous pressure
(CVP) of 8–12 mmHg, mean arterial pressure ≥
65 mmHg, urine volume ≥ 0.5 mL/kg/h, and ScvO2 ≥
70% within 6 h).
A detailed assessment of these RCTs [110–112] re-
vealed that large-volumes of fluid (crystalloid solution
30 mL/kg or more) had already been given before proto-
col initiation. Therefore, the guideline committee for this
CQ concluded that the methods of initial fluid resuscita-
tion should be assessed separately from the EGDT inter-
vention, and the next CQ was presented, “CQ7-2: What
volume of fluid should be given in the initial resuscita-
tion of patients with septic shock?”
Septic shock may be attributed not only to a relative
decrease in intravascular volume associated with vaso-
dilatation but also to a type of cardiomyopathy known as
sepsis-induced myocardial dysfunction (SIMD) [113,
114]. Therefore, “CQ7-3: Should cardiac function be
assessed using echocardiography when initiating fluid re-
suscitation in sepsis?” was presented, but no RCT con-
forming to the Patients, Intervention, Comparison,
Outcome (PICO) process was found for this CQ.
The following two CQs were presented with regard to
the fluid of choice for initial resuscitation and subse-
quent intravascular volume replacement in patients with
septic shock, “CQ7-4: Should a crystalloid solution or an
artificial colloidal solution be used in the initial fluid re-
suscitation?” and “CQ7-5: Should albumin solution be
used during the initial resuscitation fluid in septic
shock?” During the first public comment for CQ7-5, it
was pointed out that the directions of the recommenda-
tions offered and the results of the accompanying sys-
tematic review regarding mortality rate appeared to
differ. The guideline committee reevaluated the evidence
originating from the RCTs conforming to the PICO
process only and found a slight improvement in survival
associated with albumin administration. However, the
strength of this evidence was considered to be weak, and
albumin use in this context was found to have only a
limited effect. The strength of the recommendation of-
fered was determined by considering the potential for
complications such as unknown infections and allergies
caused by blood products. However, because the situa-
tions differ for patients requiring substantial amounts of
crystalloids until shock recovery and those who develop
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hypoalbuminemia, we considered it necessary to deal
with them separately and added an expert consensus.
With respect to monitoring during initial resuscitation,
the following question, “CQ7-6: What method should be
used to predict fluid responsiveness during initial resus-
citation?” was presented, and five RCTs conforming to
the PICO process were analyzed. There were four inter-
ventions involving assessment through passive leg rais-
ing (PLR), one intervention involving assessment
through transpulmonary thermodilution, and two inter-
ventions (including redundancies) involving assessment
through stroke volume variation (SVV). While a meta-
analysis was performed for each method of assessment,
the meta-analysis conducted for this CQ was unable to
show any improvement in prognosis. The intrathoracic
blood volume index obtained through the pulmonary
thermodilution method [115] as well as dynamic param-
eters such as SVV and pulse pressure variation have
been reported to be more useful for the prediction of
fluid response than CVP [116]. However, caution is war-
ranted when interpreting these findings, as test reliability
is poor in patients with arrhythmias such as atrial fibril-
lation, patients with spontaneous respiration, and
patients with restrictions in tidal volume during mech-
anical ventilation due to acute respiratory distress
syndrome. PLR also has poor reliability in patients with
elevated intra-abdominal pressure [117].
The practice guidelines reported so far [2, 29] have
highlighted the importance of measuring lactate levels as a
marker of tissue hypoperfusion. This guideline also presents
the following CQs, “CQ7-7: Should lactate levels be used as
an indicator during initial resuscitation in sepsis?” and
“CQ7-8: ScvO2 or lactate clearance: which is more useful as
an indicator of initial resuscitation?” A systematic review
was performed on the above CQs, but since only one RCT
conforming to the PICO process could be found (Jones
et al. [118]), it was judged that offering guidance at the rec-
ommendation level would be difficult for these CQs.
Regarding cardiovascular agents used in the manage-
ment of septic shock, we considered two kinds of cardio-
vascular agents, vasopressors (dopamine, noradrenaline,
adrenaline, vasopressin), and an inotropic drug (dobuta-
mine). A systematic review and meta-analysis were per-
formed for the CQ “CQ7-9: Noradrenaline or dopamine:
which should be used as a first-line vasopressor to treat
patients with septic shock that are unresponsive to initial
fluid resuscitation?” In addition, the subsequent two
CQs are presented to address situations where noradren-
aline use does not achieve a sufficient increase in blood
pressure, “CQ7-10: Should adrenaline be used in septic
shock when noradrenaline fails to improve the blood
pressure?” and “CQ7-11: Should vasopressin be used in
patients with septic shock who fail to achieve the target
blood pressure despite the use of noradrenaline?”
Because the difference between the usage of adrenaline
and vasopressin has not been established in the contents
of the above CQ and an expert consensus, a brief sup-
plement is provided on this topic. In septic shock, des-
pite appropriate fluid resuscitation and noradrenaline
administration, the following factors can create difficulty
in maintaining hemodynamics: (1) difficulty in control-
ling peripheral vascular resistance accompanying vaso-
dilatation (relative hypovolemic shock) [119] and (2)
cardiac dysfunction associated with SIMD (cardiogenic
shock) [113, 114]. These pathologies can be distin-
guished relatively easily through echocardiography.
Administering adrenaline as well as a small amount of
vasopressin (0.03 units/min) and noradrenaline is effect-
ive for patients exhibiting relative circulating hypovol-
emic shock (vasodilatory shock). On the other hand, in
cases of cardiogenic shock, administering adrenaline to
obtain a cardiac contractile potentiating effect (β1-recep-
tor stimulating action) can be effective, but administer-
ing vasopressin, which does not yield this effect, may
cause further exacerbation of this pathological state lead-
ing to cardiogenic shock. For these reasons, appropriate
vasopressors should be selected after assessing cardiac
preload and contractility via techniques such as echocar-
diography in septic shock.
Meanwhile, it has been reported that in septic shock,
intracellular signaling mediated by β1 adrenergic recep-
tors is impaired due to early-phase pro-inflammatory
cytokines, impeding the ability of dobutamine to im-
prove cardiac function [120, 121]. As such, with respect
to dobutamine, an inotropic drug, the following CQ,
“CQ7-12: Should dobutamine be used in patients with
septic shock who show evidence of cardiac dysfunction?”
was presented and a systematic review was conducted.
The 28-day mortality rate in the RCTs [122, 123] was
41.9% in the control group (adrenaline group) and 36.7%
in the intervention group (dobutamine group) (p = 0.31),
and dobutamine was demonstrated to be comparable or
non-inferior to adrenaline. According to the SSCG 2012
[29], dobutamine use is recommended (grade 1C) (a)
when cardiac function is declining and (b) in amounts of
up to 20 μg/kg/min when low perfusion persists despite
adequate fluid resuscitation. However, the Japanese
Clinical Practice Guidelines for the Management of
Sepsis and Septic Shock (1st edition) [2] states that, “As
improvement of reduced cardiac function is difficult to
achieve with dobutamine in septic shock, combined
administration with a phosphodiesterase III inhibitor or
a calcium sensitivity enhancer should be considered as
an alternative.” One RCT (the LeoPARDS (Levosimen-
dan for the Prevention of Acute oRgan Dysfunction in
Sepsis) trial) to evaluate calcium sensitivity enhancers in
patients with sepsis was performed recently, but no
prognostic improvement effect was observed [124]. It
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was determined that the quality of the evidence support-
ing the recommendation of these drugs is currently poor,
and accordingly, this guideline does not include a CQ on
their use. Meanwhile, regarding the usefulness of
β-blockers in septic shock, Morelli et al. [125] conducted
an RCT evaluating ultra-short-acting β-blockers, and
Wang et al. [126] conducted an RCT investigating the
efficacy of combination therapy of an ultra-short-acting
β-blocker and a phosphodiesterase III inhibitor. In both
of these studies, it was found that the use of β-blockers
resulted in a reduced mortality rate, suggesting the pos-
sibility that β-blockers may have effects beyond rate con-
trol. However, for reasons such as the fact that the
evidence supporting the usefulness of β-blockers in
septic shock is still somewhat controversial [127], this
guideline does not include a CQ regarding their use.
The recommendations and expert consensus concern-
ing initial resuscitation and cardiovascular agents with
respect to septic shock presented in this guideline are
based on the RCTs and/or systematic reviews that have
been reported so far. However, the treatment of sepsis
can vary significantly depending on the level of care
offered by a given facility and the level of knowledge and
skills of the attending physician and staff. This guideline
related to sepsis and septic shock should be used wisely
with these things in mind. Time is a critical factor with
respect to the effectiveness of initial resuscitation and
cardiovascular agents in septic shock, and it is important
to fully understand that “sepsis is an emergency” and to
treat patients with septic shock promptly.
CQ7-1: Is EGDT recommended for initial resuscitation in
patients with sepsis or septic shock?
Answer (recommendation)
We suggest against the use of EGDT when performing
initial resuscitation in patients with sepsis or septic
shock (2A) (rate of agreement, 100%).
Rationale
Three RCTs [110–112] conforming to the PICO process
were identified based on a search of the PubMed data-
base and were used in the final analysis for this CQ.
Regarding the 90- and 28-day mortality rates, EGDT
was not effective in improving mortality rate in compari-
son to the standard treatment (90-day mortality rate:
risk ratio 0.98 (95% confidence interval (CI) 0.88–1.10);
28-day mortality rate: risk ratio 0.98 (95% CI 0.84–
1.13)). The time to shock reversal was not assessed by
any RCT. Regarding intensive care unit (ICU) length of
stay, the mean difference (MD) was 0.27 (95% CI −
0.33–0.87) in the comparison between the EGDT group
and the standard treatment group, and no significant
difference was observed.
Regarding the benefit-risk balance, no improvement in
mortality rate as a result of complying with EGDT was
observed in comparison to the standard treatment. In
addition, no shortening of ICU length of stay as a result
of complying with EGDT was observed (MD 0.27 (95%
CI − 0.33–0.87)), and no benefit of EGDT over the
standard treatment could be found. However, dobuta-
mine dosages and the quantity of blood transfused
increased significantly in the EGDT group [110, 111],
and due to the increased frequency of arrhythmias asso-
ciated with dobutamine, greater overall risk of side
effects associated with transfusions, and increased time
and quantity of work required of hospital staff, it is pos-
sible that compliance with EGDT may increase the risk
of harm (burden) faced by patients. Based on the above,
it was determined that the potential harms presented by
EGDT likely outweigh its potential benefits.
CQ7-2: What volume of fluid should be given in initial
resuscitation in septic shock?
Answer (opinion)
We suggest that 30 mL/kg or more of an extracellular
fluid replacement solution is administrated when per-
forming initial fluid resuscitation in patients with septic
shock with a relative decrease in intravascular volume
associated with vasodilatation (expert consensus/no
evidence) (rate of agreement, 100%).
Comment: 30 mL/kg or more of an extracellular fluid
replacement solution should be administered after asses-
sing the decrease in intravascular volume.
Rationale
No RCTs applicable to this CQ could be found as a re-
sult of a search of the PubMed database. As such, it was
concluded that an expert consensus should be offered,
as the evidence for this CQ is inadequate to support a
recommendation. In addition, in three large-scale RCTs
evaluating the effectiveness of EGDT (ProCESS [110],
ARISE [111], and ProMISe [112]), when the differences
in intergroup (EGDT group vs. standard treatment
group) total volume of fluid transfused prior to study
protocol initiation were calculated, the following differ-
entials were revealed: ProCESS (2.3 ± 1.5 L vs. 2.1 ±
1.4 L), ARISE (2.5 ± 1.2 L vs. 2.6 ± 1.3 L), and ProMISe
(1.9 ± 1.1 L vs. 2.0 ± 1.1 L). All the subjects had already
received over 30 mL/kg of crystalloid solution during
the initial resuscitation prior to group assignment.
Regarding the benefit-risk balance, the concept of
large-volume initial fluid resuscitation (infusion of
30 mL/kg or 2000 mL within approximately 1 h) became
recognized as a common sense approach based on the
conventional guidelines, and there is a possibility that
the prognosis of patients with sepsis may be improved
by supplementing the relative decrease in intravascular
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volume associated with vasodilatation and optimizing
the balance of tissue oxygen supply and demand as
quickly as possible.
On the other hand, excessive extracellular fluid replace-
ment may cause a deterioration in cardiac function (heart
failure) and pulmonary function (pulmonary edema).
Frequent assessment of hemodynamics is necessary to
avoid excessive volume loading, which may increase the
burden on medical staff. The cost of extracellular fluid
replacement solution may be a burden on the intervention
group but is relatively low. Based on the above consider-
ations, it was concluded that the benefits of administering
30 mL/kg or more of an extracellular fluid replacement
solution during the initial resuscitation in septic shock
clearly outweigh the potential risks.
CQ7-3: Should cardiac function be assessed using
echocardiography when initiating fluid resuscitation in
sepsis?
Answer (opinion)
We suggest the cardiac function using echocardiography
is assessed when initiating fluid resuscitation in patients
with sepsis (expert consensus/no evidence) (rate of
agreement, 100%).
Comment: The assessment of cardiac function using
echocardiography discussed in this CQ indicates the
simple evaluation of cardiac function performed at the
bedside. It is focused on cardiac function (movement of
the heart), and measurements related to vascular (infer-
ior vena cava diameter, intracardiac volume) intended to
afford an approximate assessment of intravascular vol-
ume prior to initiating resuscitation. It is desirable that
all physicians, and not just cardiologists, involved in the
resuscitation of patients with sepsis be proficient with
this technique.
Rationale
Although a literature search was conducted to identify
RCTs examining whether the assessment of cardiac
function using echocardiography affects the prognosis of
patients with sepsis undergoing initial resuscitation, no
RCTs pertaining to this CQ could be found. Therefore,
it was concluded that an expert consensus should be
offered as the evidence for this CQ is inadequate to
support a recommendation.
Regarding the benefit-risk balance, although no sup-
porting evidence could be found, assessing cardiac func-
tion and intravascular volume using echocardiography
when initiating resuscitation in patients with sepsis is
useful in determining the infusion rate and in catechol-
amine selection. Therefore, it is believed that conducting
this assessment will lead to more appropriate fluid resus-
citation and drug administration. Echocardiography
assessment is simple and non-invasive, and little patient
burden for physicians is associated with the intervention
itself. In institutions that do not routinely use echocardi-
ography for assessment, the use of this technique will
require additional time and may contribute to delays in
initiating resuscitation. In addition, the price of most
echocardiography devices is in the range of several
million yen (approximately USD 77,000), and thus, the
financial burden placed on facilities will be substantial
when purchasing a new device. However, such devices
have high versatility, are believed to be adequate for
their desired uses, and are cost-effective. Therefore, it
was concluded that the benefits of assessing cardiac
function using echocardiography when initiating resusci-
tation in patients with sepsis clearly outweigh the poten-
tial harms.
CQ7-4: Should a crystalloid solution or an artificial
colloidal solution be used in the initial fluid resuscitation?
Answer (recommendation)
We suggest against the use of an artificial colloidal solu-
tion during the initial resuscitation of patients with sepsis
or septic shock (2B) (rate of agreement, 89.5%).
Rationale
Nine RCTs [128–136] were identified as a result of the
systematic review [137] conducted for this CQ. The
effect of infusing an artificial colloidal solution on the
risk ratios for the different mortality rates examined
were as follows: ICU mortality rate, 0.56 (95% CI 0.34–
0.94); 28-day mortality rate, 1.11 (95% CI 0.96–1.28);
and 90-day mortality rate, 1.14 (95% CI 1.04–1.26). The
impact on other risk ratios examined was as follows:
acute kidney injury (AKI) incidence risk ratio, 1.32 (95%
CI 1.09–1.60); renal replacement therapy (RRT) per-
formance risk ratio, 1.46 (95% CI 1.21–1.77); red blood
cell (RBC) transfusion risk ratio, 1.19 (95% CI 1.04–
1.36); and fresh frozen plasma transfusion risk ratio, 1.18
(95% CI 0.94–1.49). Although ICU mortality rate de-
creased because of artificial colloidal solution use, the
90-day mortality rate, AKI incidence rate, RRT perform-
ance rate, and the RBC transfusion rate each increased
significantly.
Regarding the benefit-risk balance, it is difficult to
determine whether mortality rate will improve by using
an artificial colloidal solution during the initial fluid
resuscitation, as the AKI incidence risk ratio, the RRT
performance risk ratio, and the RBC transfusion risk
ratio each increased significantly. The cost of artificial
colloidal solutions is higher than crystalloid solutions
and may cause allergies, which can place an additional
burden on the intervention group. Based on the above,
it was determined that the potential harms associated
with the use of artificial colloidal solution likely out-
weigh the potential benefits.
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CQ7-5: Should albumin solution be used during the initial
resuscitation in septic shock?
Answer (recommendation and opinion)
We suggest against the routine use of albumin solution
during the initial resuscitation of patients with sepsis (2C).
The administration of albumin solution may be consid-
ered when large volumes of crystalloid solution are required
for resuscitation, or when hypoalbuminemia is observed
(expert consensus/no evidence) (rate of agreement, 94.7%).
Rationale
A search of the PubMed database was conducted using
the keywords “sepsis,” “septic shock,” and “albumin.”
Five systematic reviews and one new RCT (CRISTAL
(Colloids Versus Crystalloids for the Resuscitation of the
Critically Ill) trial [138]) were extracted. The systematic
reviews [139] and RCT [138] found using the most re-
cent literature search period and that scored highly on
the AMSTAR (A Measurement Tool to Assess System-
atic Reviews) measurement tool (9 points) were adopted
as high-quality studies for this CQ.
Among these studies, only the SAFE (Saline Versus
Albumin Fluid Evaluation) 2011 study [140] was identi-
fied as an applicable RCT. No significant difference be-
tween the mortality risk ratio of 0.87 (95% CI 0.74–1.02)
and ICU length of stay of 0.7 (95% CI − 0.10–1.50) was
observed. No assessment was carried out regarding time
to shock reversal.
Regarding the benefit-risk balance, although there was a
tendency for a decrease in mortality rate, no significant
difference was observed between the albumin and control
groups. In addition, several complications, including infec-
tion and allergic reactions, may occur following albumin
administration. Based on these findings, the potential risks
for the albumin use as a standard resuscitation fluid likely
outweighed the potential benefits.
CQ7-6: What method should be used to predict fluid
responsiveness during initial fluid resuscitation?
Answer (opinion)
We suggest that the combination of multiple monitoring
methods is used while considering the limitations of
each indicator, for predicting fluid responsiveness during
initial fluid resuscitation in patients with sepsis and sep-
tic shock (expert consensus/quality of evidence “C”)
(rate of agreement, 94.7%).
Comment: The evidence was insufficient to support
the recommendation of specific monitoring techniques
to be used during initial resuscitation in patients with
sepsis and septic shock.
Rationale
Two hundred seventy reports were identified as a result
of a search for studies assessing survival in sepsis and
septic shock patients who had undergone initial fluid re-
suscitation using various monitoring methods. After pri-
mary and secondary screening, five RCTs were extracted
and used in the analysis [141–145]. Four RCTs included
evaluation of PLR, one for transpulmonary thermodilu-
tion, and two for SVV; a meta-analysis was performed
for each evaluation method.
No significant effect on the defined outcomes for ana-
lysis (mortality rate, ICU length of stay, time to shock
reversal) was observed for these three evaluation
methods. The monitoring methods used in the control
group also varied and “performance of initial resuscita-
tion without use of a specific monitoring method” estab-
lished as the control for PICO (C) was not adopted.
Therefore, it was determined that a serious issue regard-
ing indirectness existed. Because of the difficulty in
implementing study blinding, small sample size, the risk
of bias, and various inaccuracies, the quality of the study
was lowered, and the strength of this evidence was clas-
sified as weak (C) or very weak (D). Based on these find-
ings, it was decided that the current evidence was not
sufficient to support a recommendation and that an
opinion (expert consensus) would be presented.
Regarding the benefit-risk balance, central venous
catheters and arterial catheters are indwelled in most
cases, and the use of some form of monitoring and
optimization of infusion volume can result in improved
prognosis. Therefore, it was concluded that the benefits
of predicting fluid responsiveness during initial resusci-
tation likely outweigh the potential harms.
CQ7-7: Should lactate levels be used as an indicator
during initial resuscitation in sepsis?
Answer (opinion)
We suggest that lactate levels over time are used when
performing initial resuscitation in patients with sepsis (ex-
pert consensus/no evidence) (rate of agreement, 94.7%).
Rationale
Primary and secondary screening of literature (174
sources) obtained after a search was conducted. As no
RCTs applicable to this CQ (comparing lactate levels
over time during initial resuscitation in sepsis) could be
found, it was decided that an expert consensus would be
presented instead of a recommendation.
Regarding the benefit-risk balance, lactate levels are
associated with the patient’s prognosis in sepsis, and
measuring lactate levels can aid in identifying critically
ill patients. In addition, according to a report by Jansen
et al., as a result of comparing patients with a lactate
level of 3.0 mEq/L or higher (proportion of patients with
sepsis was approximately 40% in both groups) to a com-
parator group that underwent initial therapy with lactate
clearance as an indicator, no significant difference in in-
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hospital mortality rate was observed in a univariate ana-
lysis. However, in a multivariate analysis, in-hospital
mortality rate improved in the group in which lactate
clearance was used as an indicator [146]. Therefore,
performing initial resuscitation while monitoring and
assessing lactate levels over time may improve patient’s
prognosis in sepsis. Arterial punctures and invasive
arterial catheter insertion may also cause mechanical
complications such as hematoma and embolism as well
as infection, and in order to confirm lactate clearance,
frequently measuring and analyzing blood gas content
during initial resuscitation becomes necessary. However,
as monitoring through an arterial catheter is believed to
be performed in many patients, the quantity of blood
collected per measurement is small, and the burden on
patients appears to be minimal. Therefore, it was con-
cluded that the potential benefits of the use of lactate
levels as an indicator during initial resuscitation clearly
outweigh the potential harms.
CQ7-8: ScvO2 or lactate clearance: Which is more useful
as an indicator of initial resuscitation?
Answer (opinion)
Either ScvO2 or lactate clearance may be used as indica-
tors of initial resuscitation (expert consensus/quality of
evidence “D”) (rate of agreement, 94.7%).
Rationale
Only one RCT (Jones et al. [118]) comparing ScvO2 and
serum lactate values was identified, and there was no
significant difference in in-hospital mortality rates be-
tween using ScvO2 and lactate clearance to guide initial
resuscitation.
Regarding the benefit-risk balance, a specific central
venous catheter is needed for continuous ScvO2 moni-
toring. Collecting blood samples to evaluate ScvO2 or
lactate levels may increase the workload on physicians
and medical staff, as well as the risk of infection. How-
ever, the potential benefits were determined to outweigh
the potential harms since both measurements enable the
assessment of oxygen transport capacity in tissues.
CQ7-9: Noradrenaline or dopamine: Which should be
used as a first-line vasopressor to treat patients with
septic shock that are unresponsive to initial fluid
resuscitation?
Answer (recommendation)
We recommend the use of noradrenaline as a first-line
vasopressor to treat patients with septic shock that is
unresponsive to initial resuscitation (1B) (rate of agree-
ment, 100%).
Rationale
The systematic review reported by Avni et al. [147] was
adopted as evidence as it had the highest quality. A total
of 14 RCTs comparing noradrenaline and dopamine were
identified, but these studies did not examine the time
required to recover from septic shock. Noradrenaline ad-
ministration significantly improved the 28-day mortality
rate in comparison to dopamine (risk ratio, 0.89 [95% CI
0.81–0.98]). Regarding the ICU length of stay, the MD
was 1.01 (95% CI − 0.65–2.66) as a result of the compari-
son between noradrenaline and other vasopressors, and
no significant differences were observed. Regarding the in-
cidence of complications, noradrenaline use resulted in a
significantly lower incidence of complications compared
to dopamine (risk ratio, 0.34 [95% CI 0.14–0.84]).
Regarding the benefit-risk balance, noradrenaline use
resulted in a significant improvement in 28-day mortal-
ity rate in comparison to dopamine, and the frequency
of harmful complications (fatal arrhythmias, myocardial/
cerebral/upper, or lower limb ischemia/infarction, etc.)
was significantly lower. Therefore, it was concluded that
the potential benefits of noradrenaline use to treat
patients with septic shock clearly outweighed the poten-
tial harms.
CQ7-10: Should adrenaline be used in septic shock when
noradrenaline fails to improve the blood pressure?
Answer (opinion)
We suggest that adrenaline is used in cases in which the
maintenance of hemodynamic status is insufficient des-
pite appropriate fluid resuscitation and noradrenaline
administration (expert consensus/no evidence) (rate of
agreement, 100%).
Rationale
A literature search yielded 365 reports evaluating the
effects of adrenaline in septic shock when noradrenaline
fails to achieve a target blood pressure, and of these,
eight were identified through the primary screening. No
RCTs conforming to the PICO process for this CQ were
found.
Regarding the benefit-risk balance, no RCT was exam-
ined for this CQ. Adrenaline as a first-line vasopressor
has not shown significant improvements in mortality
rates in comparison with noradrenaline. However, 20–
40% of cases of septic shock are associated with SIMD
which predicts worse outcomes [148], and it has been
suggested that the administration of adrenaline may
improve cardiac function in cases complicated by SIMD
[149]. Although adrenaline use is associated with side
effects such as tachycardia, decreased tissue perfusion,
and lactate acidosis, no study has shown worse out-
comes following adrenaline administration. It was con-
cluded that the potential benefits of adrenaline use when
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noradrenaline fails to achieve target blood pressure
clearly outweighed the potential harms.
CQ7-11: Should vasopressin be used in patients with
septic shock who fail to achieve target blood pressure
despite the use of noradrenaline?
Answer (opinion)
We suggest that vasopressin is used in patients with sep-
tic shock who show evidence of persistent hypotension
despite adequate fluid resuscitation and the use of
noradrenaline (expert consensus/quality of evidence “B”)
(rate of agreement, 100%).
Rationale
A literature search yielded 365 records, and two RCTs
[150, 151] were extracted for the meta-analysis after
primary and secondary screening. ICU length of stay,
28-day mortality rate, and complication rate were assessed
in these two RCTs, but time to shock reversal was not
assessed. The risk ratios for 28-day mortality rate and
complication rate were 0.90 (95% CI 0.76–1.07) and 0.73
(95% CI 0.24–2.23), respectively. The MD in ICU length
of stay was − 0.95 days (95% CI − 1.73 to − 0.17).
In the two RCTs [150, 151], noradrenaline or nor-
adrenaline plus vasopressin was administered when
vasopressors were required to maintain target blood
pressure despite adequate fluid resuscitation. Compared
to using noradrenaline alone, the evidence of this sys-
tematic review and meta-analysis showed that adding
vasopressin decreased the ICU length of stay by 1 day,
but no difference was observed regarding 28-day mortal-
ity rate. In addition, no difference was observed in com-
plication rate between the two groups. Based on these
findings, it was concluded that the benefits of adding
vasopressin when using noradrenaline alone fails to
achieve target blood pressure likely outweigh the harms
of adding it.
CQ7-12: Should dobutamine be used in patients with
septic shock who show evidence of cardiac dysfunction?
Answer (opinion)
We suggest that dobutamine is used in septic shock when
cardiac function remains diminished, and maintenance of
hemodynamics is insufficient despite adequate fluid resus-
citation and noradrenaline administration (expert consen-
sus/quality of evidence “C”) (rate of agreement, 94.7%).
Rationale
Two RCTs [122, 123] were identified involving patients
with septic shock in whom blood pressure could not be
maintained with adequate fluid resuscitation and
noradrenaline administration and cardiac function was
normal or decreased. Adrenaline was administered to
the control group. The risk ratio with respect to 28-day
mortality rate was 0.88 (95% CI 0.69–1.13), and the inci-
dence rate of complications was 0.87 (95% CI 0.62–
1.22). The MD for the time to shock reversal and ICU
length of stay were −1.00 day (95% CI − 1.89 to − 0.11)
and 1.00 day (95% CI 0.33–1.67), respectively.
Regarding the benefit-risk balance, although the super-
iority of dobutamine versus adrenaline is not recognized,
the 28-day mortality rate remained at approximately
40% in the RCT including patients predicted to have a
very high risk of death, and as such, there appears to be
some benefit in administering dobutamine. There were
also no differences observed regarding the frequency of
complications such as arrhythmia in comparison to the
patients that received adrenaline. Based on the above ob-
servations, it was determined that the benefits of admin-
istering dobutamine likely outweigh the potential harms.
CQ8: Corticosteroid therapy for septic shock
Introduction
Cortisol is produced depending on the physiological
state of the body. Its production and secretion are
increased in response to various invasive insults for
maintaining homeostasis and is thus recognized as the
“stress hormone.” Corticosteroids have been used as an
adjunctive treatment for shock, since circulatory shock
often develops in cortisol-deficient patients, such as in
Addison’s disease and acute adrenal insufficiency.
In septic shock, apart from the insufficient cortisol
secretion (relative adrenal insufficiency), a reduction in
glucocorticoid receptor expression and their diminished
responsiveness are also observed, which may lead to the
so-called critical illness-related corticosteroid insuffi-
ciency (CIRCI) [152]. The administration of steroids
emerged as a treatment option suited to this particular
pathophysiology and was adopted into the Surviving
Sepsis Campaign Guidelines (SSCG) 2004 [153], accord-
ing to the concept of “relative adrenal insufficiency.”
Since then, however, the adrenocorticotropic hormone
(ACTH) stimulation test was proved not to be useful in
identifying corticosteroid-responsive patients, partly
because the concentration of free cortisol, actually
present in vivo, could not be measured or estimated by a
measurement of total cortisol concentration, and there-
fore, the rapid ACTH stimulation test was “not recom-
mended” (class 2B) in SSCG 2008 [154]. In studies
assessing the effect of low-dose corticosteroids in
patients with sepsis of various severities, their effective-
ness was observed only in critically ill patients with
septic shock [155, 156]. In 2016, Keh et al. showed that
the administration of corticosteroids to patients with
severe sepsis but without septic shock did not reduce
the incidence of shock and mortality rate by a random-
ized clinical trial (RCT) (the HYPRESS (Hydrocortisone
for Prevention of Septic Shock) randomized clinical trial)
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[157]. Based on these findings, the use of corticosteroids
is not recommended for septic patients, who are not in
shock or who have recovered from shock following
initial fluid resuscitation and administration of vasopres-
sors. Currently, low-dose corticosteroid therapy is indi-
cated in adult septic patients who are not responsive to
initial fluid resuscitation and remain in shock (systolic
blood pressure 90 mmHg or less) for more than 1 h re-
gardless of administration of high-dose catecholamines.
In addition to its effects as supplementary therapy,
corticosteroids downregulate the production of inflam-
matory cytokines by inhibiting the nuclear translocation
of NFκB and promote the recovery of catecholamine
receptor function.
Corticosteroids had been given to patients with septic
shock since the 1940s, and there was a time when this
approach received most clinicians’ and researchers’
attention. However, in 1987, Bone et al. showed that a
high-dose (also referred to as “pharmacological dose”)
corticosteroid regimen (methylprednisolone (MPSL)
30 mg/kg × 4/day) did not decrease the mortality rate,
but increased the incidence of adverse events, such as
gastrointestinal bleeding and hyperglycemia in an RCT
[158, 159]. Thus, after 2000, low-dose (also referred to
as “stress dose”) corticosteroid therapy (hydrocortisone
(HC) 200–300 mg/day) has become mainstream.
Although improvement in the proportion of shock re-
versal and shortening of the time to shock reversal have
been observed, conflicting results have been reported
with regard to mortality rate. In 2004, Annane et al.
published a meta-analysis, including their previous RCT
(French study) [156], which showed that low-dose
corticosteroids significantly decreased mortality rate, in
addition to an improvement in the proportion of shock
reversal, shortening of vasopressor therapy periods, and
without an increase in adverse events. In contrast, an
RCT, the Corticosteroid Therapy of Septic Shock (COR-
TICUS) study, with a sample size of 500, reported no
improvement in 28-day mortality rate and an increase in
the incidence of complications, including infection,
hyperglycemia, and hypernatremia in 2008 [157]. There
are criticisms that the severity of the condition of
patients enrolled into the CORTICUS study was lower,
while the timing of initial corticosteroid therapy was
later than those of the patients enrolled into the French
study.
During the long history of corticosteroid therapy for
sepsis, there have also been changes in the definition,
usual care, and the kind of corticosteroid used in sepsis.
The definitions for sepsis, severe sepsis, and septic shock
were proposed in 1992, and the usage of corticosteroid
has changed substantially from a high dosage to a lower
dosage since 2000. Usual care for patients with sepsis
has been standardized after the initiation of Surviving
Sepsis Campaign in 2004. Thus, we decided to assess
low-dose corticosteroid therapy by searching for RCTs
conducted on septic shock after 2004. The first clinical
question (CQ) on this topic is whether we should use
low-dose corticosteroid (HC) to treat adult patients with
septic shock (e.g., patients who are unresponsive to
initial fluid resuscitation and exhibit a systolic blood
pressure of 90 mmHg or lower for more than 1 h re-
gardless of the administration of high-dose vasopressors)
[160, 161]. The next practice-oriented CQs addresses
the three questions: “when should we administer corti-
costeroids?,” “what are the optimal dosage and adminis-
tration period?,” and “should we use HC among
commercially available corticosteroids?”
The largest scale double-blinded RCT is currently un-
derway in Australia, New Zealand, and Europe (Adjunct-
ive Corticosteroid Treatment in Critically Ill Patients
with Septic Shock (ADRENAL)) trial by Australian and
New Zealand Intensive Care Society (ANZICS), which
evaluated the 90-day mortality rate following low-dose
corticosteroid therapy (continuous intravenous adminis-
tration of hydrocortisone 200 mg/day for 7 days). It is
supposed to recruit 3800 patients with septic shock, and
its results are being awaited.
CQ8-1: Should we use low-dose corticosteroids (HC) for
adult patients with septic shock who are not responsive
to initial fluid resuscitation and vasopressors?
Answer (recommendation)
Corticosteroids should not be administered if patients
recover from septic shock with adequate fluid resuscita-
tion and vasopressor therapy. We suggest that a low-
dose corticosteroid (HC) is administered to promote
recovery from shock in adult patients with septic shock
that is not responsive to the initial fluid resuscitation
and vasopressors (2B) (rate of agreement, 94.7%).
Rationale
We searched for references published in 2004 or later,
when the standardized care for sepsis was introduced by
SSCG 2004 after being defined in 1992 as a systemic
inflammatory response syndrome (SIRS) accompanying
infection, with the keywords “septic shock” and “low-
dose steroid,” and identified eight RCTs (Bollaert et al.
[162], Briegel et al. [163], Chawla et al. [164], Annane
et al. [165], Oppert et al. [166], Mussack et al. [167],
Sprung et al. [156], and Arabi [168]). As these eight
studies were all included in the meta-analysis by Wang
et al. [160], we initially decided to use it for this CQ.
However, after a second search with the same keywords
at the end of December 2015, one new report by Gordon
et al. [161] was identified, and we thus performed a new
meta-analysis including this study.
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There were nine and six RCTs studying 28-day mortal-
ity rate and the proportion of shock reversal by day 7,
respectively. With regards to adverse events, six RCTs
analyzed infection, six assessed gastrointestinal bleeding,
and three assessed hyperglycemia. There were no prob-
lems regarding a risk of bias, inconsistency, or indirect-
ness in the analysis of 28-day mortality rate, the
proportion of shock reversal by day 7, and complication
rates. However, the confidence intervals (CIs) for the
two complications (infections, gastrointestinal bleeding)
were wide and susceptible to inaccuracy, and their evi-
dence levels were thus lowered by one. The risk ratios
(RRs) for 28-day mortality rate and the proportion of
shock reversal by day 7 were 0.96 (95% CI 0.81–1.13)
and 1.32 (95% CI 1.19–1.46), respectively. The RRs for
infection, gastrointestinal bleeding, and hyperglycemia
were 1.09 (95% CI 0.88–1.35), 1.35 (95% CI 0.85–2.13),
and 1.15 (95% CI 1.07–1.25), respectively.
Although the rates of adverse events increased or
tended to increase, the proportion of shock reversal by
day 7 increased significantly, and 28-day mortality rate
tended to decrease; thus, we judged that the benefits
likely outweighed the harms.
CQ8-2: Should we administer corticosteroids earlier or
later for adult patients with septic shock who are not
responsive to initial fluid resuscitation and vasopressors?
Answer (opinion)
We suggest that corticosteroids are administered within
6 h after the onset of septic shock to treat adult patients
with septic shock that is not responsive to the initial
fluid resuscitation and vasopressors (expert consensus/
no evidence) (rate of agreement, 94.7%).
Rationale
No RCTs comparing whether the therapeutic effects and
side effects of low-dose corticosteroids in adult patients
with septic shock differ depending on the timing of
administration (early initiation vs. late initiation) could
be found. The French study involving the administration
of corticosteroids within 8 h after onset of shock [165]
has demonstrated a superior 28-day mortality rate as
well as improved the proportion of shock reversal com-
pared to the CORTICUS study [156] involving cortico-
steroid administration within 72 h after the onset of
shock. Two observational studies have recently reported
efficiencies in the timing of administering corticosteroids
to treat septic shock. In 2012, Park et al. [169] con-
ducted a retrospective study using a time-dependent
Cox regression model to assess the administration of
corticosteroids in patients with septic shock (178 cases).
As a result, it was found that the 28-day mortality rate
was significantly lower in the early group that received
corticosteroids within 6 h of onset of shock compared to
the late group that received steroids after 6 h or more
from the onset of shock (51 vs. 32%, RR 0.63; 95% CI
0.42–0.93, p = 0.002). According to the prospective study
(170 cases) conducted by Katsenos et al. [170] in 2014,
inotropes may be discontinued earlier in patients with
early initiation of HC (< 9 h after inotropes) in compari-
son to patients with late initiation of HC (> 9 h after ino-
tropes) (log-rank 18.248, p = 0.000019), and 28-day
mortality rate also declined (52.2 vs. 30.6%; Fisher’s exact
test, p = 0.012). Based on the above findings, the early
administration of corticosteroids within 6 h of the onset
of shock is recommended when steroids are to be
administered for the treatment of septic shock.
Regarding the benefit-risk balance, early steroid
administration for the treatment of septic shock can be
expected to promote shock reversal, resulting in the pre-
vention of irreversible organ failure caused by prolonged
hemodynamic derangement and to reduce the mortality
rate. There have been no reports concerning complica-
tions arising due to the timing of administration, and no
increased burden on medical staff associated with the
timing of corticosteroids administration (early initiation,
late initiation) is anticipated. However, since no RCTs
conforming to the Patients, Intervention, Comparison,
Outcome (PICO) process could be found, it was deter-
mined that the benefit-risk balance is still unknown.
CQ8-3: What are the optimal dose and administration
period when administering corticosteroids?
Answer (opinion)
We suggest that 300 mg/day or less of HC for a max-
imum period of approximately 7 days is used when ste-
roids are required for patients with septic shock (expert
consensus/no evidence) (rate of agreement, 94.7%).
Rationale
No RCTs examining and comparing whether the thera-
peutic effects and side effects of corticosteroids adminis-
tered to adult patients with septic shock differ
depending on the dosage and administration period
could be found. It was concluded that high-dose steroid
administration, which had been practiced until the
1990s, was ineffective or even harmful based on the re-
sults of two RCTs and one meta-analysis [158, 159].
Low-dose, long-term administration of HC was prac-
ticed in the 2000s, and improvements in mortality rates
were also reported in addition to improvements in the
proportion of and time to shock reversal. In large-scale
RCTs by Annane et al. [165] and Sprung et al. [156], fas-
ter shock reversal was observed in both studies as a
result of administering HC 200 mg/day in four divided
doses, although the 28-day mortality rate was signifi-
cantly lower in the Annane study than that in the
Sprung study. In a meta-analysis by Annane et al. [171]
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assessing 17 RCTs, HC administration methods were di-
vided into four according to the high dose/low dose
(with a 300 mg/day limit) and long term/short term
(with a five-day limit) and examined. Improvements in
both the proportion of shock reversal and the 28-day
mortality rate were observed only in the low-dose/long-
term administration groups. Also, in the meta-analysis
of the latest Cochrane Review of dose and duration of
treatment among the steroid administration groups by
Annane et al. [172], treatment with a long course of
low-dose corticosteroids (at least 5 days and 300 mg/day
or less) significantly reduced 28-day mortality rate (RR
0.87, 95% CI 0.78–0.97), but did not improve in the
high-dose/short-term administration groups.
While several reports recommend continuous infusion
at 10 mg/h after intravenous infusion of 100 mg is given
for the management of blood glucose [152], the utility of
continuous intravenous infusion of steroids with long
half-lives is not clear. The period of administration is
not fixed at 5 days, and administration of steroids for a
long time should be avoided. When discontinuing ster-
oid therapy, gradually tapering off the dosage is safer
than sudden discontinuation from the viewpoints for
maintenance of hemodynamics and prevention of
rebounds in immune function.
As mentioned above, administration of steroids at
dosages not exceeding the 300 mg/day equivalent of HC
is recommended to promote the proportion of shock
reversal in patients with septic shock (over a maximum
period of approximately 7 days).
Regarding the benefit-risk balance, low-dose long-term
steroids that are administered until the time to shock re-
versal are expected to increase proportions of shock re-
versal and decrease the frequency of mortalities. On the
other hand, high-dose short-term steroid administration
is associated with a greater frequency of hyperglycemia
and gastrointestinal bleeding resulting in worsened prog-
nosis compared with the non-administration group.
Although low-dose/long-term steroids did not increase
the frequency of complications after an overall assess-
ment of low-dose long-term steroids, it is necessary to
pay sufficient attention to the risk of deterioration of
long-term prognosis due to hyperglycemia, gastrointes-
tinal bleeding, and increased risk of infection. However,
no RCTs conforming to the PICO process could be
found, and it was determined that the benefit-risk
balance is still unknown.
CQ8-4: Should hydrocortisone be administered?
Answer (opinion)
We suggest that HC or MPSL is administered to treat
patients with septic shock (expert consensus/no evi-
dence) (rate of agreement, 100%).
Rationale
There were no RCTs comparing the therapeutic effects
and side effects of different steroids administered in
adult patients with septic shock. Glucocorticoids re-
sulted in an improvement in the proportion of shock re-
versal and reduced the 28-day mortality rate in adult
patients with septic shock. Although HC, a pharmaco-
logic form of physiological cortisol, is most commonly
used in large-scale RCTs, it is a short-acting steroid and
has both glucocorticoid and mineralocorticoid effects. In
addition, Meduri et al. [173] administered 1 mg/kg of
MPSL, an intermediate-acting steroid with no mineralo-
corticoid effects, and then continued MPSL administra-
tion at 1 mg/kg/day for 14 days to patients with septic
shock in the same way as is given to patients with acute
respiratory distress syndrome (ARDS). MPSL is five
times more potent than HC in terms of glucocorticoid
activity, and its half-life is 1.3 times that of HC. How-
ever, the actual dosage of MPSL is approximately half of
that of HC [174]. In a retrospective observational study
[175] (involving HC: 21 patients: 50 mg × 4/day; MPSL:
19 patients: 20 mg × 2/day) comparing HC and MPSL
with bioequivalent doses, no difference in 28-day mor-
tality rate, the proportion of shock reversal, or incidence
of complications were observed. We do not recommend
combining fludrocortisone and HC. In an RCT assessing
the combination of fludrocortisone and HC [165], there
was no additional benefit associated with adding fludro-
cortisone to HC, and adding fludrocortisone increased
the infection rate, especially for urinary tract infections.
Dexamethasone which has greater glucocorticoid activity
and a longer half-life should not be administered due to
its immediate and prolonged suppressive effects on the
hypothalamic-pituitary-adrenal axis [163]. Based on the
above findings, we suggest using HC or methylpredniso-
lone MPSL in patients with septic shock.
Regarding the benefit-risk balance, even if HC, or alter-
natively, MPSL is administered, although there was no sig-
nificant difference between the groups with respect to the
incidence of complications, it is necessary to pay sufficient
attention to the risk of deterioration of long-term progno-
sis due to hyperglycemia, gastrointestinal bleeding, and in-
creased risk of infection. However, no RCTs conforming
to the PICO process could be found, and it was deter-
mined that the benefit-risk balance pertaining to patients
in either group is still unknown.
CQ9: Blood transfusion preparations
Introduction
The treatment of sepsis in Japan involves the use of
blood component preparations (red blood cell concen-
trate, fresh-frozen plasma, and platelet concentrate) as
well as plasma fraction preparations (albumin prepara-
tions, immunoglobulin preparations, and antithrombin
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preparations). Among these blood products, usage stan-
dards for blood component preparations and albumin
preparations from plasma fraction preparations have
been formulated in accordance with the “Guidelines for
Blood Product Use” (2012 revision) established by the
Ministry of Health, Labour and Welfare [176], from the
perspective of limited medical resources regarding blood
donations as well as the risk of side effects associated
with the use of human blood. The use of these products
is recommended during medical treatment covered
under Japan’s National Health Insurance system as well
based on these standards. However, whether the Guide-
lines for Blood Product Use are also valid in the context
of sepsis has not yet been established, and there are also
some who believe that blood products should be actively
administered to address coagulopathies and hypoalbu-
minemia occurring in sepsis cases. On that basis, this
guideline discusses the use of appropriate blood prod-
ucts in the management of sepsis and presents several
clinical questions (CQs) addressing key questions.
In the Japanese Guideline for the Management of
Sepsis (First Edition) [2], “blood component prepara-
tions” is not an independent item, but rather red blood
cell transfusions are discussed in conjunction with “ini-
tial resuscitation,” and fresh-frozen plasma and platelet
concentrate are discussed in the context of “dissemi-
nated intravascular coagulopathy (DIC).” In addition, of
the various plasma fraction preparations, albumin prepa-
rations are discussed alongside “initial resuscitation,”
“immunoglobulin preparations” are addressed as a separ-
ate entry, and antithrombin preparations are discussed
alongside “DIC.” Although plasma fraction preparations
are considered in a similar context as the first edition, it
was decided that blood component preparations would
be addressed as a separate “blood transfusions” entry, as
the guideline would be created based on evidence related
to sepsis and the Ministry of Health, Labour and
Welfare’s Guidelines for Blood Product Use.
The “blood transfusions” team designed a CQ to ad-
dress each type of blood component preparation (red
blood cell concentrate, fresh-frozen plasma, and platelet
concentrate). However, the recommendation that red
blood cell transfusions be performed after patients have
recovered from shock, are hemodynamically stable, and
when hemoglobin values fall below 7 g/dL is present in
both the Japanese Guideline for the Management of
Sepsis (First Edition) and the Surviving Sepsis Campaign
Guidelines (SSCG) 2012 [29] and is also not inconsistent
with the Guidelines for Blood Product Use established
by the Ministry of Health, Labour and Welfare. In con-
trast, the SSCG 2012 describes red blood cell transfusion
with a target hematocrit value of 30% as one means of
maintaining oxygen supply to tissues when performing
initial resuscitation in septic shock cases, and the debate
on this subject is ongoing. Accordingly, in this guideline,
it was determined that no consensus could be reached
regarding administering red blood cell transfusions to
patients with stable hemodynamics. Thus CQ9-1 was
formulated to focus on the topic of red blood cell trans-
fusions during initial resuscitation of septic shock
patients and addresses the question “When should red
blood cell transfusion be initiated when performing
initial resuscitation in septic shock cases?” In addition,
discussion of the appropriate performance of transfu-
sions of fresh-frozen plasma and platelet concentrate in
coagulation factor supplementation, when surgical inter-
vention is needed, or in the event of hemorrhaging was
determined to be necessary, and accordingly CQ9-2 and
CQ9-3 address the questions of “Should fresh-frozen
plasma be used in sepsis cases?” and “Should platelet
transfusions be performed in sepsis cases?”, respectively.
CQ 9-1: When should red blood cell transfusion be initiated
when performing initial resuscitation in septic shock cases?
Answer (recommendation)
We recommend initiating red blood cell transfusion dur-
ing initial resuscitation in septic shock cases at
hemoglobin levels of ≤ 7 g/dL (1B) (rate of agreement,
94.7%).
Comment: This CQ addresses red blood cell transfu-
sions during initial resuscitation in septic shock cases,
and does not address transfusions performed after the
patient is hemodynamically stable.
Rationale
Although the SSCG 2012 [29] proposed performing red
blood cell transfusions with a target hematocrit of 30%
or higher while considering the risks of hypoxia and
myocardial damage during septic shock, the debate is
currently ongoing. As such, an analysis of the timing of
initiation of red blood cell transfusions during initial
resuscitation in septic shock cases was conducted.
Two randomized controlled trials (RCTs) [177, 178]
conforming to the Patient, Intervention, Comparison,
and Outcome (PICO) process were selected as final tar-
gets for analysis as a result of a search of the PubMed
database. According to the results of a combined meta-
analysis of the control groups (group C, 520 partici-
pants) and the intervention groups (group I, 524 partici-
pants) of these two RCTs, the risk ratio for the 28-day
mortality rate in group I versus group C was 0.95 (95%
confidence interval (CI) 0.80–1.11). The incidence of is-
chemic complications with respect to organ damage was
reported for one study only, and the risk ratio for organ
damage in the control group (group C, 489 participants)
versus the intervention group (group I, 488 participants)
was 0.9 (95% CI 0.58–1.39).
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After a comparison of transfusions initiated at a
hemoglobin level of ≤ 7 g/dL with transfusions initiated
at ≤ 10 g/dL, no difference was observed with respect to
28-day mortality rate and incidence of ischemic compli-
cations, and no evidence supportive of initiating blood
transfusions at hemoglobin values of ≤ 7 g/dL or ≤ 10 g/
dL was found. However, targeting a higher hemoglobin
value requires transfusion of greater volumes of red
blood cells and increases the risk of adverse effects and
complications associated with transfusions, such as
infection and allergic reactions. In addition, in consider-
ation of medical economics and the fact that these kinds
of blood products originate from donated blood, initiat-
ing transfusions at hemoglobin values of ≤ 10 g/dL
should be avoided due to the risk of various adverse
events, and a threshold of ≤ 7 g/dL is recommended
instead. However, threshold hemoglobin values for initi-
ating red blood cell transfusions may change in cases
involving heart failure or ischemic heart disease as
underlying diseases, and further studies are required.
CQ 9-2: Should fresh-frozen plasma be used in sepsis
cases?
Answer (opinion)
We suggest against administration of fresh-frozen
plasma to correct coagulopathies when patients exhibit
no bleeding tendencies, and no surgical intervention is
required (expert consensus/no evidence) (rate of agree-
ment, 100%).
Comment: The use of fresh-frozen plasma should be
considered in keeping with the Japanese Guidelines for
Blood Product Use [176] when patients exhibit a bleed-
ing tendency or when surgical treatment is needed.
Rationale
In Japan, fresh-frozen plasma is administered to sepsis
patients who exhibit bleeding tendencies or when surgi-
cal intervention is required, but may also be given to
treat coagulopathies. To date, no consensus has been
reached regarding the clinical utility of administering
fresh-frozen plasma to correct coagulopathies in sepsis
patients. In addition, potential harms associated with
fresh-frozen plasma use include the onset of transfusion-
related acute lung injury (TRALI) (frequency of fatal
TRALI due to fresh-frozen plasma use: 1:2–300,000
products [179]), among various other dangers. Thus, the
use of fresh-frozen plasma in sepsis cases was examined
for this CQ.
No RCTs assessing the clinical utility of administering
fresh-frozen plasma to manage coagulopathies in sepsis
patients could be found in the PubMed database. As
there is currently insufficient evidence conforming to
the PICO process, no recommendation could be offered
for this CQ at this time, and an expert consensus is pre-
sented as an alternative.
Although there are currently no proven benefits or
harm associated with the administration of fresh-frozen
plasma to manage coagulopathies in patients not exhi-
biting bleeding tendencies or when no surgical interven-
tion is required, administering fresh-frozen plasma
increases patients’ risks of allergic reactions and infec-
tion accompanying blood transfusion, which can become
a burden on circulation. Moreover, as of 2016, the cost
of fresh-frozen plasma was approximately 80 United
States Dollar (USD)/unit (one unit of plasma (approx.
120 mL) corresponds to 200 mL of blood). In actual
practice, physicians should take note of patients’ individ-
ual views regarding donated blood products and also be
aware that some patients or their family members may
refuse blood transfusions for reasons such as religious
beliefs.
CQ 9-3: Should platelet transfusions be performed in
sepsis cases?
Answer (opinion)
We suggest performing a platelet transfusion in sepsis
cases when patients exhibit a bleeding tendency or when
surgical treatment is needed, in keeping with the
Japanese Guidelines for Blood Product Use [176] (expert
consensus/no evidence) (rate of agreement, 100%).
Rationale
In Japan, platelet preparations are often administered to
sepsis patients who exhibit general bleeding tendencies
or when surgical intervention is needed [176] in keeping
with the Japanese Guidelines for Blood Product Use.
However, there is currently no evidence upon which to
base an assessment of how platelet transfusions affect
the clinical course of sepsis patients. In addition, poten-
tial risks associated with platelet administration include
the onset of TRALI (frequency of fatal TRALI due to
platelet use: 1:3–400,000 products [179]), among various
others. As such, the use of platelet preparations in sepsis
patients was examined in this CQ.
No RCTs examining the clinical utility of platelet
administration to sepsis patients could be found in the
PubMed database. As there is currently insufficient evi-
dence that conforms to the PICO process, no recom-
mendation can be offered for this CQ at this time, and
an expert consensus is presented as an alternative.
Although there are currently no proven benefits or
harm associated with the administration of platelet prep-
arations to patients not exhibiting bleeding tendencies
or when no surgical intervention is required, platelet
transfusion increases patients’ risks of allergies and
infection, which can increase the circulatory burden. As
of 2016, the cost of platelet preparations was
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approximately 720 USD/10 units (200 mL), and when
administering platelets, physicians should take note of
how patients’ individual views regarding donated blood
products and the concept of blood transfusions can
differ. Also, physicians must also be aware that some
patients or their family members may refuse blood
transfusions for reasons such as religious beliefs.
CQ10: Management of the mechanically
ventilated patient
Introduction
Sepsis-induced respiratory system disorders occur at a
high frequency and can result in hypoxemia in more
severe cases, presenting as acute respiratory distress syn-
drome (ARDS). This condition is a typical organ system
disorder in sepsis cases, and the pathology of ARDS is
easy to understand if the condition is viewed as the pul-
monary component of multiple organ failure. Severe sep-
sis is considered to be an important underlying condition
together with severe pneumonia [180]. There has also
been movement in recent years towards defining severe
pneumonia as sepsis of the lungs, and under such a defin-
ition approximately 80% of ARDS cases arise from sepsis
[181, 182]. However, the incidence of ARDS among pa-
tients with sepsis as a whole is surprisingly low, and some
reports have estimated that it to be approximately 6–7%
[183, 184]. Therefore, although mechanical ventilation
plays an important role in the management of sepsis
patients, it should be noted that there are also cases where
marked deterioration in respiratory function does not
occur, as well as cases where respiratory decline may be
preventable through treatment intervention.
Since the establishment of the new definition of ARDS
in 2012, the concept of initiating therapeutic interventions
according to disease severity was introduced [35, 185],
and numerous reports have been made in recent years
describing the clinical utility of techniques such as oxygen
therapy in mild ARDS cases, oxygen therapy administered
via high-flow nasal cannula (high-flow nasal therapy), and
noninvasive positive pressure ventilation [186–189].
Administering oxygen in some form to sepsis patients pre-
senting with hypoxemia is widely practiced, and while this
approach is believed to help prevent the onset of acute
respiratory failure leading to ARDS, there is currently no
clear supporting evidence. In addition, the ventilation
strategy is of critical importance when managing sepsis
patients requiring mechanical ventilation, together with
the treatment of the underlying sepsis. Specifically, a “lung
protective ventilation” strategy is considered to be key to
reducing lung injuries, and the prevention and treatment
of ventilator-associated lung injuries (VALI) and
ventilator-associated pneumonia should also be consid-
ered once mechanical ventilation is initiated.
On this background, four clinical questions (CQs)
focusing on the general management of mechanically
ventilated patients were selected among the 13 CQs
presented in the ARDS Clinical Practice Guidelines 2016
(ARDSGL) [190] published by the Japanese Society of
Intensive Care Medicine, the Japanese Society of Re-
spiratory Care Medicine, and the Japanese Respiratory
Society. Regarding the topics of appropriate positions for
preventing complications during mechanical ventilation,
ventilation in the prone position to address severe hyp-
oxemia, and the use of muscle relaxants, it was decided
that this guideline will not describe the interventions
due to the need for safety instruction by specialists and
are not applicable in regular wards outside the ICU. For
more specialized knowledge, please refer to the ARDS
Clinical Practice Guideline 2016 [190].
CQ10-1 addresses tidal volume settings. As a result of
a large-scale, multicenter randomized controlled trial
(RCT) comparing a group of ARDS patients that had a
comparatively large tidal volume (12 mL/kg predicted
body weight) while undergoing mechanical ventilation to
another group with low tidal volume (6 mL/kg predicted
body weight), the 30-day mortality rate was significantly
lower in the low tidal volume group [191]. Based on this
report, it is apparent that the concepts underlying the
management of mechanically ventilated patients have
changed significantly, and lung-protective ventilation
strategies capable of preventing VALI have been intro-
duced into the intensive care medical practice. No RCT
comparing low tidal volume with conventional ventila-
tion volume has been published since 2006. To date, no
basis for establishing a target ventilation volume of
6 mL/kg predicted body weight has been demonstrated,
and further study is needed.
CQ10-2 addresses plateau pressure settings. VALI
tends to occur in conjunction with decreases in lung
compliance during mechanical ventilation in adult ARDS
patients. Although there has been some concern regard-
ing how VALI not only extends the period of mechanical
ventilation use but can also lead to increased mortality
[192], this increase arises from elevations in tidal volume
and airway pressure during mechanical ventilation, and
as such, it is expected that both can be controlled by
limiting plateau pressure [193]. However, the results of
limiting plateau pressure are not all beneficial; lower
plateau pressure may also lead to adverse events such as
hypercapnia [194]. Therefore, the optimum plateau pres-
sure affording benefits without causing VALI is currently
uncertain, and validation is necessary.
CQ10-3 addresses the positive end-expiratory pressure
(PEEP) setting. It is widely known that atelectasis can be
prevented and oxygenation can be improved by using
PEEP. Particularly in patients with ARDS, evidence sug-
gests that PEEP does not only help to correct hypoxemia
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but can also prevent further worsening of VALI by
stimulating the recruitment of alveoli that have become
collapsed due to inflammation or exudate [195, 196].
However, the optimum PEEP value is currently un-
known. Various other treatment concepts such as driv-
ing pressure, transpulmonary pressure, and electrical
activity of the diaphragm have been proposed in addition
to these, and future research attention is anticipated
[197–199].
Lastly, CQ10-4 addresses the management of hydra-
tion, which is closely related to the management of sep-
sis. Pulmonary edema in patients with ARDS is believed
to be caused by vascular endothelial damage or vascular
hyperpermeability [180]. A positive balance in transfu-
sion volume in ARDS patients increases the frequency of
mortality [200], and extravascular lung fluid volume is
linked to disease severity and mortality rate [201]. In
contrast, relatively high-volume fluid transfusion is
recommended in guidelines for managing septic shock
patients. Therefore, proper fluid management is required
after patients recover from the shock state in the early
stages of sepsis.
This CQ is excerpted in part from the ARDSGL [190].
CQ10-1: Should a lower tidal volume be set when
performing mechanical ventilation in adult patients with
ARDS?
Answer (recommendation)
We recommend setting the tidal volume to 6–8 mL/kg
predicted body weight when performing mechanical
ventilation in adult patients with ARDS (1B: excerpted
from the ARDSGL).
Rationale
Mechanical ventilation management in ARDS patients is
very important in addition to treatment of the under-
lying disease. In particular, mechanical ventilation set-
tings are the highest priority for ARDS patients. Several
studies have been conducted regarding ventilation strat-
egies designed for ARDS patients that restrict tidal
volume as a lung-protective measure to reduce further
lung injury and limit airway pressure.
As a result of the systematic review, only six 2013
Cochrane Review [202]-adopted RCTs [191, 203–207]
involving the use of lung protective ventilation methods
focusing primarily on low tidal volume in adult ARDS
patients were identified. Mortality statistics were
reported in all six studies (n = 1305), and while there
was a difference in the follow-up period, this period
tended to be shorter in the low tidal volume group (risk
ratio, 0.84; 95% confidence interval (CI) 0.67–1.07).
Airway pressure-associated injury (pneumothorax arising
from elevated airway pressure) was also reported in all
six studies, but no significant decrease was observed
(risk ratio 0.82; 95% CI 0.48–1.41). Although the results
of three RCTs were integrated with respect to the num-
ber of ventilator-free days (VFD), the mean difference
significantly increased to 2.52 days (95% CI 0.53–4.51).
VFDs increase despite the observation of high carbon
dioxide levels and respiratory acidosis in conjunction
with low tidal volume. Low tidal volume can be used just
by adjusting the mechanical ventilator settings, and re-
sources required remain unchanged. Therefore, it is
likely that the potential benefits outweigh the potential
harms.
CQ10-2: How should plateau pressure be set when
performing mechanical ventilation in adult ARDS
patients?
Answer (recommendation)
We suggest a plateau pressure of ≤ 30 cmH2O when per-
forming mechanical ventilation in adult ARDS patients
(2B: excerpted from ARDSGL).
Rationale
Mechanical ventilation-related lung injury in adult
patients with ARDS is likely to occur in conjunction
with decreased pulmonary compliance. There has been
some concern regarding how VALI not only extends the
period of mechanical ventilation but also leads to an in-
creased risk of mortality. Increased tidal volume during
mechanical ventilation and elevated airway pressure have
been raised as potential causes of VALI, and it is
expected that both can be controlled by limiting plateau
pressure (airway pressure at the point when airflow tem-
porarily stops at the end of inspiration). However, the re-
sults of limiting plateau pressure are not all beneficial;
lower plateau pressure may also lead to adverse events
such as hypercapnia. Accordingly, the optimum plateau
pressure for obtaining treatment benefits without caus-
ing VALI is currently uncertain, and validation is neces-
sary and a high priority.
As a result of the systematic review, four RCTs (1132
patients) [191, 204, 205, 207] were identified. Prolonged
VFD (2.5 days on average, 95% CI: 0.5-4.45) was
confirmed by setting plateau pressure to ≤30 cmH2O for
5-7 days after the initiation of mechanical ventilation.
Although the risk of death (risk ratio: 0.84, 95% CI: 0.62-
1.15) and pressure-related injury (risk ratio: 0.92, 95%
CI: 0.65-1.31) exhibited declining trends, these observa-
tions were not statistically significant.
VFDs are extended by limiting plateau pressure to ≤30
cmH2O. In contrast, hypoxemia, hypercapnia, and respira-
tory workload are each anticipated to increase, but each
has a wide range of tolerance, and the risk of iatrogenic
harm is considered low. This is possible only by adjusting
the mechanical ventilator settings, and resources required
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remain unchanged. Therefore, it is likely that the potential
benefits outweigh the potential harms.
CQ 10-3: How should PEEP values be set when performing
mechanical ventilation in adult patients with ARDS?
Answer (recommendation)
We suggest setting PEEP values within a range such that
the plateau pressure is ≤30 cmH2O and hemodynamics
are not impacted when performing mechanical ventila-
tion in adult patients with ARDS (2B: excerpted from
ARDSGL). We suggest the use of higher PEEP values in
patients with moderate or severe forms of ARDS (2B:
excerpted from ARDSGL).
Rationale
Some evidence suggests that PEEP may be a factor in
correcting hypoxemia by promoting the recruitment of
collapsed alveoli and preventing progression of VALI,
but the optimal PEEP value for this purpose remains
unclear.
Seven RCTs were found as a result of the system-
atic review, and no significant difference was observed
between the high PEEP group and the low PEEP
group with respect to in-hospital mortality (risk ratio:
0.93, 95% CI: 0.83-1.04), pressure-associated injury
(risk ratio: 0.97, 95% CI: 0.66-1.42), and VFD (risk ra-
tio: 1.89, 95% CI: -3.58 - 7.36). For the analysis of
in-hospital mortality, studies permitting interventions
other than adjustment of PEEP values capable of
influencing patient outcomes were excluded from
analysis. As a result, three studies, by Brower et al.
[208], Meade et al. [209], and Mercat et al. [210]
were included in the final analysis. As a result of a
meta-analysis involving studies in which the influence
of non-PEEP interventions could not be ignored [203,
207, 211, 212], no significant difference in mortality
rate was observed in the high PEEP group in com-
parison with the low PEEP group (risk ratio: 0.87,
95% CI: 0.74-1.02). In addition, when focusing the
analysis on moderate or severe ARDS cases (PaO2/
FiO2 ratio ≤ 200 mmHg), the results of both the sub-
analyses including the studies permitting non-PEEP
interventions as well as the sub-analyses excluding
such interventions indicated that the high PEEP group
exhibited a significantly lower mortality rate than the
low PEEP group (risk ratio: 0.82, 95% CI: 0.73-0.92,
risk ratio: 0.85, 95% CI: 0.75-0.96, respectively).
Setting the PEEP value is possible just by adjusting the
mechanical ventilator settings, and there is no extra
workload on ICU staff. However, the benefits and risks
of this technique remain unclear, and therefore, the
benefit-risk balance is currently uncertain.
CQ10-4: How should daily fluid balance be maintained in
adult patients with ARDS?
Answer (recommendation)
We suggest fluid restriction when managing adult ARDS
patients (2B; excerpted from ARDSGL).
Rationale
Pulmonary edema occurring in ARDS patients is be-
lieved to be caused by vascular endothelial damage and
vascular hyperpermeability. The larger number of ARDS
patients increases the mortality rate, and pulmonary
extravascular fluid volume is linked to ARDS severity
and frequency of mortality.
However, to date, no RCT has reported an improve-
ment in mortality with fluid management in ARDS pa-
tients. Although attempting to optimize body fluid
volume is routinely attempted in the treatment of other
conditions and is regarded as an important measure, the
mechanisms controlling fluid balance in ARDS patients
is not well understood. As such, this is a high-priority
issue, and the current recommendation is to manage
fluid balance on a daily basis to avoid excessive body
fluid volume as much as possible.
As a result of the systematic review, three RCTs com-
paring adult ARDS patients subjected to some manner
of fluid restriction against those who were not were
found. Studies permitting the adjustment of the infusion
burden on shock patients in addition to ARDS were ex-
cluded. Although a large number of cases were included
in the Fluids and Catheters Treatment Trial (FACTT
2006 study) [213], the other two studies RCTs [214, 215]
included only a small number of cases. No significant
differences in short-term mortality were observed, and
the number of VFDs within a 28-day period increased
significantly (+ 2.5 days). There were also no differences
with respect to renal replacement therapy within a
60-day period. Regarding the indicators of fluid manage-
ment, although two RCTs comparing pulmonary extra-
vascular water content with pulmonary artery wedge
pressure [216] and central venous pressure [143] were
found, neither study demonstrated an improvement in
mortality rate. The former study results demonstrated a
reduction in the mechanical ventilation period, while the
latter study failed to demonstrate any particular clinical
utility.
Shortening of the VFD can be expected as a result of
limiting fluid infusion volume. However, there is a risk of
electrolyte abnormalities when diuretics are used. There
are currently no clear standard indicators for assessing
fluid balance, but many medical institutions use some
manner of indicators to evaluate hemodynamics. The
addition of new indicators for this purpose is of low neces-
sity as treatment objectives can be achieved with general
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practice techniques. Thus, the benefits greatly exceed the
potential risks.
CQ11: Management of analgesia, sedation, and
delirium
Introduction
Delirium is a mental disorder often encountered in clin-
ical practice and on general wards. It is characterized by
a variety of neurological symptoms (such as altered con-
sciousness, attention, and sensory perception) which
mostly resolve following an improvement in the patient’s
physical condition. Delirium commonly progresses rap-
idly over a period of days, and symptoms may fluctuate.
From a psychiatric point of view, delirium is a type of
consciousness-related disorder accompanied by varying
degrees of altered perception and mild dulling of the
awareness. Patients presenting with delirium exhibit
various symptoms, and the disorder is classified into
three subtypes depending on the symptoms observed:
hyperactive, hypoactive, and mixed. Among these sub-
types, hyperactive delirium is most frequently addressed
by therapeutic intervention as it is easily recognized by
general medical staff due to the severity of its presenta-
tion and the hindrance it poses to treatment. In contrast,
hypoactive delirium rarely presents as dangerous behav-
ior and does not require extraordinary effort from the
nursing staff. At first glance, hypoactive delirium can ap-
pear to be a state of “sustained sedation,” and to date
has been actively diagnosed infrequently. However, delir-
ium presents in an extremely hypoactive form in many
cases, particularly those involving the management of
critically ill patients such as intensive care unit (ICU)
patients, and some studies have reported that many deli-
rious ICU patients are neglected and left unattended by
medical staff [217]. Another report states that delirium
occurring in critically ill patients requiring mechanical
ventilation is an independent risk factor for patient out-
come and can have a significant adverse impact on prog-
nosis [218]. ICU delirium, a type of acute cerebral
disorder that affects the central nervous system is one of
several organ disorders that affect critically ill patients.
Moreover, the central nervous system, after the respira-
tory and cardiovascular systems, is the most frequent
target of physicians’ attention regarding organ systems
that are prone to damage in critically ill patients [219].
Therefore, regular monitoring of the central nervous
system is recommended and should be accorded the
same degree of importance as monitoring the respiratory
state and hemodynamics over time using metrics such
as SpO2, blood gas content, blood pressure, and
electrocardiography.
Although the causes and underlying mechanisms of
various mental disorders and risk factors affecting ICU
patients as described above remain unknown, post-
traumatic stress disorder (PTSD), the subject with the
largest number of case reports, hallucinations, and delu-
sions experienced by ICU patients are drawing research
attention. Also, prolonged periods of delirium giving rise
to hallucinations and delusions during hospitalization
has also been recognized as a key independent risk fac-
tor [220] associated with long-term cognitive dysfunc-
tion after discharge. Currently, the onset of delirium is
considered a factor that can significantly worsen the
long-term prognosis after discharge of critically ill
patients, and it is believed that these are two iatrogenic
risks arising from deficient management by medical staff
[221, 222]. Accordingly, the general importance of taking
suitable measures to address delirium must be
emphasized.
Although haloperidol and various atypical antipsy-
chotics have been used in the management of delirium
in the past, there have been no reports to date proving
their efficacy as treatments for ICU delirium, including
postoperative delirium [223–227], and there are only a
few studies that can assert to the efficacy of quetiapine
[228]. Currently, while the use of antipsychotics may
slightly reduce the frequency of delirium onset, the con-
sensus is that their routine use is not recommended, as
it does not ultimately lead to improved patient prognosis
while exposing them to various side effects including
extrapyramidal symptoms, torsade de pointes, and ven-
tricular arrhythmias [229]. However, dexmedetomidine,
which has sedative effects and acts similarly to the
induction of natural sleep, has long been expected to
become a treatment for delirium and various clinical
studies have been conducted to date, but, due to meth-
odological inadequacies and other obstacles, a solid
conclusion is yet to be reached. Thus, the reality is that
there are currently no drugs proven to be effective as
treatments for delirium. However, as delirium manifests
as a disorder of the central nervous system and is an
independent risk factor that affects patient prognosis,
some manner of response is required, and if insufficient
results are obtained regarding pharmacological ap-
proaches, non-pharmacological approaches will become
critical.
The basic principle in treating delirium is the identifi-
cation and elimination of causative factors, and the first
step in non-pharmacological approaches is to lower pa-
tients’ stress by adjusting their environment; physicians
must determine how patients lived their lives before
being hospitalized. Among these non-pharmacological
approaches, the promotion of nighttime sleep and early
rising, in particular, have attracted attention in recent
years. Unfortunately, although no study regarding sleep
management with an overall high level of evidence has
been conducted to date, improving sleep quality is be-
lieved to offer various health benefits, and many
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authorities recommend this approach [230]. Also, the
promotion of early rising has accumulated a strong body
of supporting evidence with respect to critically ill
patients [231, 232]. In addition, as the only non-
pharmacological approach shown to be effective in the
treatment of ICU delirium is early-stage rehabilitation,
its implementation is strongly recommended.
Issues concerning analgesia/sedation have already been
highlighted in many reports as a way of addressing delir-
ium in critically ill patients and the onset of neurological
disorders after intensive care. As it is clear that exces-
sively sustained sedation unnecessarily prolongs mech-
anical ventilation periods due to factors such as the
onset of ventilator-associated pneumonia and unsuccess-
ful weaning trials [233–236], the mainstream approach
is shifting from “hypnosis-focused sedation” to a “mini-
mum sedation.” Preventing hallucinations and delusions
is also important, and to do this, attending physicians
should “avoid unnecessary sedation.” The safety of early-
stage rehabilitation in critically ill patients has also been
pointed out [237], but reports made around the same
time have highlighted how rehabilitation measures are
infrequently implemented [238, 239]. The issue of “ex-
cessive sedation” has been raised as a possible reason.
Implementing rehabilitative measures will naturally
become difficult if a patient’s sedation is excessively deep
such that delirium cannot be assessed. Establishing a
basic policy of directing physicians “to avoid unnecessary
sedation” is necessary from the perspectives of perform-
ing routine delirium assessments and early-stage
rehabilitation.
There is a need for careful planning when managing
critically ill patients, such as those under mechanical ven-
tilation, in line with the policy of “administer the mini-
mum sedation necessary while avoiding unnecessary
sedation,” with a primary focus on “sufficient pain relief.”
The sedatives currently indicated for use in mechanically
ventilated patients in Japan (midazolam, propofol, and
dexmedetomidine) alone do not have clinically satisfactory
analgesic effects, and increasing patients’ dosages and
deepening sedation in response to complaints of pain is
counterproductive. In contrast, if pain can be sufficiently
managed with opioids or similar drugs, it is possible to
manage even critically ill mechanically ventilated patients
with “no sedation” [240]. When selecting an analgesic,
opioids, whose effects are virtually predictable, should be
the first choice, followed by fentanyl or morphine,
although the former is the mainstay in Japan. However,
the use of narcotic-antagonist analgesics, which are widely
used in Japan, is desirable only after fully understanding
their analgesic mechanism, such as avoiding concomitant
use of opioids. Combination therapies such as acetamino-
phen + nonsteroidal anti-inflammatory drugs (NSAIDs)
can also be effective to reduce opioid usage.
The current basic principle in the management of
critically ill patients including sepsis patients is “mini-
mum necessary sedation based on adequate pain
management protocols and frequent delirium assess-
ment; facilitate rehabilitation as quickly as possible,”
and this concept is already encapsulated as the
ABCDE bundle [221, 222]. Recently, the Japanese Society
of Intensive Care Medicine published the Japanese
guidelines for the management of Pain, Agitation, and
Delirium in intensive care unit (J-PAD guidelines)
[241] based on the Clinical practice guidelines for the
management of pain, agitation, and delirium in adult
patients in the intensive care unit (PAD guidelines)
[242] in consideration of the medical circumstances
of Japan and new evidence after the PAD guidelines.
Therefore, the guideline committee extracted recom-
mendations from the J-PAD guidelines. Thus, the rec-
ommendations in this area included some contents of
the J-PAD and the PAD guidelines.
CQ11-1: What clinical outcomes can be expected with
respect to delirium in adult ICU patients?
Answer
1. Delirium is associated with worsened ICU patients’
prognoses (A: excerpted from the PAD guidelines).
2. Delirium is associated with longer ICU stay time and
overall hospitalization time (A:excerpted from the
PAD guidelines).
3. Delirium is linked to impaired cognitive function
following discharge from the ICU (B: excerpted
from the PAD guidelines).
Rationale
Delirium occurring in critically ill patients is an acute
cerebral disorder and a form of multiple organ dysfunc-
tion involving the central nervous system. Similar to
other types of vital organ dysfunction, it is believed to
worsen both short-term and long-term patient progno-
sis. The PAD guidelines [242] also state, based on nu-
merous high-quality observational studies, that the onset
of ICU delirium increases ICU stay time as well as the
overall hospitalization time and can be a cause of
impaired cognitive function and neurological disorders
in the long-term. The PAD guidelines further state that
the onset of delirium in critically ill patients is also an
independent risk factor for poor prognosis, irrespective
of the underlying disease. Due to these observations, it is
important for physicians attending to sepsis patients in
the ICU to correctly recognize the effects of delirium, as
such patients frequently have sepsis as an underlying
disease.
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CQ11-2: Should a non-pharmacological delirium protocol
be followed when treating adult ICU patients to reduce
the incidence and duration of delirium episodes?
Answer (recommendation)
We suggest the following:
1. Discharge from the ICU as early as possible to
reduce the onset and duration of delirium (1B:
excerpted from the PAD guidelines).
2. Use of musical interventions when possible to
decrease the amount of sedatives required and to
reduce patient anxiety (2C).
Rationale
The basic principle in treating delirium is the identifica-
tion and elimination of causative factors, and the first
step in implementing a non-pharmacological delirium
protocol is to alleviate patients’ stress through appropri-
ate adjustments to their environment. The promotion of
early rising and sleeping during the night has attracted
particular attention in recent years.
Results of early rising in interventional studies target-
ing critically ill adult subjects [231, 232] indicated
reduced delirium incidence, a reduction in excessive
sedation, and significant shortening of ICU stay time as
well as overall hospital admission time at moderate evi-
dence levels. PAD guidelines [242] have also accumu-
lated a body of supporting evidence with respect to
critically ill patients. Currently, as the only effective non-
pharmacological approach in the treatment of ICU delir-
ium is early-stage rehabilitation, its implementation is
strongly recommended. Regarding sleep promotion,
unfortunately, at the moment there is no research with a
high level of evidence, but it is easy to appreciate that
improvement of sleep quality is advantageous to pa-
tients, and many authorities recommend this.
Although one randomized controlled trial (RCT)
examining musical interventions for patients under
mechanical ventilation has been conducted [243], as
there are currently no musical therapists currently prac-
ticing at medical institutions in Japan, introducing this
type of intervention at this time is believed to be diffi-
cult. Medical interventions using music require assessing
together with related medical staff which types of music
and sound quality are likely to produce the desired clin-
ical effects, methods for reducing noise and other inter-
ferences, and the selection of suitable speaker devices,
among various other potential factors. However, it is un-
likely that interventions using music pose any harm to
patients, and even if the current body of supporting evi-
dence level is low, this approach may be considered in
addition to daily therapy regimens. Although few studies
regarding musical interventions are limited to sepsis
patients, each of these reports is considered applicable
to sepsis patients as well.
CQ11-3: Should a pharmacological delirium prevention
protocol be followed when treating adult ICU patients to
reduce the incidence and duration of delirium episodes?
Answer (recommendation)
The use of a pharmacological delirium prevention proto-
col to reduce the onset and duration of delirium in adult
ICU patients is not necessarily required (insufficient
data) (C: excerpted from the PAD guidelines).
Rationale
While haloperidol and various atypical antipsychotic
drugs have conventionally been used as drug therapies
for delirium, very few reports have been published to
date supporting the efficacy of these therapies with
respect to ICU delirium (including postoperative delir-
ium). The PAD guidelines [242] state that the use of
these drugs cannot be recommended firmly due to a lack
of supporting data. In addition, the results of a meta-
analysis [229] verifying the effects of non-pharmacologic
delirium prevention protocols in critically ill adult pa-
tients also indicate that the prophylactic administration
of antipsychotics to surgical ICU patients and the
prophylactic administration of dexmedetomidine to
mechanically ventilated patients may decrease the inci-
dence of delirium. However, others argue that these
drugs are generally used to treat delirium and cannot be
said to have a significant impact on clinical outcomes,
including mortality rate.
Currently, while there is a possibility that antipsy-
chotics may cause a slight decrease in the frequency of
delirium, this may not necessarily lead to improvement
in a patient’s final prognosis, and in consideration of the
various side effects of antipsychotics (e.g., onset of extra-
pyramidal symptoms, torsade de pointes, ventricular
arrhythmias), the use of these drugs cannot be recom-
mended as a routine approach. As the recognition of
these observations is not yet mainstream, the import-
ance of this particular clinical question is considered to
be high.
CQ11-4: Should a “discontinue daily sedation” or an “aim
for a mild depth of sedation” protocol be followed when
treating adult patients under mechanical ventilation?
Answer (recommendation)
We recommend the routine application of a “discon-
tinue daily sedation” protocol or an “aim for a mild
depth of sedation” protocol when treating adult patients
under mechanical ventilation (1B: excerpted from the
PAD guidelines).
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Rationale
A moderate level of evidence indicates that a protocol
calling for “discontinuing daily sedation” can improve
prognosis more than continuous sedation in critically ill
mechanically ventilated adult patients. A moderate level
of evidence similarly indicates that a protocol calling for
“aiming for a mild depth of sedation” can improve
patient prognosis more than maintaining a deep level of
sedation. For these reasons, the PAD guidelines [242]
also recommend that either of these protocols is used
when determining a type and depth of sedation. How-
ever, there is currently insufficient data to support proto-
cols calling for “discontinuing daily sedation” or “aiming
for a mild depth of sedation,” and even the PAD guide-
lines have not yet been able to offer a consensus.
Based on the above, the current consensus is that
attending physicians may select sedation protocols
calling for either “discontinuing daily sedation” or “aim-
ing for a mild depth of sedation.” In addition, although
there were few studies limited to sepsis patients and
most of the studies forming the basis for this consensus
targeted general critically ill adult patients, each of these
studies is considered also to apply to sepsis patients.
It is already clear that excessive maintenance of a se-
dated state unnecessarily prolongs the period of mech-
anical ventilation leading to the occurrence of ventilator-
associated pneumonia and unsuccessful weaning trials.
Critically ill patients must be kept as alert as possible to
conduct routine delirium monitoring, which has high
clinical importance.
CQ11-5: Should “analgesia-first sedation” or “hypnosis-
focused sedation” be used when treating adult patients
under mechanical ventilation?
Answer (recommendation)
We suggest the use of “analgesia-first sedation” when
treating adult patients under mechanical ventilation (2B:
excerpted from the PAD guidelines).
Rationale
Analgesia-first sedation has been demonstrated to result
in greater improvement in patient prognosis in compari-
son to hypnosis-focused sedation in critically ill adult
patients under mechanical ventilation, and the PAD
guidelines [242] also recommend this approach with the
support of a moderate level of evidence. In addition,
although critically ill patients must be kept as alert as
possible in order to routinely assess for delirium, main-
taining the sedation level of these patients, who are
under a great deal of stress, as low as possible must also
provide “sufficient pain relief” and has high clinical
importance.
Many of the studies underpinning these observations
targeted general critically ill adult patients, and although
there are few studies limited to sepsis patients, each of
these reports is considered to apply to sepsis patients as
well.
CQ12: Acute kidney injury/blood apheresis
Introduction
The Risk, Injury, Failure, Loss, End-Stage Kidney Disease
(RIFLE) classification proposed by the Acute Dialysis
Quality Initiative (ADQI) in 2004 [244] was the first spe-
cific, internationally accepted, universally understand-
able, and widely accepted definition of acute renal
failure. The clinical utility of the RIFLE criteria with re-
spect to metrics such as prognostic prediction has
already been demonstrated via meta-analysis [245]. A
subsequent report stated that slight increases in serum
creatinine values could have a substantial impact on pa-
tient prognosis [246]. In 2007, the Acute Kidney Injury
Network (AKIN) defined acute kidney injury (AKI) as a
condition characterized by a very mild increase in serum
creatinine (sCre) as well as (1) ΔsCre ≥ 0.3 mg/dL
(within 48 h), (2) a 150% increase from the baseline sCre
value (within 7 days), and (3) hourly urine volume of ≤
0.5 mL/kg. The AKIN criteria, a modified version of the
RIFLE criteria, was also proposed at the same time
[247]. Furthermore, the Kidney Disease: Improving Glo-
bal Outcomes (KDIGO) group presented the AKI Clin-
ical Practice Guidelines in 2012, which summarized the
then-current body of evidence and also proposed the
KDIGO criteria, which integrated the RIFLE and AKIN
criteria [248]. Today, the KDIGO criteria are widely used
in the assessment of acute-stage renal disorders and
have also been adopted as an entry standard in various
clinical studies.
Some epidemiological studies using the internationally
accepted AKI definition in this manner have since been
reported. Among the various etiologies of AKI, AKI aris-
ing from sepsis (sepsis-induced AKI) most frequently oc-
curs in patients requiring intensive care and is said to
comprise 30–70% of all cases of AKI [249]. Other re-
ports have also stated that sepsis-induced AKI occurs in
approximately 10–20% of all intensive care unit (ICU)
patients [250]. Furthermore, because sepsis-induced AKI
often results in serious injury to vital organs due to the
persistent overproduction of inflammatory mediators,
this type of AKI increases in severity more rapidly than
AKIs of other etiologies, and various studies have
highlighted its association with a high rate of mortality.
Conversely, recovery of renal function can be easily
achieved if a patient’s general condition improves [249].
Based on these observations, diagnosing AKI at an early
stage is particularly critical in sepsis cases in order to
prevent disease progression. Thus, the first clinical ques-
tion (CQ) in this chapter addresses the diagnosis of
sepsis-induced AKI.
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Acute blood apheresis techniques such as hemodialysis
and hemofiltration are initiated to avoid life-threatening
events when AKI progresses and a marked decline in
renal function is observed. Blood apheresis is a supple-
mentary therapy to the function of the kidney, rather
than a curative treatment for kidney damage. There is
believed to be no room for debate concerning the utility
of emergency initiation of blood apheresis in cases of
pathological conditions such as life-threatening hyperka-
lemia, advanced acidosis, and overflow. However, to
maintain homeostatic conditions such as the electrolyte
and acid-base equilibria and the adjustment of body
fluid volume, earlier initiation of blood apheresis, adjust-
ments in treatment approaches (amount of treatment
given, etc.), and stronger measures to improve abnor-
malities are likely correlated with improved survival
rates and recovery of kidney function, and various stud-
ies have been conducted from this standpoint. Several
CQs on this topic as well as the AKI clinical practice
guidelines behind the creation of KDIGO are presented.
Sepsis-induced AKI often develops as a type of organ
disorder in which the dysfunction of several vital organs
is induced sequentially as a result of prolonged secretion
of large quantities of inflammatory mediators as de-
scribed above. As such, the goal of acute blood apheresis
is not only to supplement normal renal functions such
as maintaining the balance of electrolytes, the acid-base
equilibrium, and appropriate body fluid volume but has
also come to include the treatment and prevention of
organ disorders through the removal and control of
these inflammatory mediators. Although there have been
many studies examining whether earlier initiation of
blood apheresis or adjustments in treatment approaches
can be expected to lead to further improvements in
survival rates and recovery of renal function in sepsis-
induced AKI, it must be emphasized that there are nu-
merous studies examining renal supplementation as well
as other treatment objectives, and careful interpretation
is necessary when assembling bodies of evidence.
With respect to the performance of acute blood apher-
esis, it cannot be overstated that there were never any
standardized aspects (e.g., modality selection, initiation/
discontinuation criteria, treatment procedure) at any
point of treatment provision. Because of this, not only
treatment modality and initiation/discontinuation cri-
teria, but also the volume of blood filtered (and if dialy-
sis and filtration are performed simultaneously, the
proportion of blood filtered as well), the route used to
administer fluid supplementation, the type of dialysis/
apheresis apparatus, the frequency of exchange, the
type(s) of anticoagulants administered, as well as many
other factors pertaining to treatment methodology must
be clarified to determine the optimal treatment approach
for a given pathology in actual practice. While selecting
CQ topics in this area, it was believed that of the various
aspects of the methodology of treatment mentioned pre-
viously, CQ12-2 on whether blood apheresis should be
performed early, CQ12-3 on whether blood apheresis
should be performed continuously or intermittently, and
CQ12-4 on whether the volume of blood to be filtered
should be increased were suitable for presentation in
consideration of their respective importance and quality
of the accompanying evidence.
Polymyxin B-immobilized fiber column direct hemo-
perfusion (PMX-DHP) is performed as a specialized
acute blood apheresis technique intended for the control
and removal of inflammatory mediators. This technique
was developed in Japan in 1994 as an endotoxin adsorp-
tion column, is covered by the Japan National Health
Insurance (NHI), and is widely performed as a support-
ive therapy in patients with septic shock. As such,
CQ12-5 discusses this technique.
Next, no specific and effective treatment for AKI has
been established to date. The utility of some drugs (fur-
osemide, dopamine, and carperitide) has been studied,
and these studies are discussed in CQs 12-6 to 12-8.
Furosemide is expected to be useful in the treatment of
AKI, as it prevents renal tubular obstruction caused by
detached cells through its diuretic action arising from
suppression of sodium reabsorption, raising oxygen con-
centration and increasing blood flow to the renal me-
dulla. Dopamine is believed to have renoprotective
effects due to its ability to cause renal vasodilation and
to suppress sodium reabsorption, especially at low doses
(1–3 μg/kg/min). Carperitide (atrial natriuretic peptide;
ANP) has demonstrated a vasodilative action, a suppres-
sive action on sodium reabsorption, and an ability to in-
crease glomerular filtration rate by means of afferent
arteriolar dilation and efferent arteriolar contraction and
is also believed to have renoprotective effects arising
from its diuretic and glomerular filtration rate enhancing
properties. Many reports have stated that these drugs do
not improve outcomes as measured by survival rates and
rates of initiation of dialysis. Meanwhile, furosemide has
been associated with side effects such as tinnitus and
hearing loss, dopamine may increase the risk of develop-
ing arrhythmias, and carperitide has been associated
with side effects such as hypotension. Accordingly, the
corresponding CQs for these drugs will examine their
clinical utility.
CQ 12-1: Are the KDIGO clinical practice guidelines useful
for diagnosing sepsis-induced AKI?
Answer (opinion)
We recommend applying of the KDIGO clinical practice
guidelines for diagnosing and determining the severity of
sepsis-induced AKI (expert consensus/quality of evi-
dence “D”) (rate of agreement, 100%).
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Rationale
Seven observational studies [251–257] examining patient
mortality rate as a clinical outcome were extracted dur-
ing an assessment comparing the KDIGO guidelines and
the AKIN and RIFLE criteria, and as a result of compar-
ing AKI diagnoses based on the KDIGO guidelines with
diagnoses based on the RIFLE or AKIN criteria, diagno-
ses based on the AKIN criteria were found to have
higher accuracy or were reflective of similar in-hospital
mortality rates. Although only the study by Peng et al.
[257] focused specifically on sepsis cases, the KDIGO
guidelines are currently still considered to be useful in
predicting prognosis in patients with sepsis-induced
AKI. However, few studies regarding renal prognosis
have been conducted to date, and currently little is
known about this aspect. All published studies found
were observational studies, and there have been no stud-
ies assessing diagnostic criteria as an interventional
approach. No additional burden is placed on patients or
medical personnel during diagnostic assessment. Additional
medical costs are required for tests procedures such as
measurement of sCre and urine volume measurement over
time. Virtually, all ICUs are capable of performing such
measurements, and it is likely that the potential benefits
outweigh the potential harms.
CQ 12-2: Should blood apheresis be initiated at an early
stage in patients with sepsis-induced AKI?
Answer (recommendation)
We suggest against the initiation of blood apheresis at
an early stage in sepsis-induced AKI except when emer-
gency apheresis is necessary, such as those involving
advanced metabolic acidosis, hyperkalemia, or renal
overflow (2C) (rate of agreement, 100%).
Rationale
Blood apheresis in sepsis-induced AKI has come to be
performed not only to supplement renal function but
also to prevent or treat organ disorders through the re-
moval and control of inflammatory mediators. Initiation
of blood apheresis at an early stage is believed to im-
prove the ease with which inflammatory mediators can
be removed and controlled, and many relevant random-
ized controlled trials (RCTs) have been conducted in
recent years. Although most of these RCTs are multiple
objective studies examining both renal supplementation
and inflammatory mediator removal, attempting to as-
sess these purposes separately is not practical. A new
meta-analysis was conducted after the results of two
large-scale RCTs were reported in May 2016.
Three RCTs [258–260] were used to perform the new
meta-analysis. In the results, the impact of early-stage
initiation of blood apheresis on 28- or 30-day mortality
was a risk ratio of 0.83 (95% confidence interval (CI)
0.64–1.09), and a risk ratio of 0.51 for the rate of dialysis
dependence on day 60 (95% CI 0.25–1.06). No statisti-
cally significant differences and no benefits of early-stage
initiation were observed. However, although there was
no significant difference in the rate of dialysis dependence,
early-stage initiation is expected to have some benefits re-
garding clinical utility. Two multicenter RCTs [261, 262]
were ongoing as of June 2016, and the consensus on this
subject may change based on their results.
Although decreased mortality rate is an expected
benefit of this intervention, no differences between the
intervention group and the control group were observed
with respect to ICU stay time, 28-day mortality rate, or
rate of transition to chronic dialysis. In general,
hemorrhagic complications and other adverse events are
recognized as potential harms, but no differences in the
incidence of these events were observed between the
study groups in these two RCTs. The burden on medical
staff will also increase as a result of this intervention.
The potential harms will outweigh the potential benefits,
and associated medical costs and staff burden will also
increase. Moreover, there are serious concerns over the
feasibility of performing this intervention at facilities
without adequate human resources or staff proficient in
its implementation.
CQ 12-3: Should blood apheresis be performed continuously
or intermittently in patients with sepsis-induced AKI?
Answer (recommendation and opinion)
We suggest that attending physicians select either continu-
ous or intermittent blood apheresis when treating sepsis-
induced AKI patients exhibiting stable hemodynamics (2B)
(rate of agreement, 94.7%).
We suggest selecting continuous apheresis in patients
exhibiting unstable hemodynamics (expert consensus/no
evidence) (rate of agreement, 84.2%).
Rationale
When deciding whether to perform continuous or inter-
mittent blood apheresis, it is important to consider vari-
ous factors such as whether the medical staff can cope
with the additional workload and whether suitable
equipment are available. If either option is feasible, the
discretion of the attending clinician during selection is
considered to be of high importance.
Only one new RCT has been conducted since the
existing systematic review [263], which also yielded the
same results as the systematic review, and so the assess-
ment was made using the existing systematic review. A
total of 15 studies were examined; “in-hospital mortality”
was assessed based on seven RCTs [264–270] and
yielded a risk ratio of 1.01 (95% CI 0.92–1.12); “transi-
tion to chronic dialysis” was examined based on three
RCTs [264, 266, 269] and yielded a risk ratio of 1.01
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(95% CI 0.92–1.07); no difference was observed between
apheresis performed continuously and intermittently.
Three RCTs [269–271] were also examined with respect
to reduction in blood pressure, and no differences in the
risk ratio of 0.92 (95% CI 0.72–1.16) were observed in
the studies. However, the two RCTs [266, 268] extracted
from the systematic review followed protocols that
excluded cases involving patients with unstable
hemodynamics. Continuous blood apheresis is already
recognized as a standard treatment in such cases, and
no RCT conducted to date has compared continuous
and intermittent apheresis.
Continuous and intermittent blood apheresis are
considered to be equivalent regarding potential benefits
relating to in-hospital mortality rate and rate of transi-
tion to chronic dialysis. Although there is currently a
lack of evidence regarding potential harms, continuous
blood apheresis is associated with an increased risk of
bleeding, greater medical costs arising from a longer
implementation period, and increased workload on
medical technicians and nurses.
Based on the above, the expert consensus reached is that
continuous apheresis is preferable when patients present
with unstable hemodynamics. However, because continu-
ously and intermittently performed variants of blood
apheresis have different characteristics, in cases where
minimizing anticoagulant use is necessary, attending in-
tensive care physicians or renal specialists must carefully
consider these characteristics when determining whether
to implement measures such as performing short-term
apheresis without administering an anticoagulant.
CQ12-4: Is increasing the volume of blood filtered via
blood apheresis beneficial in sepsis-induced AKI cases?
Answer (recommendation and opinion)
We recommend against increasing the volume of blood fil-
tered beyond the international standard volume (20–25 mL/
kg/h)(1B) (rate of agreement, 89.4%). It should also be noted
that the evidence supporting the blood filtration volume
covered by the NHI system (10–15 mL/kg/h) is weak
(expert consensus/no evidence) (rate of agreement, 73.7%).
Rationale
RCTs are actively being conducted elsewhere to assess
whether increasing blood filtration volume (filtrate vol-
ume + dialysis volume) can improve patient outcomes in
sepsis-induced AKI. However, the NHI system defines
an upper limit for filtration volume that is coverable
under the system. As such, this CQ will reassess the
current body of evidence.
No new RCTs were completed since the existing sys-
tematic review [272], and the assessment for this CQ
was conducted using this systematic review. Eight RCTs
comparing an intervention group (high-volume, 40 mL/
kg/h) and a control group (international standard quan-
tity, 25 mL/kg/h) were assessed with respect to “28-day
mortality rate.” In addition, “recovery from kidney fail-
ure” was used to evaluate “transition to chronic dialysis.”
The risk ratio for “28-day mortality rate” was 0.89 (95%
CI 0.76–1.04) and the risk ratio for “recovery from
kidney failure” was 1.12 (95% CI 0.95–1.31). Treatment
effects were evaluated in the same manner even if the
blood filtration volume was increased. There is no
evidence from Japan regarding a comparison of the
NHI-defined filtration volume and the international
standard volume, and so evaluation was not possible.
No differences between the intervention and control
groups were observed with respect to 28-day mortality
rate and the rate of transition to chronic dialysis. Based
on these findings, the effects of blood apheresis remain
unchanged even after increasing the blood filtration vol-
ume. Although there is no supporting evidence, when
selecting a fluid replacement solution for blood filtra-
tion, which are widely used as dialysis fluids or fluid
replenishers in Japan, electrolyte imbalances such as
hypokalemia and hypophosphatemia can easily occur as
a result of increasing the apheresis volume. The labor
burden placed on medical technicians and nurses who
replace fluid pouches will increase as a result of this
intervention. In consideration of the above, the potential
harms likely outweigh the potential benefits.
CQ12-5: Is performing PMX-DHP recommended when
treating patients with septic shock?
Answer (recommendation)
We suggest against performing PMX-DHP as a standard
treatment for patients with septic shock (2C) (rate of
agreement, 84.2%).
Rationale
PMX-DHP is a specialized variant of acute blood apher-
esis used to remove and control inflammatory mediators.
This technique was developed in Japan in 1994 as an
endotoxin adsorption column, is covered by the NHI,
and is widely performed as a supportive therapy in pa-
tients with septic shock.
Three RCTs (Vincent [273]; Cruz [274]; and Payen
[275]) were extracted as a result of the systematic review
conducted for this CQ. However, the participants in each
of these studies presented with septic shock arising from
intraperitoneal infection requiring emergency abdominal
surgery. Each of these RCTs reported increased mortal-
ity, and two reported increased mean blood pressure. In
contrast, none of these RCTs reported results related to
shock recovery rate. The odds ratio with regard to the
impact of PMX-DHP on mortality rate was 1.1 (95% CI
0.68–1.79), and no improvements in survival rate were
observed. The studies by Vincent [273] and Cruz [274]
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examined increases in mean blood pressure. The mean
difference observed was 4.59 (95% CI − 1.71–10.90), and
no significant improvements in blood pressure were
observed. No differences between the intervention and
control groups were observed with respect to decreases
in mortality rate or increases in mean blood pressure.
Moreover, these RCTs did not assess shock recovery
rate, and also did not recognize thrombocytopenia as an
adverse event. Meanwhile, Payen [275] reported a sig-
nificant decrease in the incidence of thrombocytopenia
occurring on day 3 of treatment in the PMX-DHP
group, but did not quantify the reductions in platelet
count. Based on the above, the potential risks associated
with PMX-DHP are likely to outweigh the potential
benefits.
All RCTs extracted for this CQ-targeted subjects
presenting with septic shock arising from intraperitoneal
infection, and no RCTs targeting other patients with
septic shock could be found. For this reason, cases other
than those involving intraperitoneal infections cannot be
examined at this time due to a dearth of evidence. One
large-scale RCT, the EUPHRATES (Evaluating the Use
of Polymyxin B Hemoperfusion in a Randomized
controlled trial of Adults Treated for Endotoxemia and
Septic shock) study [276] is currently in progress and is
scheduled to be completed in 2016. The results of the
EUPHRATES study are expected to be noteworthy as it
targets participants presenting with septic shock arising
from diseases other than intraperitoneal infection such
as pneumonia, and also focuses on severe cases.
CQ12-6: Should furosemide be administered to prevent
or treat sepsis-induced AKI?
Answer (recommendation)
We suggest against administering furosemide to prevent
or treat sepsis-induced AKI (2B) (rate of agreement,
94.7%).
Rationale
Although furosemide inhibits sodium reabsorption and
produces a diuretic effect, this drug is expected to pre-
vent or promote improvement in AKI by maintaining
steady urine volume, and numerous clinical studies have
been conducted to assess this potential.
Two meta-analyses [277, 278] and 11 RCTs were
extracted. The results of both meta-analyses indicated no
effect on in-hospital mortality rate and the need for blood
apheresis as a result of furosemide administration, and no
new RCTs have been completed to date. Although
decreased mortality and need for dialysis were the
expected benefits of this intervention, no significant differ-
ences between the intervention groups that received fur-
osemide as a preventive or treatment and the control
groups were observed with regard to in-hospital mortality
and necessity of dialysis. Administration of high-dose fur-
osemide (1–3.4 g/day) was associated with temporary
hearing loss and tinnitus [278] (risk ratio, 3.97; 95% CI
1.00–15.78). Based on the above findings, the potential
harms likely outweigh the potential benefits.
According to the meta-analysis by Ho et al. [277],
furosemide administration demonstrated no significant
effect on in-hospital mortality or the need for blood
apheresis. Likewise, furosemide is not recognized as
effective for the prevention of AKI or for promoting re-
covery of impaired renal function. Neither of the two
RCTs that were limited to AKI patients undergoing
blood apheresis showed a significant decrease in the
blood apheresis period (days) or earlier recovery from
renal dysfunction in the furosemide group. In addition,
the results of another meta-analysis [278] indicated that
high-dose furosemide, which is often given to treat AKI,
resulted in a significantly increased incidence of symp-
toms such as tinnitus and hearing loss in comparison
with the control group. In contrast, it has also been
reported in actual clinical practice that the administra-
tion of furosemide improves electrolyte imbalances such
as excessive body fluid volume and hyperkalemia.
However, no RCTs limited to AKI patients presenting
with such clinical signs have been reported to date. It
should be noted that the above recommendation does
not rule out the use of furosemide to manage excess
body fluid volume.
CQ12-7: Should dopamine be administered to prevent or
treat sepsis-induced AKI?
Answer (recommendation)
We recommend against adinistering dopamine to prevent
or treat sepsis-induced AKI (1A) (rate of agreement,
100%).
Rationale
Although dopamine is expected to cause renal vasodila-
tion and natriuresis at low doses (1–3 μg/kg/min) result-
ing in a renoprotective effect, its clinical utility has not
yet been verified. In contrast, there are also concerns
that dopamine administration can lead to the incidence
of adverse effects such as tachycardia, myocardial ische-
mia, and reduced intestinal blood flow. Complications
such as arrhythmia and cardiac/limb/skin ischemia have
occurred clinically, but no significant increase in these
events was observed in the meta-analysis targeting AKI
cases. However, it has been reported that dopamine
administration in the treatment of sepsis significantly
increases the frequency of arrhythmias [279]. Based on
the above observations, clarifying the clinical utility of
low-dose dopamine in patients with sepsis-induced AKI
is considered to be of importance to attending
physicians.
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Two meta-analyses were extracted [279, 280], and it has
been shown that administering dopamine does not lead to
improvement in terms of either prolonged survival time
after receiving low-dose dopamine or decreased rate of
dialysis initiation. No new RCTs involving patients with
sepsis have been completed to date.
Although reduced mortality and need for dialysis were
expected benefits of this intervention, no significant
differences between the intervention and control groups
in terms of in-hospital mortality rate and the need for
dialysis were observed.
The risk ratio for adverse effects relating to arrhythmia
and ischemic findings was 1.13 (95% CI 0.90–1.41) and
was not statistically significant. Based on the above, the
potential harms likely outweigh the potential benefits.
CQ12-8: Should ANP be administered to prevent or treat
sepsis-induced AKI?
Answer (recommendation)
We suggest against administering ANP to prevent or
treat sepsis-induced AKI (2B) (rate of agreement,
94.7%).
Rationale
ANP (carperitide, a synthetic analogue) is a cardiac hor-
mone discovered in Japan together with brain natriuretic
peptide (BNP) and C-type natriuretic peptide (CNP) and
acts as a vasodilator, suppresses sodium reabsorption,
and increases glomerular filtration rate via dilation of
the afferent renal arterioles and contraction of the effer-
ent renal arterioles. In the prevention and treatment of
AKI, ANP is expected to exhibit a renoprotective effect
resulting from its diuretic effect and ability to increase
glomerular filtration rate, and many clinical studies have
been conducted to verify this effect. However, some have
reported that the administration of high doses of ANP
can increase the frequency of adverse events such as
hypotension and arrhythmia. Based on the above, clarify-
ing the clinical utility of ANP in patients with sepsis-
induced AKI is considered to be of importance to
attending physicians.
Two meta-analyses were extracted, and neither dem-
onstrated any reduction in the frequency of blood apher-
esis. Subsequently, no new RCTs on this subject have
been completed to date. The incidence of complication
by hypotension significantly increased (risk ratio, 1.69;
95% CI 1.29–2.22), but lower doses did not yield a sig-
nificant association with hypotension (risk ratio, 1.25;
95% CI 0.87–1.81). In addition, the AKI preventive effect
obtained with low doses has been verified based primar-
ily on cases of AKI occurring after heart surgery, and
the results of another meta-analysis [281] also suggest
the utility of ANP. However, the level of assessment with
respect to sepsis cases remains insufficient.
Although reduced mortality and need for dialysis were
expected benefits of this intervention, no significant dif-
ferences between the intervention and control groups
were observed regarding in-hospital mortality rate and
the need for dialysis.
Overall, associated risks included the significantly
greater likelihood of complication by hypotension, and
lower doses did not yield a significant association with
hypotension. Based on the above, the potential harms
likely outweigh the potential benefits.
CQ13: Nutrition
Introduction
Catabolism is accelerated during serious conditions such
as trauma, burns, or sepsis [282–284]. Malnutrition pro-
gresses due to catabolic processes, increasing susceptibility
to infection and resulting in a deterioration of physio-
logical function. Then, it leads to an increase in the
frequency of infections, duration of ventilation, the length
of hospital stay, and mortality rate [285]. Appropriate
nutritional intervention has been demonstrated to control
these vital reactions and improve prognosis [286].
This guideline presents five clinical questions (CQs)
focusing on basic aspects of administering nutritional
supplementation to sepsis patients. Recommendations
offered by CQ13-1, CQ13-3, CQ13-4, and CQ13-5 were
formulated based on either the same procedures for con-
ducting systematic reviews and meta-analyses applied in
the preparation of the Japanese Guidelines for Nutrition
Support Therapy in the Adult and Pediatric Critically Ill
Patients (hereinafter, the JSICM guidelines) [287], or
were created based on the results of a meta-analysis
examining randomized controlled trials (RCTs) pertain-
ing to the subject of the CQ. While CQ13-2 was
prepared based on the existing international guidelines
reflected in the JSICM guidelines, a literature review,
systematic review, and meta-analysis were each con-
ducted again in the preparation of this CQ. Little evi-
dence limited to sepsis patients could be found for any
CQ, and recommendations are offered based on the
results of RCTs targeting critically ill patients.
The first CQ on the topic of nutrition management
offers a recommendation on how to prioritize the route
of administering nutritional support (i.e., enterally or
parenterally). Six meta-analyses were conducted to
analyze 36 RCTs that compared the influence of enteral
and parenteral nutrient delivery routes on various clin-
ical outcomes (such as mortality rate, incidence of infec-
tion, and length of ICU/hospital stay) by targeting
various disease/injury states (including external trauma,
surgery, acute pancreatitis, and burns). These RCTs are
also systematically reviewed in the JSICM guidelines
[287], but only one study specifically targeted sepsis
patients. As such, the literature upon which this
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guideline is based is limited to RCTs targeting “critically
ill patients requiring ICU management.” Stated differ-
ently, literature sources targeting postoperative patients,
and those with mild or chronic diseases were excluded.
CQ13-2 offers a recommendation for when enteral
nutritional support should be initiated. In the meta-
analysis, enteral nutrition within 24 h after ICU admis-
sion decreased mortality [288–290], the frequency of
complication from infection [288–290], and length of
hospital stay [291]. However, the RCTs targeted by these
meta-analyses were small-scale studies, and many were
of low research quality. Many of the RCTs that reported
observing decreased mortality rates were prone to selec-
tion bias and execution bias, and according to the results
of the most recent meta-analysis, initiating early enteral
nutrition was not found to reduce mortality rates when
only studies less prone to bias were examined [292]. The
studies targeted for this CQ initially included critically ill
patients because there are few studies on sepsis. How-
ever, some of these studies included patients who were
not critically ill. For this reason, studies that may have
involved patients on parenteral nutrition or included
patients who were not critically ill were excluded from
the analysis. Sensitivity analysis was conducted with six
RCTs that grouped participants who received enteral nu-
trition within 24 h of ICU admission into “early” groups.
CQ13-3 offers a recommendation concerning optimal
quantities for enteral feeding. The definitions of dose-
limiting groups vary among the studies on this topic,
and how nutritional supplementation administered is
limited must be assessed carefully. Types of dose limita-
tion can be roughly classified as follows: (1) low-volume
administration refers to the so-called trophic feeding.
This method involves approximately 25% of daily calorie
consumption or 500 kcal/day (20 kcal/h) and is often
used to maintain the intestinal mucosa or immune func-
tion. (2) Mild calorie restriction: this method is also
referred to as the so-called permissive underfeeding or
hypofeeding and calls for approximately 60–70% of daily
caloric consumption. This method is designed to provide
slightly less than the typical daily caloric consumption to
avoid oxidative stress and autophagic disorders. (3)
Standard administration: supplementation starts with a
small quantity and increases to the typical daily caloric
consumption over time. (4) Administration of the typical
daily caloric consumption from the beginning: an
amount approximating the typical amount of calories
consumed daily is administered from the start of nutri-
tional supplementation, which can be reduced if symp-
toms of intolerance such as increased stomach volume
or diarrhea are observed. This method is used to
minimize a patient’s caloric deficit as much as possible.
In accordance with the rules of guideline committee, the
recommendations offered in this CQ cite the latest
version of the meta-analysis conducted while formulat-
ing the JSICM guidelines. The meta-analysis for this
guideline was conducted using three distinct groups: (1)
a trophic feeding group, (2) a permissive underfeeding
or hypofeeding group, and a “full feeding” group com-
prised of supplementation methods (3) and (4) together.
However, there were only a few references available for
each group, and no significant differences or trends were
observed regardless of the outcome. As such, methods
(1) and (2) together are presented as the “underfeeding”
group, which is compared with the “full feeding” group.
As a result, it was also found that no significant differ-
ences exist between the groups with respect to mortality
rate and the incidence of complication by infection. In
the “full feeding” group, concerns regarding the risk of
aspiration and the increased frequency of diarrhea in-
crease in proportion with increases in the residual gas-
tric volume. In addition, the potential need for renal
replacement therapy also increases. Accordingly, provid-
ing enteral nutrition in quantities approximating the typ-
ical daily caloric consumption from the start is not
recommended. According to a study by Rice et al. [293],
while even 15 or 25% of daily caloric consumption could
be sufficient to provide optimal nourishment, the body
mass index (BMI) of the patients targeted was close to
30, and the average age was 53 years. This situation is
often encountered when adapting evidence derived from
such patients in Japanese ICUs, where many patients are
elderly and have an average physique. Meanwhile, no
RCTs involving malnourished patients could be found,
and the optimal volume of supplementation for such pa-
tients remains unknown. However, recommendations are
offered in consideration of the observation that complica-
tions tend to increase with increasing caloric deficit [294].
CQs 13-4 and 13-5 offer recommendations regarding
when to initiate parenteral nutrition and the optimal
quantities. Stated differently, these recommendations con-
sider the difference between energy consumed and the
caloric value of enteral nutrition (i.e., whether it is neces-
sary to supplement a caloric deficit parenterally or to ad-
minister parenteral nutrition at an early stage in cases
where enteral nutrition is not possible). The discussion of
when to initiate parenteral nutrition in CQ13-4 is based
on a novel meta-analysis targeting six RCTs extracted dur-
ing the formulation of the JSICM guidelines ([295]; [296];
[297]; [298]; [299]; and [300]; please refer to the CQ com-
ments for further details on each study).
Meanwhile, no studies targeting patients with malnu-
trition could be found for the corresponding CQ, and
recommendations were formulated based on inter-
national guidelines and the expert opinions of members
of the Guideline Committee. As no studies capable of
serving as an evidentiary basis for a recommendation re-
garding the optimal quantity of parenteral nutrition
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addressed by CQ13-5 could be found, it was suggested
that the recommendation be based on three RCTs
([295]; [297]; and [298]; please refer to the CQ com-
ments for further details on each study). These RCTs
influenced the recommendations offered for the corre-
sponding topics in the JSICM guidelines, as well as one
additional relevant RCT identified by conducting an-
other literature search using the same search parameters
(please refer to the CQ comments for further details on
this study). The recommendation for this CQ is pre-
sented as the opinion of the Guideline Committee
(expert consensus).
CQ13-1 which route of nutrient delivery should be
prioritized: Enteral or intravenous?
Answer (recommendation)
We recommend that enteral nutrition rather than paren-
teral nutrition in sepsis patients (1B) (rate of agreement,
94.7%).
Rationale
Several studies targeting critically ill patients requiring
ICU management were extracted from the JSICM guide-
lines. These studies included 11 RCTs concerning mor-
tality rates [301–311] and seven RCTs concerning
infection frequency [303–307, 310, 312].
Regarding potential benefits, although no improve-
ment in mortality rate was observed in seven studies
focusing on trauma, one on sepsis, one on pancreatitis,
and two on surgery or serious internal illness, the benefit
of enteral nutrition with respect to reduced infection
frequency was confirmed in five studies focusing on
trauma, one on sepsis, and one on pancreatitis. However,
the study by Harvey et al. was not included in the ana-
lysis regarding the incidence of infection as it did not
describe the incidence of all infections. Also, no compli-
cations impacting prognosis were observed, and as
enteral nutrition was found to reduce the burden of
medical costs as well [295], it was concluded that the
benefits outweigh the potential risks.
CQ13-2: When should enteral nutrition be initiated?
Answer (recommendation)
We recommend that enteral nutrition be initiated early
(within 48 h) if a patient will be unable to maintain a
sufficient oral caloric intake during the first several days
after the onset of sepsis (1C) (rate of agreement, 94.7%).
Rationale
Nine RCTs were extracted based on the systematic re-
view conducted for this CQ [313–321]. Mortality rate
was assessed by eight RCTs; infection frequency, the
length of ICU stay, and duration of ventilation were
assessed by seven RCTs, and length of hospital stay was
assessed by four RCTs. The risk ratio for the impact of
early enteral nutrition on mortality rate was 0.9 (95%
confidence interval (CI) 0.52–1.41), the risk ratio for the
impact on infection frequency was 0.7 (95% CI 0.51–
1.02), the impact on length of ICU stay was − 2 days
(95% CI − 5.25–1.18), no impact was observed with
respect to length of hospital stay (0 days; 95% CI −
17.18–16.53), and the impact on duration of ventilation
was − 1 day (95% CI − 4.82–2.49).
Regarding potential benefits, although no differences
in mortality rate, duration of ventilation, or length of
hospital stay were observed based on a comparison of
patients that were started on enteral nutrition within
48 h of ICU admission and patients receiving enteral nu-
trition after 48 h, the incidence of infections was lower
in the early feeding group. In the sensitivity analysis, an
additional intervention group started on enteral nutri-
tion within 24 h of ICU admission was established, and
it was found that the incidence of infection and length
of ICU stay were significantly lower in the early feeding
group. Regarding potential harm, no clear adverse effects
were observed, and as enteral nutritional solutions are
inexpensive and their use does not increase medical staff
workload, it was concluded that the benefits outweigh
the potential risks.
CQ13-3: What is the optimal amount of calories in early
enteral nutrition?
Answer (recommendation and opinion)
We suggest against administering an amount of calories
approximating typical caloric intake during the initial
ICU period (approximately 1 week) if the patient was
not malnourished before the onset of sepsis (2C) (rate of
agreement, 89.5%).
We suggest against limiting caloric intake in malnutri-
tion. In this situation, nutrition should be provided while
considering the risk of developing refeeding syndrome
(expert consensus/no evidence).
Rationale
Six RCTs [322–327] included in the systematic review of
the JSICM guidelines were extracted. All six RCTs
reported on mortality rate, three reported on infection
frequency, two RCTs reported on the duration of venti-
lation, the length of ICU stay, and length of hospital
stay; four RCTs reported on ventilator-associated pneu-
monia (VAP); and two RCTs reported on the frequency
of continuous renal replacement therapy (CRRT) use.
The risk ratio for the impact of caloric restriction on
mortality rate was 0.93 (95% CI 0.83–10.7), and the risk
ratio for the impact on the frequency of infection was
1.08 (95% CI 0.83–1.41). In addition, the effect of caloric
restriction on duration of ventilation was − 1.04 days
(95% CI − 3.29–1.20), the effect on length of ICU stay
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was −1.8 days (95% CI − 4.22–0.86), the impact on
length of hospital stay was − 0.84 days (95% CI − 19.2–
17.5), the risk ratio for the effect on VAP incidence was
0.9 (95% CI 0.68–1.17), and the risk ratio for the effect
on frequency of CRRT use was 0.64 (95% CI 0.45–0.91).
The observed benefit was a lower frequency of CRRT
administration in the calorie restricted feeding group.
No clear adverse effects were observed. However, some
previous studies have reported observing adverse out-
comes (such as more hospital transfers than discharges)
associated with low-volume enteral nutrition (trophic
feeding). In addition, enteral nutrition is inexpensive and
requires small quantities of feeding solution, and as
such, its potential risks are small.
CQ13-4: When should parenteral nutrition be initiated?
Answer (recommendation and opinion)
We suggest against that the initiation of parenteral nutri-
tion within the first week of hospitalization if there was no
malnutrition prior to the onset of sepsis/septic shock.
However, enteral nutrition may be initiated within 1 week
of hospitalization (2D) (rate of agreement, 84.2%).
We suggest that initiating parenteral nutritional sup-
plementation should be considered while monitoring the
risk of developing refeeding syndrome if malnutrition is
observed before ICU admission, or enteral nutrition can-
not be initiated within 1 week of hospitalization (expert
consensus/no evidence).
Rationale
In a meta-analysis of six RCTs extracted from the JSICM
guidelines [287] ([328], [296], [297], [298], [299], and
[300]), all six reported on mortality rate, four reported
on bloodstream infection or respiratory infection, and
five reported on urinary tract infection. The risk ratio
for the impact of initiating parenteral nutrition within
1 week on mortality rate was 0.95 (95% CI 0.81–1.11),
the risk ratio for the impact on bloodstream infections
was 1.22 (95% CI 1.02–1.46), the risk ratio for the im-
pact on respiratory infections was 1.07 (95% CI 0.87–
1.32), the risk ratio for the impact on urinary tract infec-
tions was 1.12 (95% CI 0.84–1.49), and bloodstream
infections significantly increased.
Although no benefits were observed in the context of
this CQ, the incidence of bloodstream infections in-
creased in the group that was started on total parenteral
nutrition within 1 week. In addition, the greater cost of
parenteral nutrition could place an additional burden on
these patients. Based on these observations, the potential
harm was determined to outweigh the potential benefits.
Selective bias in the studies adopted for this CQ was
higher in those involving patients with a higher BMI
compared to the Japanese patients and the group with
high caloric deficit because we excluded patients in
whom malnutrition was observed prior to ICU admis-
sion. In addition, the EPaNIC (Early versus Late Paren-
teral Nutrition in Critically Ill Adults) study accounted
for 70% of the participants in both groups, more than
half of whom were post-cardiac surgery patients. The
fact that many of these studies were conducted as open-
label studies has been pointed out as a source of execution
bias. Thus, in light of the weak body of clinical trial evi-
dence, it was determined that the benefits and risks of this
intervention should be assessed in the clinical setting.
CQ13-5: What is the optimal amount of calories in
parenteral nutrition?
Answer (recommendation and opinion)
We suggest that the use of parenteral nutrition in cases
where enteral nutrition cannot be initiated within 1 week
after the onset of sepsis/septic shock or if malnutrition
is observed (expert consensus/no evidence) (rate of
agreement, 94.7%).
We suggest against administering 100% of the target
caloric value in such cases (2C). However, the optimal
value remains uncertain (expert consensus/no evidence).
Rationale
No RCTs conforming to the PICO process could be
found. Evidence for this CQ was gathered from three es-
sential papers [297, 298, 328]. Differences in the nutri-
tional management discussed in these three papers were
examined, and the results were used to formulate the
opinions serving as a basis for the recommendation of-
fered by this CQ (expert consensus). One more RCT
[329] was found as in an additional search. This was a
small-scale study examining 50 cases involving gastro-
intestinal disease. The incidence rates of sepsis in 50
consecutive cases requiring nutritional therapy for 5 days
or more were compared between a group receiving 60%
of the typical caloric value based on Schofield’s estima-
tion formula and a group receiving 100% of the typical
caloric value. The incidence of sepsis (3 cases vs. 12
cases; p = 0.003), the incidence of systemic inflammatory
response syndrome (SIRS) (9 cases vs. 16 cases; p = 0.017),
and the frequency of nutrition-related complications (2
cases vs. 9 cases; p = 0.016) were significantly lower in the
60% administration group. Based on these results, it is rec-
ommended that 100% of the target caloric value should
not be given at least during the acute phase.
Regarding potential harm, early parenteral nutrition is
expected to prevent various complications arising from
an increased caloric deficit, particularly in malnutrition.
However, the possibility that administering 100% of the
target caloric value during parenteral nutrition may
increase the risk of complication by infection could not
be ruled out.
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CQ14: Blood glucose management
Introduction
Hyperglycemia can worsen patient prognosis by ad-
versely affecting immune function and increasing the
risk of infection. Thus, blood glucose management is
considered a crucial component of the treatment of pa-
tients with sepsis. An important adverse effect associated
with insulin-based glycemic control is hypoglycemia. As
its onset can worsen the prognosis in critically ill
patients, attending physicians must carefully consider
the benefits and risks of different target levels of blood
glucose control. Erroneous blood glucose measurements
can also lead to the improper use of insulin.
According to the results of a single-center randomized
controlled trial (RCT) involving cardiac surgery patients
in the ICU [330], ICU mortality declined as a result of
administering intensive insulin therapy with a target
blood glucose level of 80–110 mg/dL. Also, the results
of a subsequent RCT involving patients whose ICU stay
was estimated to be 3 days or longer indicated that
intensive insulin therapy did not reduce the mortality
rate of all patient groups [331]. In the Normoglycemia in
Intensive Care Evaluation and Survival Using Glucose
Algorithm Regulation (NICE-SUGAR) trial, intensive
insulin therapy was demonstrated to have increased the
90-day mortality rate [332]. A meta-analysis by Friedrich
et al. reported that intensive insulin therapy was not
beneficial to critically ill patients [333]. Another meta-
analysis by Song et al. involving sepsis patients also
showed that intensive insulin therapy carried a high risk
of hypoglycemia [334]. Given these findings, intensive
insulin therapy cannot currently be recommended for
sepsis patients. Based on the results of the NICE-
SUGAR trial, both the Surviving Sepsis Campaign
Guidelines (SSCG) 2012 and previous guidelines recom-
mend the initiation of insulin protocol at a blood glu-
cose level of ≥ 180 mg/dL and establish a target blood
glucose level of 144-180 mg/dL [2, 29].
However, although there have been numerous compar-
isons of target blood glucose values ≤ 110 mg/dL with
values ≥ 180 mg/dL among the various RCTs comparing
the impact of target blood glucose levels on mortality
rates, there is little direct evidence comparing other tar-
get blood glucose ranges. Therefore, the optimal range
of these two target blood glucose levels (110–144 and
144–180 mg/dL) was unknown. Because of this, the net-
work meta-analysis (NMA) method was used to conduct
indirect comparisons to be examined when direct com-
parisons did not exist to determine which of four differ-
ent target blood glucose ranges, ≤ 110, 110–144, 144–
180, or ≥ 180 mg/dL, was optimal in terms of balance of
clinical benefits and potential harm.
The incidence of in-hospital mortality and hospital
infections did not differ in direct comparisons. NMA
revealed that the 144–180 mg/dL range was significantly
lower than ≥ 180 mg/dL with respect to mortality rate.
The incidence of hypoglycemia, a potential adverse
effect of blood glucose control, was significantly higher
for the ≤ 110 and 110–144 mg/dL ranges in direct com-
parison to the 144–180 and ≥ 180 mg/dL ranges. As a
result of the NMA, no significant differences were
observed between the 144–180 and ≥ 180 mg/dL ranges.
We recommend a target blood glucose range of 144–
180 mg/dL based on these findings.
Blood glucose measurements in the ICU are often taken
using a glucometer or an arterial blood gas analyzer. How-
ever, the results may differ depending on the device used
as well as the blood sampling method. Glucometers are
used in many ICUs, but because this method of measure-
ment is frequently inaccurate and often yields an overesti-
mation, it is possible that the onset of hypoglycemia may
be overlooked [335]. Glucometer measurements using ca-
pillary blood are significantly less accurate in comparison
to glucometer measurements using venous blood or a
blood gas analyzer [336]. Erroneous glucometer measure-
ments using capillary blood is a clinically significant prob-
lem particularly in hypoglycemia cases (blood glucose
level ≤ 72 mg/dL), and blood glucose measurements taken
with blood gas analyzers are more accurate [335]. Regard-
ing measurement time, the use of an arterial blood gas
analyzer is recommended as well as the use of glucometer
with arterial/venous blood. We do not recommend the
use of glucometer with capillary blood. However, meas-
urement errors can occur even with these recommended
methods, and thus, measurements should be taken at a
central laboratory as appropriate in order to confirm
accuracy.
CQ14-1: What is the optimal blood glucose target level in
patients with sepsis?
Answer (recommendation)
We suggest an optimal target blood glucose range of
144–180 mg/dL in patients with sepsis (2C) (rate of
agreement, 100%).
Rationale
Our analysis included 14,495 patients from 27 studies
[128, 330–332, 337–359]. None of the studies were espe-
cially prone to bias. We performed an NMA in addition
to a direct comparison because there were no studies
that directly compared patients with a target blood
glucose level > 180 mg/dL to those with a target blood
glucose level of 144–180 mg/dL.
The direct comparison revealed that compared with
target blood glucose levels of 144–180 and > 180 mg/dL,
target blood glucose levels of 110–144 mg/dL were asso-
ciated with a significantly higher risk of hypoglycemia;
Nishida et al. Journal of Intensive Care  (2018) 6:7 Page 45 of 77
however, there were no significant differences in the risk
of mortality and infection.
The NMA showed that target blood glucose levels of
144–180 mg/dL were associated with a significantly
lower risk of hospital mortality and sepsis or blood-
stream infection compared with blood glucose levels >
180 mg/dL, and there were no significant differences in
the risk of hypoglycemia between the target blood
glucose levels of 144–180 and > 180 mg/dL.
The quality of evidence in the direct comparison was
B (moderate) to C (weak), and that in the NMA was C
(weak) to D (very weak). Finally, we decided that the
quality of evidence was C (weak).
Reduction of hospital mortality and infection is con-
sidered a benefit of blood glucose management. Our
NMA showed that compared with the target blood glu-
cose levels > 180 mg/dL, levels of 144–180 mg/dL were
associated with a significantly lower risk of hospital mor-
tality and sepsis. Furthermore, there were no significant
differences between the target blood glucose levels < 110
and 110–144 mg/dL with regard to these outcomes. The
increase in the incidence of hypoglycemia is considered
an adverse effect of blood glucose management.
Therefore, we assessed the balance between the risk
and benefit of blood glucose management as follows: (1)
target blood glucose levels < 110 and 110–144 mg/
dL—equilibrium or uncertain, (2) target blood glucose
levels of 144–180 mg/dL—benefit may exceed risk, (3)
target blood glucose level > 180 mg/dL—risk may exceed
benefit.
CQ14-2: What devices/instruments should be used to
measure blood glucose in sepsis patients?
Answer (recommendation)
We recommend against the use of a glucometer with
capillary blood in patients with sepsis (1B) (rate of agree-
ment, 94.7%).
We suggest the use of a glucometer with arterial/ven-
ous blood (2B) and recommend the use of an arterial
blood gas analyzer (1C) in patients with sepsis (rate of
agreement, 94.7%).
Rationale
The recommendation presented for this CQ was based
on the results of a systematic review conducted by Inoue
et al. [336] In a comparison of measurements taken
using a glucometer with capillary blood or a blood gas
analyzer using arterial blood, measurements taken using
the arterial blood gas analyzer were less likely to include
measurement errors falling significantly outside the
acceptable range (odds ratio, 0.04; 95% confidence inter-
val (CI) 0.01–0.14) [336]. In addition, in a comparison of
glucometer measurements using capillary blood or arter-
ial blood, the risk of measurement error was significantly
lower when arterial blood was used (odds ratio, 0.36;
95% CI 0.25–0.52). No significant difference was ob-
served between glucometer measurements using arterial
blood and blood gas analyzer (arterial blood), but meas-
urement errors tended to be lower when the blood gas
analyzer (arterial blood) was used (odds ratio, 0.17; 95%
CI 0.01–2.46) [336].
Regarding the benefit-risk balance, it was determined
that (1) the potential risks of glucometer (capillary
blood) use clearly outweighed the benefits, (2) the bene-
fits of glucometer (arterial/venous blood) use likely out-
weighed the potential risks, and (3) the benefits of using
a blood gas analyzer (arterial blood) clearly outweighed
the potential risks.
CQ15: Body temperature regulation
Introduction
Body temperature is an important indicator of the general
condition of the body. It is not uncommon to initiate new
medical treatment after observing hypothermia or fever
[360]. Fever is caused by endogenous interleukin-1 and
tumor necrosis factor-α, which are produced in response
to exogenous stimuli, and promote cyclooxygenase-
mediated prostaglandin E2 production in the arachidonic
acid cascade [361]. Fever is an important indicator of the
presence of infection, but can also be caused by factors
other than infection, such as surgery [362], blood transfu-
sion [363], drug therapy [364, 365], and acute rejection
[366]. In addition, there are often multiple causes of fever
in critically ill patients. In the Fever and Antipyretic in
Critically ill patients Evaluation (FACE) study, a multicen-
ter prospective observational study conducted in 25 facil-
ities located in Japan and South Korea, fever over 38.5 °C
occurred in 40.5% of ICU patients, and fever over 39.5 °C
occurred in 11.5% of ICU patients [367]. Fever causes pa-
tient discomfort, increased respiratory demand and myo-
cardial oxygen demand [368], and central nervous system
disorders. However, fever is also a defensive reaction that
increases antibody production, T cell activation, cytokine
synthesis, and activation of neutrophils and macrophages.
The heart rate and oxygen consumption can both be
expected to decrease if body temperature decreases as a
result of antipyretic therapy for fever. Antipyretic ther-
apy is generally administered to critically ill patients to
minimize discomfort and reduce minute ventilation.
Although antipyretic therapy may be given to reduce or
prevent fever-related adverse events, this type of therapy
is routinely administered to relieve the fever itself [367].
However, antipyretic therapy may also suppress benefi-
cial self-defense reactions. In addition, side effects may
occur, such as gastrointestinal, liver, or kidney disorders
[369].
The first clinical question (CQ) on this topic is
“Should antipyretic therapy be administered to sepsis
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patients presenting with fever?” Few studies have
assessed the impact of antipyretic therapy on patient
prognosis. Analyzing subgroups of patients treated via
external cooling or antipyretic medication was not pos-
sible. In addition, the threshold of body temperature for
initiating antipyretic therapy varies, and there is still no
consensus regarding the body temperature at which
antipyretic therapy should be initiated. At the very least,
the uniform administration of antipyretic therapy as a
standard treatment in adhering to the “initiate antipyr-
etic therapy after body temperature reaches 38.5 °C or
higher” approach is considered to be undesirable.
Reduction in the body temperature of patients with
sepsis is believed to be caused by the loss of the body’s
capacity to regulate temperature, sedation/muscle relax-
ation, or extracorporeal circulation. This phenomenon is
more likely to occur in severe cases than those with
fever. The definitions of Acute Physiologic Assessment
and Chronic Health Evaluation II (APACHE II) score
[370], sepsis [371], and Infection-related Ventilator-
Associated Complication (IVAC) [372] each specify
temperature values < 36 °C as abnormal. It has also been
reported based on the results of an analysis of the
Japanese Sepsis Registry that sepsis patients who
developed hypothermia with body temperatures below
36.5 °C within 24 h of hospitalization had a high rate of
mortality [373].
The second CQ presented on this topic is “Should we
attempt to correct the body temperature of hypothermic
sepsis patients?” There have been no studies conducted
to date that examine the influence of body temperature
correction on prognosis in hypothermic sepsis patients.
In addition, to carry out an interventional study in
patients with hypothermia to compare (1) leaving the
patients to recover naturally and (2) correcting body
temperature would be unethical. Attending physicians
should carefully monitor patients recovering from
hypothermia since they may become hemodynamically
unstable. Thus, physicians should consider a balance
between the adverse effects of hypothermia itself and
the risk associated with body temperature correction.
When necessary, body temperature should be corrected
gradually through methods such as extracorporeal circu-
lation, passive incubation, and covering the patient with
a blanket.
CQ 15-1: Should antipyretic therapy be administered to
sepsis patients presenting with fever?
Answer (recommendation)
We suggest against the routine use of antipyretic therapy
for septic patients presenting with fever (2C) (rate of
agreement, 94.7%).
Comment: Administering antipyretic therapy may be
considered as a method of alleviating physiological
responses accompanying fever, such as tachycardia, tach-
ypnea, and discomfort.
Rationale
Six randomized controlled trials (RCTs) were extracted
as a result of the systematic review conducted for this
CQ [374–379]. All six RCTs assessed mortality rates,
one assessed ICU-free survival days, four examined the
length of ICU stay, and two examined the rates of com-
plication from infection.
The risk ratio for the impact of antipyretic therapy on
mortality rate was 1.12 (95% confidence interval (CI)
0.83–1.51), the impact on the number of ICU-free sur-
vival days was + 1 day (95% CI − 0.38–2.38), and the risk
ratio for the impact on the length of ICU stay was −
0.04 days (95% CI − 0.76–0.68). Regarding the incidence
of infection, one RCT reported the frequency of infec-
tion and another RCT reported the number of patients
who developed infections; thus, it was not possible to
compare the two.
In this CQ, mortality rate, ICU-free survival days, and
length of ICU stay were assessed as benefits of antipyr-
etic therapy, and the incidence of infectious complica-
tions was assessed as a potential harm associated with
antipyretic therapy. The strength of the evidence con-
cerning the primary outcome of mortality rate was C
(weak). While the strength of the evidence regarding
ICU-free survival days and length of ICU stay was B
(moderate strength), there was no consistent assessment
method for the potential harm of complication by infec-
tion, and evaluating the strength of this evidence was
not possible. The strength of the evidence regarding all
outcomes was C (weak) in keeping with the strength of
the evidence on mortality rate as the primary outcome.
The risk ratio for the impact of antipyretic therapy on
mortality rate was 1.12 (95% CI 0.83–1.51), but the
extent to which it reduces mortality is unclear. The re-
sults of one RCT suggested that ICU-free survival days
may increase by approximately 1 day. No significant
shortening in length of ICU stay was observed. The re-
sults of two other RCTs indicated the clear potential for
an increased risk of complication by infection as a result
of antipyretic therapy. Accordingly, the balance of risk
and benefit of administering antipyretic therapy for sep-
tic patients with fever is still uncertain. In addition, the
use of antipyretic drug therapy or external cooling can
be expected to increase the workload of medical staff.
CQ15-2: Should we attempt to correct the body
temperature of hypothermic sepsis patients?
Answer (opinion)
We suggest that the correction of body temperature
while carefully considering hemodynamic stability for
hypothermic sepsis patients with hypothermia-related
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complications such as diminished cardiac contractility/
dilatability or coagulation abnormalities (expert consen-
sus) (rate of agreement, 100%).
Rationale
There were no RCTs conforming to the Patient, Interven-
tion, Comparison, Outcome (PICO) process. Attempts to
gradually correct patient body temperature in cases where
diminished cardiac contractility/dilatability or coagulation
abnormalities occur in hypothermia [380, 381] are be-
lieved to offer potential benefits when such symptoms are
determined to be hypothermia-related. However, carefully
monitoring for possible hemodynamic instability due to
factors such as decreased blood pressure or the relative
decrease in circulating blood volume is necessary while
patients recover from hypothermia.
The benefit-risk balance can differ depending on the
condition of the patient. Attending physicians should
determine whether to act while considering both the ad-
verse effects of hypothermia itself as well as the risk of
attempting to correct body temperature and if treatment
is necessary, body temperature should be corrected grad-
ually through methods such as extracorporeal circulation,
passive incubation, or covering the patient with a blanket.
CQ16: Diagnosis and treatment of disseminated
intravascular coagulation in patients with sepsis
Introduction
Coagulation and fibrinolytic changes in sepsis
In the clinical course of sepsis, coagulation/fibrinolytic
abnormalities are identified early on, and the risk of
death due to multiple organ failure increases markedly
when complicated by disseminated intravascular coagu-
lation (DIC) [382, 383]. DIC in sepsis manifests primar-
ily as a state of severe systemic activation of the blood
coagulation cascade, and it is believed that microcircula-
tory damage caused by intravascular coagulation can
become a cause of organ damage [384]. In DIC, although
fibrinolytic function also increases in response to the
activation of the coagulation cascade, the extent of this
increase varies depending on the underlying disease, and
thus, DIC can occur with suppressed fibrinolysis or with
enhanced fibrinolysis. Of these, DIC occurring in sepsis
exhibits typical fibrinolytic suppression patterns in which
fibrinolytic function is suppressed relative to the en-
hancement of coagulation [385]. In addition, DIC with
suppressed fibrinolysis is considered to have a poor
prognosis, particularly when complicated by multiple
organ disorders [385].
Necessity of diagnosing DIC in sepsis
There are two factors underlying the significance of
evaluating the coagulation/fibrinolytic status of patients
with sepsis: (1) gaining an accurate grasp of the patient’s
disease state and (2) determining the need for thera-
peutic intervention [386]. The results of numerous stud-
ies have indicated that DIC is linked with poor
prognosis in sepsis [387], and diagnosing DIC is neces-
sary to predict outcomes and to determine the timing of
interventions. As anticoagulant therapy carries a risk of
excessive bleeding, selecting appropriate cases and
applying rationally planned timing are essential [382].
Administering anticoagulants inappropriately will not
only fail to produce the desired results but can also in-
crease patients’ risk of adverse events [388]. Therefore,
when treating patients with sepsis, attending physicians
should acquire a sufficient grasp of the state of coagula-
tion/fibrinolytic functions in real-time and perform suit-
able interventions after the diagnosis of DIC.
Usefulness of anticoagulant therapy for sepsis-associated
DIC
Many anticoagulants have been evaluated to date in con-
nection with sepsis-associated DIC based on the under-
standing that excessive coagulation activity can cause
microcirculatory damage leading to organ failure [389].
However, there is currently no unified view regarding
the efficacy of these drugs. One reason for this is that in
the USA and European countries, the clinical utility of
various anticoagulants has been studied primarily in
large-scale randomized controlled trials (RCTs) involving
patients with severe sepsis [390, 391]. These studies did
not focus on sepsis-associated DIC, and the anticoagu-
lant therapies administered to the participants of these
studies clearly differed from those used in Japan.
According to the results of a recent meta-analysis, anti-
coagulants cannot be expected to be effective in general
sepsis cases, and their effectiveness is reported to be lim-
ited to the treatment of sepsis-associated DIC [387].
This guideline was formulated based on the entirety of
available data, although the current body of evidence
regarding anticoagulant therapy for sepsis-associated
DIC is still limited in both quality and quantity.
CQ16-1: Is the Japanese Association for Acute Medicine
DIC diagnostic criteria useful in diagnosing sepsis-
associated DIC?
Answer (opinion)
The Japanese Association for Acute Medicine (JAAM)
DIC diagnostic criteria have been recognized as valid
both as treatment initiation criteria and useful as an
index of severity and are also considered useful in diag-
nosing sepsis-associated DIC (expert consensus/no evi-
dence) (rate of agreement, 94.7%).
Rationale
The question of what diagnostic criteria should be used
for the diagnosis of sepsis-associated DIC is frequently
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encountered in routine practice, and the current state of
this issue on the background of multiple diagnostic cri-
teria in use is addressed by this CQ. Given the fact that
the JAAM DIC diagnostic criteria (hereinafter referred
to as “acute-phase criteria”) created in 2005 by the
Research Committee on DIC of the JAAM have gained
widespread acceptance in Japan, this CQ focuses the dis-
cussion on the clinical utility of the acute-phase criteria.
The main diagnostic criteria currently in use are the
Japanese Ministry of Health, Labour and Welfare DIC
Diagnostic Criteria [392], the International Society on
Thrombosis and Hemostasis (ISTH) overt DIC Diagnos-
tic Criteria [393], and the acute-phase criteria [382]
created by the JAAM.
It is impossible to discuss the superiority or inferiority
of these diagnostic criteria, as there is no “correct diag-
nosis” for DIC. The acute-phase criteria was formulated
for the purpose of facilitating early-stage DIC diagnoses,
of the three diagnostic criteria, DIC should be diagnosed
for the most widespread coagulopathies [382, 394]. This
criterion has become the most widely used diagnostic
criterion for sepsis-associated DIC in Japan because of
the simplicity of its associated diagnostic procedures.
The acute-phase criteria are considered to be useful
for diagnosing sepsis-associated DIC because they have
been recognized as valid both as treatment initiation
criteria [395] and also suitable as an index of disease
severity [396]. The acute-phase criteria are considered to
be useful for diagnosing sepsis-associated DIC and ap-
pear to present minimal risks. As such, it is believed that
the potential benefits likely outweigh the potential risks.
CQ16-2: Should recombinant thrombomodulin be
administered to patients with sepsis-associated DIC?
Answer (opinion)
No clear recommendation can be offered at this time
concerning the use of recombinant thrombomodulin
preparations in sepsis-associated DIC (expert consensus/
quality of evidence “B”) (a rate of agreement of 67% or
higher in support of its use could not be obtained).
Rationale
Recombinant thrombomodulin, which was first launched
in 2008, is one of the several anticoagulants that have
come into wide use in treating sepsis-associated DIC in
Japan. However, to date, no consensus has been reached
regarding its usefulness. Although the bulk of clinical
evidence regarding this drug has been the product of a
Japanese phase III trial [397] and a multiregional Phase
II trial [398], the scales of these studies were determined
to have been inadequate, and no recommendation was
offered. Another multiregional phase III trial is currently
in progress with results expected in 2018, and this clin-
ical question (CQ) was formulated based on the
currently available body of evidence in view of the im-
portance of clarifying the potential benefits and risks of
recombinant thrombomodulin use in sepsis-associated
DIC treatment. An existing systematic review [399] was
used to formulate this recommendation.
The systematic review for this CQ was conducted
using three RCTs [398, 400, 401] as mentioned previ-
ously. The quality of evidence was “B” (moderate), and it
was determined that the potential benefits likely out-
weigh the potential risks. The estimated effect of this
treatment intervention on mortality rate was represented
by a risk ratio (RR) of 0.81 (95% confidence interval (CI)
0.62–1.06), and the point estimate for the number
needed to treat was 15, with moderate benefits expected.
The estimated effect on hemorrhagic complications was
represented by an RR of 0.83 (95% CI 0.22–3.11), and it
was determined that there was a low risk that the treat-
ment intervention increases the frequency of hemorrhagic
complications. Meanwhile, a study by Aikawa [400] com-
paring thrombomodulin therapy against heparin as a con-
trol was excluded from analysis due to the possibility that
its evaluation of hemorrhagic complications may not have
been appropriate. As a result, the RR was 1.11 (95% CI
0.59–2.11), and the possibility that thrombomodulin may
cause a slight increase in the frequency of hemorrhagic
complications could not be eliminated.
The potential benefits of treatment intervention in this
CQ were evaluated in terms of its capacity to improve
mortality rate. Although the possibility of increased fre-
quency of hemorrhagic complications as a result of
thrombomodulin therapy could not be ruled out, it was
determined to be highly likely that the potential benefits
of its use outweigh the potential risks. However, there
are different viewpoints regarding how to interpret the
benefit-risk balance, and no consensus could be reached
as some committee members emphasized that no signifi-
cant differences in beneficial outcomes were observed. It
was decided that no recommendation would be offered
at this time in anticipation of the results of the afore-
mentioned ongoing phase III trial in 2018.
CQ16-3: Should antithrombin replacement therapy be
administered in sepsis-associated DIC?
Answer (recommendation)
We suggest the use of antithrombin replacement therapy
in patients with sepsis-associated DIC whose antithrom-
bin activity has decreased to ≤ 70% (2B) (rate of agree-
ment, 68.4%).
Rationale
Guidelines for use in various countries do not recom-
mend the use of antithrombin based on the results of a
large-scale clinical trial (the KyberSept trial) [390]. In
contrast, antithrombin replacement therapy is often used
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in patients with sepsis-associated DIC in Japan. On this
background, this guideline discusses the clinical utility of
antithrombin replacement therapy based on a repeat
analysis of patients with sepsis-associated DIC.
This analysis targeted studies limited to patients with
sepsis-associated DIC. The KyberSept trial [390]
assessed severe sepsis rather than sepsis-associated DIC,
and so could not be adopted as evidence for this CQ, as
it does not consider treatments for sepsis patients with-
out DIC. Thus, a post hoc analysis in a study by Kienast
et al. [402], which was limited to sepsis-associated DIC,
was adopted. Meanwhile, the efficacy and risks of the
dosage covered by the National Health Insurance for the
intervention itself (1500 units/day for patients with
sepsis-associated DIC with antithrombin activity levels
of 70% or lower, and 40–60 units/kg in surgical cases)
were also assessed.
In addition, four Japanese and overseas studies
[395, 402–404] were analyzed. The treatment intervention
was expected to be beneficial in terms of reduced mortal-
ity rate based on an RR of 0.68 (95% CI 0.49–0.93), but
bias risk/indirectness may lower the reliability of the effect
estimate. Although the estimated effect on hemorrhagic
complications was represented by an RR of 1.17 (95% CI
0.45–3.01) and the possibility of harm could not be elimi-
nated, the confidence interval was wide, and thus, the
reliability of this finding was low.
The benefit of this treatment intervention was evaluated
in terms of its capacity to reduce mortality. Although the
possibility of increased frequency of hemorrhagic compli-
cations as a result of antithrombin replacement therapy
could not be ruled out, it was determined to be highly
likely that the potential benefits of use outweigh the
potential risks.
CQ16-4: Should protease inhibitors be administered to
patients with sepsis-associated DIC?
Answer (opinion)
We suggest against the use of protease inhibitors as stand-
ard treatment in sepsis-associated DIC (expert consensus/
quality of evidence “D”) (rate of agreement, 89.5%).
Rationale
The body of evidence concerning the usefulness of prote-
ase inhibitors is poor, and only two RCTs [404, 405] have
been conducted to date. However, the results of these
studies are currently referred to frequently in Japan. On
this background, this guideline offers a discussion of the
results of an analysis of the clinical utility of protease
inhibitors in patients with sepsis-associated DIC.
There have been two RCTs that have evaluated the
utility of protease inhibitors in sepsis-associated DIC;
Hsu et al. [405] reported a lack of utility, while
Nishiyama et al. [404] reported a potential utility.
However, both reports were based on small-scale studies
that were not double-blinded. Although these studies
also assessed 28-day mortality rate, they did not assess
the frequency of hemorrhagic complications or the DIC
recovery rate. No significant improvements in mortality
rates were observed in these studies, and it was con-
cluded that no prognostic improvement effect attribut-
able to protease inhibitors could be determined, and at
present, the available evidence is insufficient to support
a recommendation. In addition, although the RCT
conducted by Nishiyama et al. [406] included trauma
patients, it was ultimately decided that the results of this
study were not suitable for adoption as evidence for this
CQ due to a lack of sub-analysis results.
The benefits of the treatment intervention were
considered in terms of its ability to improve mortality
rate, but the confidence intervals in the results were
determined to contain major inaccuracies. Hemorrhagic
complications were raised as a potential harm associated
with this intervention and a major outcome, but the two
RCTs extracted did not assess this outcome. As such, it
was determined that the risks of this intervention could
not be assessed, and thus, its benefit-risk balance is
uncertain.
CQ16-5: Should heparin or heparin analogs be
administered in sepsis-associated DIC?
Answer (opinion)
We suggest against the use of heparin or heparin analogs
as a standard treatment in sepsis-associated DIC (expert
consensus/quality of evidence “D”) (rate of agreement,
84.2%).
Rationale
As mentioned previously, no conclusions have been
reached regarding the utility of anticoagulant therapy for
sepsis-associated DIC. This assessment is particularly
difficult because heparin and heparin analogs are often
administered to sepsis patients to prevent deep vein
thrombosis regardless of the presence of DIC. Thus, to
verify the clinical efficacy of heparin/heparin analogs as
treatments for sepsis-associated DIC, this CQ discusses
the results of an assessment limited to patients with
sepsis-associated DIC.
28-day mortality rate, hemorrhagic complications, and
DIC recovery rate were adopted as outcomes. Three
RCTs [400, 407, 408] conforming to the Patient, Inter-
vention, Comparison, Outcome (PICO) process were
selected to be included in the analysis. Of these three
RCTs, unfractionated heparin was used in the study by
Aikawa et al. [400] as a control for recombinant throm-
bomodulin, while in the study by Aoki et al. [407],
unfractionated heparin was used as a control for acti-
vated protein C concentrate. A report by Liu et al. [408]
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focused on patients with sepsis-associated pre-DIC as
defined in the Chinese diagnostic criteria. The 28-day
mortality rate statistics were reported by Aikawa et al.
[400] and Liu et al. [408], and the quality of evidence
was determined to be “D” (very weak) as a result of the
meta-analysis.
Statistics pertaining to hemorrhagic complications
were reported by Aikawa et al. [400] and Aoki et al.
[407], and the quality of evidence was determined to be
“D” (very weak) as a result of the meta-analysis. Only
Aikawa [400] reported on DIC recovery rate, and the
quality of this evidence was also determined to be “D”
(very weak) as a result of the meta-analysis.
It was determined that the treatment intervention had
the beneficial effect of improving the mortality rate, but
the supporting evidence was found to be inadequate.
Hemorrhagic complications were cited as potential ser-
ious adverse outcomes of this intervention, and it was
concluded that the available evidence was insufficient to
support a recommendation regarding hemorrhagic com-
plications. In addition, although beyond the scope of the
meta-analysis, heparin-induced thrombocytopenia (HIT)
is a known complication associated with heparin use,
and caution is required when administering heparin.
Accordingly, it was concluded that the benefit-risk bal-
ance for this intervention is currently uncertain.
CQ17: Venous thromboembolism (VTE)
countermeasures
Introduction
The clinical importance of the “prevention of venous
thromboembolism (VTE)” was highlighted during the
public comment stage for this clinical question (CQ)
while formulating this guideline. VTE includes both
deep vein thrombosis (DVT) and pulmonary embolism
(PE). Although initially considered common in European
and American populations, the prevalence of VTE in
Japan has increased in recent years due to the
westernization of lifestyle habits, an aging population,
greater awareness of the condition, and advancements in
diagnostic techniques [409]. The actual pathogenesis of
VTE tends to begin following surgery, after child birth,
or during hospitalization for an acute illness and can
result in serious outcomes such as PE. As such, the pre-
vention, diagnosis, and treatment of VTE are of clinical
concern. The VTE team accordingly assessed through a
review of the literature whether the risk of developing
VTE in sepsis patients is actually higher than in other
acute conditions.
Only one recent report by Kaplan et al. (2015) [410]
was found as a result of a literature search for papers
regarding VTE in sepsis patients. This paper discussed
the results of a multicenter prospective study on the
incidence of VTE based on venous echocardiography
examinations of patients with sepsis or septic shock ad-
mitted to the intensive care unit (ICU) and reported that
although measures to prevent VTE were taken in all
cases, the incidence of VTE was high (42 of 113 cases
[37.2%]). Although the results of this paper alone cannot
be applied to general clinical practice in Japan, prevent-
ing and treating VTE is widely recognized as having
great importance in the clinical management of sepsis
patients. Based on the above, it was determined that
presenting a view applicable to the medical care environ-
ment in Japan was needed, and this guideline addresses
several clinically important CQs related to the occur-
rence of VTE in patients with sepsis.
One recent development of note was the inclusion of a
section on DVT prophylaxis in the Surviving Sepsis
Campaign Guidelines (SSCG) 2012, which calls for the
prevention of VTE [23]. The discussion provided in this
section mentions reports indicating that the risk of VTE
is higher in ICU patients [411] and that sepsis patients
are believed to have an equal or higher risk of develop-
ing VTE compared to general ICU patients. Francesco et
al. examined the relationship between patients with
acute illnesses and the prevalence of VTE based on a
review of the relevant literature published after SSCG
2012, and as a result, asymptomatic DVT was reported
in 4.7% of cases, symptomatic DVT in 0.99%, PE in
0.6%, and DVT-related death occurred in 1.9% of cases.
It was also reported that for all patients, only the devel-
opment of acute infection was positively correlated with
the onset of VTE [412]. Tichelaar et al. also demon-
strated that the relative risk of VTE rises to 1.9–2.7
during pneumonia and to 1.8–2.1 during a urinary tract
infection, in comparison to patients without infection
[413]. In contrast, a study of the perioperative period
conducted by Donze et al. compared patients presenting
with either systemic inflammatory response syndrome
(SIRS) or sepsis prior to surgery against patients without
SIRS, and reported an increase in the adjusted odds ratio
for postoperative thrombotic complications to 3.3. When
viewed in terms of disease severity, the risk of thrombosis
increased in tandem with the severity of sepsis; the odds
ratio was 2.6 in SIRS patients, 3.7 in patients with typical
sepsis, and 6.1 in patients with severe sepsis [414].
As described above, the risk of VTE is considered to
be high in the presence of any infection, even if not as-
sociated with sepsis, and methods used to prevent and
diagnose VTE are considered to be of great clinical
importance.
For this CQ, the VTE team formulated and addressed
the questions “Should anticoagulant therapy, compression
stockings, and/or intermittent pneumatic compression be
used to prevent DVT in sepsis patients?” (CQ17-1) and
“How should sepsis-associated DVT be diagnosed?”
(CQ17-2), and provide the results of their discussions.
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There have been virtually no report of VTE cases in
Japan limited only to sepsis patients, and this is expected
to be one of the various issues to be clarified in the
future to ensure that appropriate preventive and diag-
nostic procedures are implemented.
CQ17-1: Should anticoagulant therapy, compression
stockings, and/or intermittent pneumatic compression be
used to prevent DVT in sepsis patients?
Answer (opinion)
We suggest the use of anticoagulant therapy, compres-
sion stockings, and/or intermittent pneumatic compres-
sion for the prevention of DVT in accordance with a
patient’s risk level (expert consensus/no evidence) (rate
of agreement, 94.7%).
Rationale
VTE affecting inpatients and postoperative patients is
widely recognized as a complication requiring preventa-
tive measures. In Japan, the Guidelines for the Diagnosis,
Treatment and Prevention of Pulmonary Thrombo-
embolism and Deep Vein Thrombosis (Revised 2009)
[409] and the Guidelines for Preventing Pulmonary
Thromboembolism/Deep Vein Thrombosis (Venous
Thromboembolism) [415], offer a classification of vari-
ous risk factors for developing VTE as well as corre-
sponding prophylactic measures. Among them, severe
infection is classified as a moderate risk factor for VTE
and establishing a patient’s risk level based on the under-
lying disease and clinical history are recommended.
SSCG 2012 [23] recommends the administration of low
molecular weight heparin (grade 1B) or unfractionated
heparin (grade 2C) in addition to intermittent air com-
pression of the lower extremities (grade 2C) for prophy-
laxis against DVT. However, the recommendations
offered by these guidelines are based on studies not lim-
ited to sepsis patients, as well as data from postoperative
or critically ill patients admitted to the ICU. The analysis
conducted for this guideline was limited to sepsis
patients to allow for the assessment of DVT prevention
measures in such patients.
While no studies limited only to sepsis patients were
found as a result of the literature search, DVT prophy-
lactic measures are expected to prevent both pulmonary
thromboembolism and mortality in sepsis patients,
similar to other critically ill patients. However, there is
currently no evidence limited only to sepsis patients,
and the frequency and severity of adverse effects are
unknown. The potential risks associated with anticoagu-
lants include hemorrhagic complications and heparin-
induced thrombocytopenia (HIT), and care must be
taken with their use. Compression stockings and inter-
mittent pneumatic compression should be used with
caution in patients with arterial blood flow disorders,
such as diabetes, due to the associate risk of exacerba-
tion of circulatory disorders. However, because the inter-
ventions addressed in this CQ include intravenously
administered pharmacologic therapies, compression
stocking use, and intermittent pneumatic compression,
the intervention itself creates little physical burden on
patients. Based on the above, the potential benefits of
VTE prevention measures clearly outweigh the risks.
CQ17-2: How should sepsis-associated DVT be diagnosed?
Answer (opinion)
We suggest diagnosing DVT using techniques such as
clinical symptoms, D-dimer fluctuations, venous com-
pression ultrasonography findings, and contrast-
enhanced computed tomography scan in assessing risk
factors and adverse effects (expert consensus/no evi-
dence) (rate of agreement, 100%).
Rationale
Because no evidence limited only to sepsis patients was
found as a result of the literature search, an expert con-
sensus about general DVT diagnostic methods, such as
the use of risk factors, clinical symptoms, D-dimer
values, and imaging, is presented.
1. Risk factors/clinical symptoms
Risk factors such as age, history of VTE, malignant
tumor presence, prolonged bedridden periods, obesity,
pregnancy, trauma, spinal cord injury, surgery, and
cerebrovascular disorders should be assessed in the
patient’s medical history. Additional risk factors to be
considered in sepsis cases include sedation, vasopres-
sor use, a history of artificial respiration, and central
venous catheter placement. Clinical symptoms poten-
tially indicative of acute DVT of the lower extremities
include local tenderness, swelling, pitting edema, and
skin discoloration of the affected limb. The diagnosis
of DVT based on symptoms is difficult in a sedated
sepsis patient; diagnoses based on signs are also diffi-
cult due to the generalized edema.
2. D-dimer value
Sepsis patients often present with high D-dimer values
accompanying disseminated intravascular coagulation,
and ruling out DVT based only on D-dimer values can
be difficult. However, actively monitoring for DVT onset
in cases involving prolonged elevation or repeated spikes
in D-dimer values during treatment is considered to be
good practice.
3. Imaging diagnostics
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(a)Venous compression ultrasonography: While a
relatively simple bedside test, venous compression
ultrasonography can be difficult to perform when
the subcutaneous tissue is thickened as a result of
edema, which can block ultrasonic waves.
(b)Venography: Originally, the gold standard for the
diagnosis of DVT, venography is now considered
unsuitable for routine examination because it is
invasive [416].
(c)Computed tomography venography (CTV):
Performing CTV can be difficult in sepsis cases due
to the need for the use of a contrast agent and
patient movement. According to other Japanese
guidelines, CTV should be performed in patients in
whom venous ultrasonography is difficult, and PE is
suspected and is similarly indicated for sepsis
patients [409].
(d)Magnetic resonance imaging (MRI): Although
noninvasive, routinely performing MRI is not
recommended for the diagnosis of severe DVT in
septic patients, due to the time required for
performing an MRI and the risk of encountering
difficulties or making observations.
Patients with sepsis are at a high risk of developing
VTE, but it should be noted that their clinical symptoms
are easily masked by factors such as sedation. As a re-
sult, attending physicians should check for associated
features such as elevated D-dimer values. The early diag-
nosis and treatment of DVT is considered to have a high
potential for benefiting patients. In contrast, the use of
contrast agents is contraindicated in sepsis cases accom-
panied by cardiac and renal dysfunction, and the burden
on the patient should be carefully evaluated in cases
involving artificial respiration or continuous apheresis
due to the risks involved in transporting patients.
Accordingly, the benefit-risk balance may also vary de-
pending on the condition of the patient.
CQ18: ICU-acquired weakness (ICU-AW) and post-
intensive care syndrome
Introduction
The concepts of ICU-acquired weakness (ICU-AW) and
post-intensive care syndrome (PICS) were first proposed
by the Society of Critical Care Medicine (SCCM) [417]
in 2010, on the backdrop of the increasing attention on
somatic and psychological issues appearing during the
subacute and chronic periods after discharge from the
intensive care unit (ICU). ICU-AW is a condition mani-
festing as acute symmetrical limb muscle weakness after
ICU admission. PICS is a disorder of motor, cognitive,
and neurological functions occurring during ICU admis-
sion or at the time of discharge, and in some cases even
sometime after discharge. Both conditions are increasingly
gaining wide recognition as affecting not only the long-
term prognosis of ICU patients but also psychologically
affect their families. Recent reports have stated that sub-
acute and chronic conditions such as PICS and ICU-AW
are closely linked with severe sepsis patients in the ICU,
and the Japanese Clinical Practice Guidelines for Manage-
ment of Sepsis and Septic Shock 2016 also devote separate
chapters to these conditions. This guideline presents an
overview of these conditions as well as respective clinical
questions (CQs) concerning their diagnosis and preven-
tion based on systematic reviews of the most recent rele-
vant literature.
ICU-acquired weakness
Pathologies manifesting as acute symmetrical limb
muscle weakness after ICU admission due to serious
illnesses such as sepsis are attracting increasing atten-
tion [418]. This concept is referred to as ICU-AW
and encompasses diffuse muscle weakness syndrome
caused by critical illness polyneuropathy (CIP) and
critical illness myopathy (CIM). It has been reported
that ICU-AW occurs in 46% of critically ill patients
who present with sepsis, multiple organ failure, and
need long-term artificial respiration [419]. According
to a detailed assessment, the most frequently occur-
ring type of ICU-AW was CIP accompanying CIM,
then CIM alone and CIP alone was the least frequent
[420]. While even quadriplegic ICU-AW patients can
recover from CIM in several weeks to several months,
CIP has been reported to leave sequelae affecting
motor functions lasting for years in some cases [421].
Polyneuropathy has conventionally been cited as the
primary cause of muscle weakness occurring in critic-
ally ill patients. However, severe sepsis accompanied
by multiple organ failure is actually closely related to
myopathy [422, 423]. According to the systematic re-
view by Stevens et al. [419], sepsis and multiple organ
failure were risk factors for the onset of ICU-AW.
However, most studies on sepsis and muscle weakness
conducted to date have focused mainly on respiratory
system muscles, particularly the diaphragm and few
studies have looked closely at the muscular strength
in the extremities [423].
The guidelines for the diagnosis of ICU-AW were
published by the American Thoracic Society in 2014
[424]. According to these guidelines, the diagnosis of
ICU-AW should be based on physiological findings
(84%, 26/31), electromyogram (EMG) findings (90%, 28/
31), and nerve conduction study (NCS) results (84%, 26/
31), according to the results of a systematic review of 31
papers selected from the literature. The bedside manual
muscle test (MMT) was used to gather physiological
findings, and the Medical Research Council (MRC) score
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[425], which comprises numerous items, was also fre-
quently used. A correlation between MMT and MRC
score was confirmed for EMG and NCS, and severe
muscle weakness was often defined as an MRC score of
≤ 48/60 total points. Maintaining the patient in an alert
state is important for diagnoses based on these physical
findings, and accurate judgments cannot be made unless
the patient is in a suitable conscious state following
reversal of sedation. Diagnosis is particularly inappropri-
ate while patients are in a state of delirium or sepsis-
associated encephalopathy, and careful attention is
necessary.
Clinical factors associated with ICU-AW include sep-
sis, immobility, hyperglycemia, use of steroid drugs, use
of muscle relaxants, among others [426]. In particular,
according to the above guidelines, if the aggregate of se-
vere sepsis patients targeted by the referenced studies
(262 patients in total) is taken, the percentage of patients
also exhibiting severe muscle weakness was higher than
that of other patient groups (504 patients in total) (64
vs. 30%, p < 0.001). It has also been pointed out that
ICU-AW incidence increases as the artificial respiration
period lengthens.
Post-intensive care syndrome
The SCCM hosted a consensus conference focusing on
PICS in 2010 [417]. It was decided that the capacity of
PICS to affect patients’ (1) motor function and (2) cogni-
tive function, as well as cause (3) psychiatric disorders
and (4) adverse effects on the mental condition of pa-
tients’ family members during ICU admission, shortly
after discharge, and during the subsequent long-term
period should be widely recognized. The second SCCM
consensus meeting was held in 2012, and the agenda
topics included more concrete details regarding PICS,
such as understanding the condition, preventative mea-
sures, risk assessment during treatment, and research
promotion [427].
Factors related to PICS can be broadly divided into
four categories. (1) The patient’s disease and its severity,
(2) treatment intervention(s), (3) ICU environmental fac-
tors (alarm sounds, light levels), and (4) patient’s mental
state (various stressors, economic aspects of the patient’s
condition, family anxiety). These factors are considered
to be complexly intertwined, and each contributes to the
onset of PICS. In 2000, Nelson et al. [428] reported that
the use of sedatives and muscle relaxants in patients
with acute lung injury was associated with depression
and the development of post-traumatic stress disorder
(PTSD), and therapeutic factors such as drug therapies,
blood transfusions, fluid transfusions, artificial respir-
ation, and blood apheresis may also contribute to the
onset of PICS. Aside from treatment, care factors may
also be related to the onset of PICS. Specifically,
aspirating sputum and changes in posture have been
cited. Psychological factors potentially contributing to
the onset of PICS include delirium, insomnia, restless-
ness, and psychological stress, while environmental fac-
tors include electronic noises produced by monitors,
alarm sounds, and the enclosed ICU environment. One
fascinating method of preventing PICS that incorporates
a variety of care and psychological factors is the ICU
diary. In 2010, Jones et al. [429] reported based on a
multicenter prospective study that patients’ family mem-
bers or attending medical professionals can suppress the
onset of PTSD by keeping a diary of ICU inpatients.
This report also pointed out that PICS is linked to sep-
sis, and severe sepsis survivors exhibited greater use of
social welfare resources than non-severe sepsis patients
during a one-year period [430].
Although there have been several reports regarding
ICU-AW and PICS published in recent years, most
involve observational studies, and the evaluation of func-
tional prognosis based on multiple randomized con-
trolled trials (RCTs) has only been conducted with
respect to electrical muscle stimulation therapy and
rehabilitation programs. For this reason, this guideline
presents CQs addressing the validity and efficacy of
these two interventions based on meta-analyses.
Understanding ICU-AW and PICS, and administering
treatment interventions should be done with the aim of
enabling ICU patients to return to society, and cooperat-
ing with medical personnel not involved in intensive care
is also necessary. Both goals are attracting increasing
attention as new tasks for those practicing intensive care
medicine, and it is important to share the latest knowledge
regarding methods of prevention and treatment.
CQ18-1: Should electrical muscle stimulation be
performed as a method of preventing ICU-AW?
Answer (recommendation)
We suggest against performing electrical muscle stimula-
tion as an ICU-AW preventative measure when handling
sepsis or ICU patients (2C) (rate of agreement, 100%).
Rationale
Although artificial respiration period, ICU stay time, and
hospitalization period may each increase as a result of
ICU-AW, no consensus has been reached regarding
effective therapies for ICU-AW, and preventative mea-
sures are expected. Electrical muscular stimulation
induces muscle contractions by percutaneously channel-
ing low-frequency electrical currents. In some cases, suf-
ficient rehabilitative therapy may not be implemented
for patients with chronic heart failure and chronic
obstructive pulmonary disease arising from exertional
dyspnea, and electrical muscle stimulation, which can be
performed even in a resting state is used as an alternative
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therapy [431, 432]. Although improvements in muscular
strength and exertion capacity have been reported as results
[433], the effectiveness of this intervention in critically ill
patients or sepsis patients is currently unknown. As such,
this CQ examines the capacity of electrical muscle stimula-
tion to prevent the onset of ICU-AW.
Two single-center RCTs have reported on the efficacy
of electrical muscle stimulation as a measure to prevent
ICU-AW [434, 435]. According to the results of an
intent-to-treat analysis [436] of the findings obtained by
Routesi et al. [434] and Kho et al. [435], there were no
significant differences in the incidence of ICU-AW in
comparison with the control group. This body of evi-
dence can be said to be inadequate, in consideration of
the low number of subjects in the electric muscle stimu-
lation group and the associated risk of bias, in addition
to the lack of a high-quality systematic review or meta-
analysis at this time. Three single-center RCTs examin-
ing whether muscle mass increases as a result of elec-
trical muscle stimulation [437–439] were identified and
subjected to a meta-analysis [440]. Although subject
muscle mass increased significantly, the total number of
subjects in the electric muscle stimulation group was
low (72 subjects) and the bias risk was high, and accord-
ingly, this evidence may be considered to be of poor
quality. No studies analyzing the period of artificial res-
piration and ICU stay time have been conducted.
Although the incidence of ICU-AW is the most import-
ant outcome considered by this CQ, due to the low stat-
istical power of the two studies examined, this body of
evidence was rated C (weak).
To perform this intervention, patients must undergo
electrical muscle stimulation in the lower limbs for ap-
proximately 1 hour each day with time allotted for rest
periods. Some pain may occur during this intervention.
Although the labor burden placed on nurses, attending
physicians and physical therapists in connection with
this intervention is not anticipated to be great, medical
facilities must possess an electrical stimulation apparatus
to perform the intervention, and equipping all facilities
for this intervention is considered to be impracticable.
CQ18-2: Should early-stage rehabilitation be implemented
to prevent PICS (as well as ICU-AW)?
Answer (recommendation)
We suggest implementing early-stage rehabilitation as a
PICS preventative measure for sepsis or ICU patients
(2C) (rate of agreement, 100%).
Rationale
PICS, in which the functional prognosis of the body’s
physical, cognitive, and psychological capacities deterior-
ate as a result of staying in the ICU, has increasingly
been cited in recent years as a concern facing ICU
patients, including sepsis patients. The epidemiology,
prevention, and treatment of PICS are also gaining
greater research attention. Early-stage rehabilitation in-
terventions are conducted as preventive measures. No
RCTs assessing such interventions in sepsis cases only
has been conducted to date. However, several RCTs tar-
geting intensive care patients have been completed, and
it was determined that this evidence could be extended
to sepsis cases as well to assess validity.
We evaluated the effect of early-stage rehabilitation on
PICS-related outcomes used in our meta-analysis (eight
studies: [441], [442], [443], [444], [445], [446], [447], and
[231]) and two meta-analyses [436, 448]. These results
revealed that implementation of early-stage rehabilita-
tion interventions resulted in significantly improved
motor function, 6-min walk distance (6MWD), and
shortened artificial respiration periods. Although no
significant differences were observed regarding the inci-
dence of PICS, because intervention subjects’ exhibited
significant improvements in MRC score (an ICU-AW
assessment tool), 6MWD, and artificial respiration
period, this intervention is expected to be more benefi-
cial than harmful. However, patients targeted by the
studies examined were ICU patients rather than sepsis
patients, and moreover, the scale of the studies for each
PICS-related outcome was small. As such, in considering
the influence of the median/interquartile range to mean/
standard deviation conversion applied during the meta-
analyses, the level of this body of evidence cannot be
said to be high. In addition, the lack of analysis of side
effects also increased the difficulty of the assessment.
To administer this intervention, patients must partici-
pate in a rehabilitation program scheduled on a daily
basis. This intervention will increase the workloads of
nurses, physical therapists, and attending physicians. Ad-
ministering the intervention with great care and under
adequate observation is necessary in serious disease
cases, and this intervention should be considered to be
highly technical. As such, serious concern is warranted
regarding the feasibility of performing this intervention
at facilities without sufficient medical personnel or other
appropriately trained staff.
CQ19: Pediatric considerations
Introduction
The sepsis-related mortality rate in children is over 15% in
patients with severe sepsis cases and even higher in septic
shock [449–451], according to reports published as of
2012. The Surviving Sepsis Campaign Guidelines (SSCG)
2012 edition includes recommendations pertaining to
child patients as “Pediatric Considerations” [29]. However,
no content related to pediatric patients was included in
the Japanese Society of Intensive Care Medicine (JSICM)
guidelines [1] published the same year. Therefore, a
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separate and independent chapter on pediatric patients
was originally planned for inclusion in the Japanese Clin-
ical Practice Guidelines for Management of Sepsis and
Septic Shock 2016 during its creation. The clinical ques-
tions (CQs) presented in this chapter were formulated in
reference to the aforementioned SSCG 2012 [29] and the
consensus statement for the management of pediatric se-
vere sepsis in 2014 [452] (included the American College
of Critical Care Medicine/Pediatric Advanced Life Support
(ACCM/PALS) algorism [453]), while considering the
degree to which they could be supported by the related
literature and their importance in the clinical setting.
The definition of pediatric sepsis presented the greatest
challenge to the team responsible for this subject matter. A
new definition of sepsis (Sepsis-3) was published in 2016
[5], characterizing sepsis as “infection accompanied by
organ dysfunction.” In essence, the new definition of sepsis
is closer to the conventional definition of severe sepsis, and
it was decided that the term “severe sepsis” would no lon-
ger be used. However, this new definition only applies to
adult patients, and to date, there has been no movement
by any nation towards establishing a definition specific to
pediatric patients. Meanwhile, there have been no concrete
efforts to accumulate and analyze clinical data from
pediatric sepsis patients, making it difficult to propose a
new definition of sepsis that also conforms to the Sequen-
tial Organ Failure Assessment (SOFA) criteria for adult
sepsis patients [454]. As such, currently, the description of
“infection-induced systemic inflammatory response
syndrome (SIRS)” based on the criteria and definition pro-
posed by Goldstein et al. in 2005 [455] is designated as
sepsis (“‘old’ sepsis”), and the conception of severe sepsis as
“infection accompanied by organ dysfunction” is desig-
nated as “‘old’ severe sepsis”, and “sepsis” has been newly
defined to include “infection accompanied by organ dys-
function” as well, in line with the Sepsis-3 [5] definition.
However, it should be noted that various important
concerns have been identified concerning the criteria
proposed by Goldstein et al. [455]. First, the following is-
sues have been raised regarding the SIRS diagnostic
criteria for pediatric patients:
1. There is no basis for requiring the inclusion of body
temperature or white blood cell count.
2. The threshold value for respiratory rate overlaps
with the normal range.
3. The results of several recent large-scale studies
[456–459] examining normal heart rate and respiratory
rate in children are not reflected in the threshold values
for respiratory rate and heart rate.
Next, various concerns have also been raised regarding
the pediatric evaluation criteria for organ dysfunction,
such as the following:
1. There have been no studies evaluating the validity of
the respective definitions for each type of organ
dysfunction.
2. There is a lack of evidence supporting the threshold
value for hypotension used to diagnose septic shock.
3. The evaluation criteria state that severe sepsis may
be diagnosed based on single organ dysfunction in
acute respiratory distress syndrome (ARDS) or
circulatory failure cases, and although an initial
diagnosis of severe sepsis may be made based on the
observation of the dysfunction of two or more other
organ systems, the basis for this is weak.
In the future, a pediatric version of the definition of
sepsis reflecting a confirmed correlation with prognosis
based on clinical data will need to be developed.
Pediatric intensive care units (PICU) primarily handle
infant and preadolescent patients as well as neonates less
than 28 days old. Problems concerning premature births
and unborn fetuses, or complications arising during the
postnatal period to the transitional period are also the
jurisdiction of the neonatal intensive care unit (NICU),
and this guideline does not present any CQs related only
to neonates. However, the accompanying data analyses
and discussions do address in part neonates (regular
term/mature fetuses). However, as the definition of the
age range considered as “pediatric” differs among papers
from different countries or regions, this aspect was not
strictly defined. High-quality scientific evidence focusing
only on pediatric cases is given priority, and in unclear
cases, consideration is given to ensure consistency with
the recommendations pertaining to adult patients. This
can be seen in the consensus opinions in the SSCG 2014
[29] or the 2014 consensus statement for the manage-
ment of pediatric severe sepsis [452], and supplementing
the findings in children in accordance with the basis of
the adult recommendations was considered to be both a
scientific and rational approach.
CQ19-1: Should sepsis in pediatric patients be defined as
infection (including the possibility of infection)
complicated by SIRS?
Answer (opinion)
Pediatric sepsis is currently defined as “SIRS arising
from infection” according to the criteria and definitions
proposed by Goldstein et al. in 2005 [455]. Although “se-
vere sepsis” was defined as “a condition accompanying
organ dysfunction” in the definition of Goldstein et al.,
this term has now been replaced with “sepsis,” in line
with the terminology revision in the Sepsis-3 [5] defin-
ition. When using this criterion, refer to the proposed
changes presented in CQ19-2 below pertaining to the
number of inspirations, hypotension, and creatinine
value. However, because the concept of SIRS was
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excluded from the adult Sepsis-3 definition [5], equating
similar expressions, specifically “organ dysfunction accom-
panying infection,” to “sepsis” should not be dismissed
(expert consensus/no evidence) (rate of agreement, 100%).
Rationale
The pediatric sepsis definition proposed by Goldstein et
al. [455] in 2005 (the “Goldstein definition”) was refer-
enced. The diagnostic criteria for SIRS included in the
Goldstein definition [455] are described in Table 1.
Table 2 describes the diagnostic criteria for organ dys-
function, which are preconditions for severe sepsis under
the same definition. This guideline also allows for the
use of the conventional replacement of “severe sepsis” as
“sepsis” when using these criteria, in consideration for
consistency with the SOFA scoring system [454].
Meanwhile, a new definition for adult sepsis (Sepsis-3)
was proposed in 2016 [5]. Under this new definition,
sepsis refers to infection (including suspected infection)
accompanying organ dysfunction with a SOFA score of
two or higher [454]. However, no pediatric SOFA score
system currently exists. The definition of pediatric sepsis
is expected to be revised internationally in the future.
CQ19-2: What criteria should be used with regard to
respiratory rate?
Answer (opinion)
A clear recommendation regarding the threshold value
for respiratory rate in the diagnosis of pediatric SIRS
cannot be offered at this time. As an example, refer to
the criteria proposed by Nakagawa & Shime [460] (ex-
pert consensus/no evidence) (rate of agreement, 100%).
Rationale
The reference values given in the Goldstein definition
regarding the number of inspirations in the diagnosis of
SIRS of 18/min for patients aged 6–12 years and 14/min
for patients aged 13–18 years are both lower than the
20/min mentioned in the adult SIRS diagnostic criteria
and also overlap with the normal range [455]. In
addition, according to many widely used guidelines such
as the pediatric resuscitation guidelines [461] and the
triage standards [462], abnormal respiratory rate in
infants is defined as ≥ 60 inspirations per minute. In
consideration of these, the standards proposed by
Nakagawa and Shime [460] were created based on the re-
sults of Fleming’s research [456] (Table 3). The suitability
of the use of this standard should be verified in the future.
CQ19-3: What criteria should be used with regard to
hypotension?
Answer (opinion)
A clear recommendation concerning a threshold value
for systolic blood pressure as a diagnostic criterion for
pediatric septic shock cannot be offered at this time. As
an example, refer to the hypotension criteria used in the
SPROUT (Sepsis Prevalence, Outcomes, and Therapies)
study [463] (expert consensus/no evidence) (rate of
agreement, 100%).
Rationale
The diagnostic criteria for severe sepsis under the
Goldstein definition are shown in Table 4 of CQ19-1
[455], but as the threshold value for systolic blood
pressure does not steadily increase with age, an
unnatural impression is unavoidable. Therefore, with
respect to hypotension criteria for the diagnosis of
septic shock, the criteria prepared based on the inclu-
sion criteria of the SPROUT study [463] have been
cited as creating less discomfort than those of the
Goldstein definition (Table 4). The validity of the use
of these criteria must be confirmed in the future.
To reach a septic shock diagnosis under Sepsis-3, two
conditions must be satisfied: (1) vascular inotropic drugs
must have been used to maintain a specific mean blood
pressure (65 mmHg in adults) and (2) a serum lactate
level of ≥ 2 mmol/L [5]. In contrast, to diagnose septic
shock under the Goldstein definition, a patient must
meet the following criteria despite having received ≥
40 mL/kg of fluid during resuscitation within 1 hour
after hospitalization [455]:
1. Hypotension
2. Use of vascular inotropic drugs to maintain blood
pressure
Table 1 Pediatric diagnostic criteria for SIRS (excerpted from [455])
Tachycardia (bpm) Bradycardia (bpm) Respiratory rate (breaths/min) WBC count (×1000/μl) Systolic blood pressure (mmHg)
0 days–1 week > 180 < 100 > 50 > 34 < 59
1 week–1 month > 180 < 100 > 40 > 19.5 or <5 < 79
1 month–1 year > 180 < 90 > 34 > 17.5 or < 5 < 75
2–5 years > 140 – > 22 > 15.5 or < 6 < 74
6–12 years > 130 – > 18 > 13.5 or < 4.5 < 83
13–17 years > 110 – > 14 > 11 or < 4.5 < 90
Systolic blood pressure also draws reference from [492]
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3. Any two of the following conditions: metabolic
acidosis, high serum lactate level, oliguria,
prolonged CRT, or central/peripheral temperature
discrepancy
Therefore, although septic shock can be said to be a
relatively broad concept under Goldstein’s definition
[455], under the Sepsis-3 definition [5], severe septic
shock is defined in the group of patients presenting with
shock facing a particularly high degree of mortality risk
(approximately 40% mortality in adults). That is, the
Goldstein definition [455] anticipates an intention to
administer early-stage treatment, while the Sepsis-3 def-
inition [5] is considered to isolate a specific group of
patients with a relatively high mortality risk. The propor-
tion of pediatric patients satisfying the criteria for septic
shock under both the Goldstein definition [455] and the
Sepsis-3 definition [5] is currently unknown.
Currently, the Goldstein definition [455] is used as a
standard for pediatric septic shock, and the low blood
pressure thresholds to be used in such cases are de-
scribed in Table 4.
CQ19-4: Is establishing reference creatinine values for
pediatric use necessary?
Answer (opinion)
We suggest establishing respective reference creatinine
values for pediatric patients in different age groups (ex-
pert consensus/no evidence) (rate of agreement, 100%).
Rationale
Measuring creatinine values is indispensable for diagnos-
ing renal dysfunction, but the reference values vary
widely depending on the age group of the patient. When
assessing organ dysfunction based on SOFA score [454],
the normal upper limit threshold value for pediatric
patients is adjusted to 0 points, and the following four
items are multiplied by several numerical values accord-
ing to the SOFA score [454] (Table 5). The appropriate-
ness of this method must be verified in the future.
Regarding reference values, the PELOD (Performance of
the Pediatric Logistic Organ Dysfunction) -2 (Tables 6)
[464] scoring system is widely used in international clin-
ical research as an index of pediatric organ dysfunction
and do not necessarily match with the age-specific refer-
ence values proposed in Japan (Tables 6 and 7) [465].
Because the serum creatinine value depends on the
muscle mass, particularly in post-pubescent patients,
large gaps can arise between different genders and
ethnicities and may also result from differences in
Table 2 Organ dysfunction criteria for the diagnosis of severe
sepsis (excerpted from [455])
Cardiovascular system
Despite the infusion of ≥40 mL/kg of fluid for 1 hour, presentation of:
▪ Hypotension
▪ Use of vascular inotropic drugs to maintain blood pressure
▪ Any two of the following conditions: metabolic acidosis, high
serum lactate level, oliguria, prolonged capillary refill time (CRT),
or central/peripheral temperature discrepancy
Respiratory system
▪ PaO2/FiO2 ratio < 300
▪ PaCO2 > 65 Torr or increase from the standard value by 20 Torr
▪≥ 92% SpO2 despite maintenance of FiO2 > 0.5
▪ Need for mechanical ventilation requiring tracheal intubation,
or noninvasive positive pressure ventilation
Nervous system
▪ Score of ≤11 on the Glasgow Coma Scale (GCS)
▪ Acute changes in state of consciousness (fall of ≥3 on the GCS)
Coagulatory function
▪ Platelet count under 80,000/μL or 50% decrease in 3-day peak
platelet count
▪ Prothrombin time-international normalized ratio (PT-INR) > 2
Renal function
▪ Two-fold or higher serum creatinine value compared with the
normal upper limit creatinine value applicable to the age group
or two-fold increase from the typical creatinine value
Hepatic function
▪ Total bilirubin ≥ 4 mg/dL
▪ Two-fold or higher alanine aminotransferase (ALT) level compared
to the normal upper limit applicable to the age group
Table 3 Threshold values for respiratory rate (excerpted from
[460]) Table values are normal upper limit values for respiratory
rate proposed by the Guideline Committee
0 days–1 week 60
1 week–1 month 60
1 month–1 year 50
2–5 years 30
6–12 years 24
13–18 years 20
Table 4 Threshold values for hypotension (excerpted from
[463])
Age range Hypotension (mmHg)
Up to 1 week 60
1 week–1 month 65
1 month–1 year 70
2–5 years 75
6–12 years 85
13–18 years 90
Instead of Table 4, you can use the following formula; 70 + 1.6x [age] (for
patients ≥1 year old)
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measuring methods (e.g., Jaffe method, enzyme method),
and validation will be necessary here as well.
CQ 19-5: Should a pediatric blood culture bottle be used
for pediatric patients?
Answer (opinion)
We suggest the use of pediatric blood culture bottles for
pediatric patients (until approximately school-age) (ex-
pert consensus/no evidence). We also suggest the use of
adult bottles even in pediatric patients if their physique
is similar to an adult’s and the patient can safely sustain
blood collection (approximately ≥ 36 kg) (expert con-
sent/no evidence) (rate of agreement, 100%).
Rationale
Blood culture testing is an essential technique for the
optimization of antibiotic therapy in the treatment of
infections/sepsis. In adults, typically as much blood is
collected as possible to improve test accuracy. However,
when handling pediatric patients, the collection of large
volumes of blood is more difficult due to issues related
to circulating blood volume, and collection methods
similar to those employed in adult patients are generally
not used [466]. Blood culture test procedures suitable
for children, including the use of pediatric blood culture
bottles, are therefore necessary.
No randomized controlled trials (RCTs) conforming to
the Patient, Intervention, Comparison, Outcome (PICO)
process could be found. In observational studies, the com-
parison of aliquots (up to 5 ml) of blood from both adult
and pediatric bottles revealed a high rate of positivity in
the pediatric bottles and a short time to positive test re-
sults [467]. In essence, this suggests that test results are
more likely to be positive when a pediatric bottle is used
even if the volume of blood collected is smaller. The target
blood sample volume for neonates is 1–2 mL, 2–3 mL for
infants, 3–5 mL for infants/school-age children, and 10–
20 mL for pubescent children [468]. The use of pediatric
bottles is generally desirable with pediatric patients. The
use of adult bottles is appropriate with older children of
school-age (approximately ≥ 36 kg) who are able to pro-
vide a sufficient volume of blood.
Because the positivity rate for blood volumes lower than
1 mL is low even when a pediatric bottle is used [466],
pediatric bottles should contain at least 1 mL of blood. As
the same amount of blood is collected, the frequency of
adverse effects is not likely to increase. Therefore, the
potential benefits likely outweigh the potential risks.
CQ19-6: How should circulatory inotropes be used to
address septic shock in pediatric patients?
Answer (opinion)
Adrenaline is the first-line vasopressor drug for use in
treating septic shock in pediatric patients (expert con-
sensus/quality of evidence: “C”).
Table 5 Renal SOFA scoring criteria for pediatric patients scores are calculated based on the respective standard values for each age
group
SOFA
score
0 1 2 3 4
Kidney < Cr0 (standard value by age group) 1–1.6 × Cr0 1.7–2.8 × Cr0 2.8–4.1 × Cr0 ≥ 4.2 × Cr0
Table 6 Standard values by age (Cr0): Upper limit threshold
value for PELOD-2 [464] renal disorder score of 0 points (unit:
converted to mg/dL)
0– < 1 month 0.8 mg/dL
1–11 months 0.3 mg/dL
1–2 years 0.4 mg/dL
2–5 years 0.6 mg/dL
5–12 years 0.7 mg/dL
≥ 12 years 1.0 mg/dL
Table 7 Standard values by age (Cr0): Normal creatinine values
by age as obtained from a Japanese multicenter study [465]
Age 2.5th percentile
(mg/dL)
50th percentile
(mg/dL)
97.5th percentile
(mg/dL)
M F M F M F
3–5 months 0.14 0.20 0.26
6–8 months 0.14 0.22 0.31
9–11 months 0.14 0.22 0.34
1 year 0.16 0.23 0.32
2 years 0.17 0.24 0.37
3 years 0.21 0.27 0.37
4 years 0.20 0.30 0.40
5 years 0.25 0.34 0.45
6 years 0.25 0.34 0.48
7 years 0.28 0.37 0.49
8 years 0.29 0.40 0.53
9 years 0.34 0.41 0.51
10 years 0.30 0.41 0.57
11 years 0.35 0.45 0.58
12 years 0.40 0.40 0.53 0.52 0.61 0.66
13 years 0.42 0.41 0.59 0.53 0.80 0.69
14 years 0.54 0.46 0.65 0.58 0.96 0.71
15 years 0.48 0.47 0.68 0.56 0.93 0.72
16 years 0.62 0.51 0.73 0.59 0.96 0.74
Nishida et al. Journal of Intensive Care  (2018) 6:7 Page 59 of 77
Noradrenaline should not be used as the first-line
treatment drug in pediatric patients with septic shock
(expert consensus/no evidence).
Vasopressin should not be used to treat vasodilatory
septic shock in pediatric patients (expert consensus/
quality of evidence: “C”).
Dobutamine or milrinone may be used to treat
pediatric septic shock as appropriate given the patient’s
condition (expert consensus/no evidence) (rate of agree-
ment, 100%).
Rationale
As with adults, the infusion of appropriate volumes of
fluid often does not improve the hemodynamics of
pediatric septic shock patients, and the use of circulatory
inotropes often becomes necessary. Although the con-
sensus statement for the management of pediatric
patients with severe sepsis mentions that “positive ino-
tropes/vasoconstrictors should be administered as soon
as possible to pediatric patients who are unresponsive to
transfusion loading,” no specific drugs were recom-
mended [452].
SSCG 2012 also does not offer strong recommenda-
tions regarding the use of any specific circulatory ino-
trope in children [23]. Noradrenaline is recommended
for use in adults, but there have been no RCTs upon
which to validate its use in children. The selection of cir-
culatory inotropes for use in children presenting with
septic shock is a routinely encountered issue in practice,
and it is important to maintain current knowledge about
which drugs are effective under different circumstances.
One RCT [469] reported that adrenaline use in pediatric
patients with sepsis was associated with a lower mortality
rate in comparison to dopamine [469] and recommended
adrenaline as a first-line drug therapy. However, this was a
single-center study with 120 participants, and it is neces-
sary to recognize that the design of this study weakens it
as an evidentiary basis for the use of adrenaline as a first-
line drug.
While there have been no RCTs conducted to date
comparing noradrenaline with other drugs or placebo,
noradrenaline may also be considered for first-line use
in patients exhibiting high cardiac output and peripheral
vascular dilatation. Another RCT investigating children
presenting with vasodilatory shock reported that low-
dose vasopressin temporarily increased the blood pres-
sure compared with placebo, but worsened survival and
prognosis [470]. It is important to note, however, that
this study did not focus only on sepsis patients. In the
management of pediatric patients with septic shock, va-
sodilators may be considered in cases characterized by
peripheral vasoconstriction and blood pressure is main-
tained, but there is currently no basis for recommending
the use of milrinone. Moreover, there have been no
RCTs conducted to date comparing dobutamine with
other drugs or placebo.
In another study [469] comparing adrenaline and
dopamine, adrenaline was associated with a lower rate of
mortality than dopamine. Potential risks include a ten-
dency for dopamine to exacerbate inflammation, and
adrenaline was linked to hyperglycemia and persistent
hyperlactatemia. Based on these observations, the poten-
tial benefits of adrenaline use are believed to outweigh
the risks. According to the results of a comparison of
vasopressin and placebo [470], vasopressin was linked to
a higher mortality rate and incidence of adverse events,
and the risks likely exceed the potential benefits.
CQ19-7: Should CRT be used as a circulatory
management indicator in pediatric sepsis cases?
Answer (opinion)
CRT should be used in conjunction with other
hemodynamic indicators to monitor the state of circula-
tory management in pediatric sepsis patients (expert
consensus/no evidence) (rate of agreement, 100%).
Rationale
According to SSCG 2012 [29], when performing initial
resuscitation, ideal conditions include a CRT within 2 s,
normal blood pressure for the age group, normal heart
rate, no difference in between the central and peripheral
pulses, warmness of the extremities, 1 mL/kg/h urine
volume, normal consciousness, central venous oxygen
saturation (ScvO2) of 70% or higher, and a cardiac index
of 3.3–6.0 L/min/m2. However, the measurement of
ScvO2 requires the insertion of a central venous line, and
accurately measuring the cardiac index in children can be
difficult. A CRT of ≤ 2 s in children admitted to the PICU
has been reported to be correlated with an ScvO2 ≥ 70%
[471]. A meta-analysis also found that abnormal CRT was
linked to a higher risk of mortality [472].
It is important to verify the significance of CRT as a non-
invasive and continuous circulatory management index that
can easily be used by clinicians in the initial diagnosis of
pediatric patients with sepsis, particularly in Japan, which
has underdeveloped intensive care treatment systems.
No RCTs conforming to the PICO process could be
found. CRT is an index of circulatory management that
can be evaluated noninvasively and repeatedly over time.
Correlations between CRT and ScvO2 as well as between
abnormal CRT and mortality have also been reported
[472], and the use of CRT as an indicator of hemodynamic
status is believed to offer substantial benefits to patients.
In contrast, the use of CRT alone to gauge the state of
circulatory management may lead to excessive treatment
intervention. CRT is also influenced by a variety of fac-
tors such as measurement site, compression time, and
temperature [473], and it must be recognized that
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inconsistencies in the method of evaluation may lead to
erroneous interpretation [474]. However, there are no
RCTs conforming to the PICO process, and therefore,
the benefit-risk balance is currently unknown but is be-
lieved to differ depending on the unique circumstances
of individual patients.
CQ19-8: Should ScvO2, or serum lactate value be used as
a circulatory management indicator in pediatric sepsis
cases?
Answer (opinion)
Both ScvO2 and serum lactate values may be used as indi-
cators of circulatory management in pediatric sepsis cases.
However, use of comprehensive circulatory evaluation
together with other hemodynamic indicators is required
(expert consensus/no evidence) (rate of agreement, 100%).
Rationale
ScvO2 and serum lactate value are both indicators of the
tissue oxygen supply/demand balance, and numerous
studies have been conducted to investigate the positive
and negative aspects of their use as indicators of
hemodynamic status in patients with sepsis. ScvO2, in
addition to central venous pressure, mean arterial pres-
sure, and urine volume, have been recommended as
hemodynamic indicators when performing initial resus-
citation in adult sepsis patients [29]. However, the clin-
ical utility of quantitative protocols for circulatory
management applying these metrics has been called into
question in recent years. In children, the measurement of
ScvO2 has been recommended in conjunction with the
use of indices measurable through noninvasive methods,
such as vital signs, peripheral circulation, and urine
volume [29, 453]. However, the invasiveness and costs
accompanying this technique warrant its reconsideration.
SSCG 2012 recommends the use of normalization of
serum lactate values as an indicator of initial resuscita-
tion in adult sepsis patients presenting with hyperlacta-
temia [29]. Also, according to Sepsis-3 [5], elevated
serum lactate level is used to define septic shock. The
utility of the absolute or chronological lactate value in
predicting mortality or organ dysfunction in pediatric
patients with severe sepsis has also been reported based
on an observational study [452]. An evaluation of the
utility of these metrics in sepsis cases as well must be
conducted in the future.
One RCT [475] conforming to the PICO process was
found. Application of the American College of Critical
Care Medicine (ACCM)/Pediatric Advanced Life Support
(PALS) guideline [453], which calls for the continuous
monitoring of ScvO2, was linked to a decrease in 28-day
mortality rate and a lower incidence of novel organ disor-
ders in comparison to cases where ACCM/PALS was not
applied. However, this was an unblended overseas study,
and it must also be recognized that baseline characteristics
of the two study groups were different.
No RCTs investigating the use of serum lactate value
in managing circulation could be found.
ScvO2 and serum lactate value are both indicators of the
tissue oxygen supply/demand balance, and implementing
circulatory management aiming for normalization of these
indices is considered valid. However, the placement of a
central venous catheter or an arterial catheter is necessary.
While both are useful in the management of pediatric pa-
tients with sepsis, adverse events such as mechanical com-
plications during placement, catheter-related bloodstream
infection (CRBSI) following placement, thrombosis, or
peripheral blood flow disorders may occur. Also, sedation,
as well as tracheal intubation, may be necessary when
placing the central venous catheter in pediatric patients,
and the workload of attending medical staff can also be
expected to increase. However, the frequency of complica-
tions will vary depending on the physician/technician, the
facility environment, and individual patient characteristics,
and clinical benefits obtained will also vary depending on
the patient’s condition. Therefore, the benefit-risk balance
is expected to vary by case.
CQ19-9: What should the target hemoglobin (Hgb) value
be in pediatric sepsis cases?
Answer (opinion)
Hgb > 7 g/dL may be used as a target value as appropri-
ate based on the patient’s condition after shock and hyp-
oxemia have been corrected, although each patient’s
course will be different. (expert consensus/no evidence)
(rate of agreement, 100%).
Rationale
Anemia develops readily in sepsis as a result of multiple
concurrent events, such as bleeding tendency due to dis-
seminated intravascular coagulation and frequent blood
sampling for diagnostic testing. Correcting anemia is im-
portant to normalize the supply of oxygen to tissues and
to ease the burden on the heart. Contrastively, cardiac
overflow due to excessive blood transfusion may worsen
respiratory condition and hemodynamics. Performing
blood sampling and transfusions only when necessary is
also advantageous from the perspective of infection con-
trol and prevention.
The Transfusion Requirements in the Pediatric Inten-
sive Care Unit (TRIPICU) study [476] investigated target
Hgb values for pediatric intensive care patients. Slightly
less than 40% of the patients targeted were sepsis pa-
tients, and the study compared two groups that under-
went “blood transfusion with Hgb < 7 g/dL ; target range:
8.5-9.5g/dL” and “blood transfusion with Hgb < 9.5 g/dL;
target range: 11-12g/dL”. As a result, the average Hgb
values were 8.7 ± 0.4 g/dL vs. 10.8 ± 0.5 g/dL, respectively,
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and the mortality rate, incidence of multiple organ failure,
and hospitalization time did not differ between the two
groups. When determining the target Hgb levels in
pediatric sepsis patients, a literature review of relevant
studies was considered to be an important clinical task.
No RCTs conforming to the PICO process could be
found. By establishing Hgb > 7 g/dL as the target value
in septic shock cases or patients presenting with hypox-
emia despite stable hemodynamics, blood transfusion
frequency can be reduced, medical resources can be uti-
lized more effectively, medical costs can be reduced, and
the frequency of complications associated with blood
transfusion may be lowered.
In contrast, gaining a sufficient grasp of the patient’s cir-
culatory condition is necessary if Hgb > 7 g/dL is to be
established as the target Hgb value after hemodynamics
have stabilized. Also, when maintaining a lower Hgb value,
responses to acute hemorrhaging may narrow the scope
of options for managing shock. As no RCTs conforming
to the PICO process were found, the benefit-risk balance
is currently unclear. However, this balance is believed to
differ depending on the condition and circumstances of
individual patients.
CQ19-10: Should steroids be administered in pediatric
sepsis cases?
Answer (recommendation)
We suggest against the administration of steroids as a
standard treatment in pediatric septic shock cases (2D)
(rate of agreement, 100%).
Rationale
Administering steroid therapy in sepsis cases had long
been considered to be a vital clinical task. However,
according to SSCG 2012 [29], the routine use in adult
septic shock patients is not recommended. The use of
steroids in pediatric patients with severe sepsis has not
been linked with survival prognosis in the overseas or
Japanese literature [451, 477].
In contrast, steroid therapy is recommended in the
pediatric section of SSCG 2012 [29]. This recommenda-
tion is based on the observation that pediatric septic shock
cases in Europe and the USA are often caused by menin-
gococcal bacteria, and the effect of the rapid development
of acute adrenal dysfunction and the high rate of mortality
in the pediatric population must also be taken into ac-
count. Japan has a low incidence of this condition, and its
treatment warrants a different approach than in the west-
ern nations [478]. In addition, dengue fever patients with
shock have been disproportionately represented in other
clinical studies assessing the significance of steroids in the
treatment of pediatric sepsis, which is far from the situ-
ation in Japan. As such, further investigations not influ-
enced by the results of studies on dengue heat shock are
believed to be necessary. Although many clinical studies
have assessed neurological prognosis by administering
multiple steroid drugs from the start of meningitis treat-
ment, this CQ only addresses the use of steroids to sup-
port recovery from shock.
Administering steroids will not lead to a reduced risk
of mortality or shortened shock recovery period in
pediatric septic shock patients who are unresponsive to
fluid resuscitation and dependent on circulatory ino-
tropes. However, the incidences of complications such as
bleeding and secondary infections do not increase. The
evidence upon which this recommendation is based was
limited to a single RCT conducted in a developing coun-
try [479]. The most important outcome considered in
this CQ is mortality rate, and shock recovery rate and
the incidence of complications are somewhat less im-
portant. As the evidence pertaining to mortality rate is
rated “D” (very weak), the overall evidence regarding this
outcome is also rated “D” (very weak).
Decreased mortality rate and increased shock recovery
rate/faster shock recovery are considered to be benefits
of this intervention. However, no significant differences
with respect to mortality rate and shock recovery period
were observed in the only RCT adopted for this CQ.
Meanwhile, potential harm associated with this interven-
tion include an increased incidence of complications
(e.g., bleeding and secondary infection), but no signifi-
cant difference was observed. Accordingly, the benefit-
risk balance for this intervention is currently suspected
to be unfavorable, or uncertain.
CQ19-11: Should blood apheresis be performed as a
treatment for septic shock in pediatric patients?
Answer (opinion)
No recommendation regarding the use of blood apher-
esis as a treatment in pediatric septic shock cases can be
offered at this time due to insufficient evidence (expert
consensus/no evidence) (rate of agreement, 100%).
Rationale
SSCG 2012 [29] does not address the use of blood
apheresis to treat septic shock in adult or pediatric
patients. However, as several new RCTs [274, 275, 480]
to investigate the utility of blood apheresis in the treat-
ment of sepsis in adult patients have been announced
successively in Europe and the USA, assessing the
significance of this intervention for pediatric patients is
believed to be valuable.
Only a single study [481] conforming to the PICO
process was found. However, this study enrolled few
subjects and was terminated early; thus, the body of
evidence for this CQ is currently considered to be inad-
equate. Accordingly, no recommendation could be of-
fered, and an expert consensus is presented instead.
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Patient condition may be improved as a result of per-
forming blood apheresis to aid in regulating immuno-
logical response through the removal of inflammatory
cytokines and mediators. However, no meta-analysis or
RCT has been conducted to date assessing renal replace-
ment therapy and direct hemoperfusion with polymyxin
B-immobilized fiber in children, and a study on plasma fil-
tration [481] found no improvement in mortality rate even
after adjusting for disease severity. Adverse events associ-
ated with blood apheresis include bleeding while securing
venous access, drops in blood pressure after initiation of
blood apheresis, electrolyte anomalies, hypothermia,
bleeding due to anticoagulant use, among others.
Mechanical complications occurring while securing
blood access are expected to be particularly high in
pediatric patients. When handling pediatric patients, the
experience level of the attending medical personnel can
affect the frequency of adverse events. A decision to per-
form blood apheresis may greatly increase the workload
of medical personnel, and this is considered to have a
major impact. Although the evidence obtained from the
literature search was inadequate to form a basis for any
conclusion, the severity of the potential risks associated
with this intervention must be considered fully.
CQ19-12: Should immunoglobulin therapy be
administered in pediatric sepsis cases?
Answer (opinion)
We recommend against the administration of immuno-
globulin therapy as a standard treatment in pediatric
sepsis cases (expert consensus/no evidence) (rate of
agreement, 94.7%).
Rationale
The use of immunoglobulin therapy to address severe
infections is covered under the Japanese National Health
Insurance program and is in wide use despite unclear
evidence regarding its capacity to improve clinical prog-
nosis. Meanwhile, although numerous studies have been
conducted overseas to assess a technique known as
immunomodulation, which involves administering large
doses of immunoglobulin preparations, the results of
these studies have not been consistent. Also, with the
exception of neonates, high-quality RCTs targeting
pediatric patients are currently lacking. Immunoglobulin
preparations are expensive, and further clarification of
their clinical efficacy will have great significance.
The adult patient-oriented sections of SSCG 2012 [29]
do not support the administration of intravenous im-
munoglobulin (IVIG) preparations, and while the ac-
companying commentary touches on the significance of
the International Neonatal Immunotherapy Study (INIS)
trial [482], a multicenter RCT that verified the efficacy
of IVIG in neonates, SSCG 2012 does not contain a
pediatric patient-oriented chapter on IVIG. The INIS
trial is the largest multicenter RCT on this subject, and
the fact that IVIG’s effectiveness was not observed in
adult or pediatric patients cannot be ignored. The fact
that IVIG was found to be ineffective despite how many
subjects were premature infants with a history of hypo-
gammaglobulinemia is particularly significant.
No studies conforming to the PICO process were
found. According to the results of a systematic review or
meta-analysis [107] limited to neonates only, no
improvement in mortality rate as a result of polyclonal
IVIG use was observed, and in the INIS trial [482]
(n = 3493) as well, which was also adopted for this
systematic review, no significant differences between the
intervention and control groups were observed with re-
spect to mortality rate and incidence of severe sequelae.
Although adverse effects such as hyperviscosity syndrome
and acute renal failure have been associated with this
intervention, these were not among the frequently occur-
ring adverse events reported for the intervention group in
the INIS trial [482] (intervention group: 12/1759; control
group: 10/1734). The INIS trial [482] was not adopted as a
direct basis for the recommendation decision for this CQ
because the majority of subjects were premature infants
and the targets differed. It can, however, be inferred from
the fact that the administration of IVIG preparations to
adult sepsis patients leads to neither benefits nor risks that
the same is likely true for pediatric patients.
CQ19-13: Should strict glycemic management be
implemented for pediatric sepsis patients?
Answer (recommendation)
We do recommend against applying strict glycemic
management in pediatric sepsis cases (1B) (rate of agree-
ment, 100%).
Rationale
As with adult patients, numerous reports have suggested
relationships between hyperglycemia and high mortality
rate, as well as hyperglycemia and hospitalization period
in pediatric patients as well. Although not limited to
sepsis cases, several successively announced large-scale
RCTs [483–486] have assessed the significance of imple-
menting strict glycemic management in critically ill chil-
dren. Thus, investigating the importance of this type of
intervention in patients with severe sepsis is considered
to be an important task.
While four RCTs [483–486] targeting critically ill
pediatric patients were adopted for a meta-analysis of strict
glycemic management (Srinivasan 2014) [487], all four
studies involved intensive care unit (ICU) patients other
than sepsis patients, and no subgroup analysis limited to
sepsis patients was reported.
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While the incidence of complication by secondary
infection declines as a result of implementing strict glycemic
management in pediatric sepsis or PICU patients,
hypoglycemia occurs more frequently, and no significant im-
provement in mortality rate can be expected. Hypoglycemia
is a serious complication that can lead to severe neurological
sequelae over the longer term in children, particularly infants.
Therefore, it was concluded that the potential risks associ-
ated with this intervention likely outweigh the benefits, and
so it is not recommended, regardless of cost or feasibility.
Although lowered mortality is an expected benefit of this
intervention, no significant difference was observed between
the intervention and control groups, and the corresponding
odds ratio was 0.79 (95% confidence interval (CI) 0.55–
1.15). Meanwhile, the decline in complications by secondary
infections is also considered to be a clinical benefit, but one
of less overall importance. The corresponding odds ratio
was 0.76 (95% CI 0.59–0.99), and a statistically significant
decrease was observed in the intervention group. While in-
creased incidence of hypoglycemia is a harm caused by this
intervention, the odds ratio for this adverse effect was 6.14
(95% CI 2.74–13.78) and was significantly higher in the
intervention group. Given that severe hypoglycemia is a ser-
ious complication that gives rise to concerns regarding its
long-term impact on neurological development, it was con-
cluded that the potential harms associated with this inter-
vention likely outweigh its potential benefits.
CQ19-14: Is the ACCM-PALS algorithm useful for managing
septic shock in pediatric patients?
Answer (opinion)
The ACCM-PALS initial treatment algorithm may be
used as necessary in consideration of patient condition
and needs of the clinical environment (expert consen-
sus/no evidence) (rate of agreement, 100%).
Rationale
Performing resuscitative measures without delay and
facilitating recovery from the shock state as soon as possible
is desirable when treating pediatric septic shock. As such,
the application of the ACCM-PALS algorithm for pediatric
septic shock has been globally adopted, and use of its trans-
lated version has entered the mainstream in Japan [29]. At
the same time, it is also important to carefully consider the
reliability and validity of other algorithms and their transla-
tions and to confirm the utility of existing algorithms.
No RCTs applicable to the subject of this CQ could be
found during a literature search of the PubMed data-
base. Although no systematic reviews or RCTs evaluat-
ing the validity and utility of the ACCM-PALS algorithm
itself currently exist, several observational studies were
found [488–490]. However, it was determined that sum-
marizing these observational studies (conducting a
meta-analysis) would be difficult due to the low quality
study design, variation in outcome indicators, and the
possibility for high heterogeneity, and no repeat system-
atic review and meta-analysis was conducted during the
formulation of this guideline. In line with the above, the
supporting evidence for this CQ is currently insufficient,
and no recommendation can be presented at this time.
However, as the expert consensus reached by the Guide-
line Creation Committee, it was determined that the
ACCM-PALS initial treatment algorithm might be used
as necessary in consideration of patient condition and
needs of the clinical environment during the treatment
of pediatric sepsis. The usefulness and validity of the
algorithm itself will need to be verified in the future.
By following this algorithm, various pediatric sepsis
treatments can be administered as appropriate and with-
out omission. Contrastively, by adhering to the algorithm,
excessive treatments may be offered while treatments not
covered by the algorithm may be ignored or their imple-
mentation delayed. In addition, some increase in workload
can be expected to accompany the work of monitoring
and confirming adherence to the algorithm, but this
additional burden is considered to be minor. No RCTs
conforming to the PICO process were found and as such
the benefit-risk balance for this technique is currently
unclear and is believed to vary depending on patient con-
dition. Because the ACCM-PALS algorithm is freely
accessible, no additional medical costs will be incurred,
and the drugs and medical devices covered by the algo-
rithm are available in many intensive care units.
CQ19-15: Should the intraosseous route be used
temporarily for the administration of fluid resuscitation
and circulatory inotropes when treating septic shock in
pediatric patients?
Answer (opinion)
The intraosseous route may be used as a temporary route
of administration for fluid resuscitation and circulatory
inotropes in pediatric septic shock cases, in consideration
of patient condition and needs of the clinical environment
(expert consensus/no evidence) (rate of agreement, 100%).
Rationale
The use of the intraosseous route as a temporary deliv-
ery route for the administration of fluids and circulatory
inotropes is well recognized as a pediatric resuscitative
technique. However, the use of the intraosseous route
accelerates the start of initial resuscitation and may in-
fluence outcomes even in pediatric patients with septic
shock requiring rapid infusion and the use of circulatory
inotropes, and as such the clinical utility of this tech-
nique is worth considering.
No RCTs examining the utility of the intraosseous
route in pediatric sepsis cases have been conducted to
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date, but according to the results of one RCT [491], the
intraosseous route is as useful as the peripheral venous
route in pediatric patients with severe dehydration. In
this RCT, all bone marrow needles were placed within
5 min (100%), while the venous route was successfully
secured 67% of the time. In addition, successfully secur-
ing a venous route required much more time in com-
parison to the time needed when using bone marrow
needles (venous route: 129 ± 13 s, 95% CI 103–156 s vs.
intraosseous route: 67 ± 7 s, 95% CI 55–80 s).
Patients requiring resuscitation treatment due to shock
or similar conditions exhibit collapsed peripheral blood
vessels and securing a venous delivery route frequently
presents difficulties. At the same time, resuscitation
treatments such as fluid transfusion and drug therapy
are also impeded as they often cannot be initiated with-
out access to a venous delivery route. In situations such
as these, the intraosseous route can allow for rapid
transfusion and drug delivery and is believed to have a
high potential for being beneficial to patients. The use of
the intraosseous route is also believed to cause little
additional increase in workload in comparison to central
venous puncture in cases where securing peripheral
venous access during resuscitation is difficult. However,
careful attention should be paid to the potential for
complications when using bone marrow needles, such as
malpositioning, hemorrhage, osteomyelitis, compartment
syndrome, fat embolism, and tibial fractures.
Although there is currently insufficient evidence to
support a recommendation, based on the available
evidence pertaining to use of the intraosseous route in
pediatric patients with severe dehydration in addition to
the accepted understanding of the difficulty in securing
peripheral and central venous access in such patients
compared to adults, it was determined by expert opinion
that both the intraosseous route and the peripheral
venous access may be used to facilitate initial fluid resus-
citation and administration of circulatory inotropes as
treatments in pediatric patients with sepsis.
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